CN110636853B - 重组溶瘤病毒 - Google Patents
重组溶瘤病毒 Download PDFInfo
- Publication number
- CN110636853B CN110636853B CN201880032491.4A CN201880032491A CN110636853B CN 110636853 B CN110636853 B CN 110636853B CN 201880032491 A CN201880032491 A CN 201880032491A CN 110636853 B CN110636853 B CN 110636853B
- Authority
- CN
- China
- Prior art keywords
- vsv
- protein
- ser
- cells
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000309459 oncolytic virus Species 0.000 title description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 108
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 95
- 201000011510 cancer Diseases 0.000 claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 51
- 239000013598 vector Substances 0.000 claims abstract description 49
- 230000003612 virological effect Effects 0.000 claims abstract description 44
- 239000013603 viral vector Substances 0.000 claims abstract description 32
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 claims abstract description 26
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 23
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 14
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 14
- 102000011727 Caspases Human genes 0.000 claims abstract description 13
- 108010076667 Caspases Proteins 0.000 claims abstract description 13
- 239000012190 activator Substances 0.000 claims abstract description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 127
- 210000004027 cell Anatomy 0.000 claims description 126
- 239000000203 mixture Substances 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 24
- 108091006027 G proteins Proteins 0.000 claims description 22
- 102000030782 GTP binding Human genes 0.000 claims description 22
- 108091000058 GTP-Binding Proteins 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 241001493065 dsRNA viruses Species 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 108700026220 vif Genes Proteins 0.000 claims description 9
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 108060003393 Granulin Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000711513 Mononegavirales Species 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010011732 Cyst Diseases 0.000 claims description 4
- 102000011931 Nucleoproteins Human genes 0.000 claims description 4
- 108010061100 Nucleoproteins Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 108010089430 Phosphoproteins Proteins 0.000 claims description 4
- 102000007982 Phosphoproteins Human genes 0.000 claims description 4
- 208000031513 cyst Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 101150082239 G gene Proteins 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 2
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 abstract description 55
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 abstract description 49
- 238000000034 method Methods 0.000 abstract description 26
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract description 4
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 description 76
- 230000004900 autophagic degradation Effects 0.000 description 65
- 230000006907 apoptotic process Effects 0.000 description 39
- 208000015181 infectious disease Diseases 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 25
- 238000011282 treatment Methods 0.000 description 23
- 230000008685 targeting Effects 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 241000711404 Avian avulavirus 1 Species 0.000 description 15
- 108091007065 BIRCs Proteins 0.000 description 15
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 15
- 102000004072 Beclin-1 Human genes 0.000 description 13
- 108090000524 Beclin-1 Proteins 0.000 description 13
- 230000000174 oncolytic effect Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 230000002438 mitochondrial effect Effects 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 108090000765 processed proteins & peptides Chemical group 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 8
- 108090000397 Caspase 3 Proteins 0.000 description 8
- 102100029855 Caspase-3 Human genes 0.000 description 8
- 108090000566 Caspase-9 Proteins 0.000 description 8
- 102000004039 Caspase-9 Human genes 0.000 description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 101710181008 P protein Proteins 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100037907 High mobility group protein B1 Human genes 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 102100020814 Sequestosome-1 Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 108020001580 protein domains Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 102100034574 P protein Human genes 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 229960001467 bortezomib Drugs 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 5
- 108010089804 glycyl-threonine Proteins 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000034217 membrane fusion Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- ZPBYVFQJHWLTFB-UHFFFAOYSA-N 3-methyl-7H-purin-6-imine Chemical compound CN1C=NC(=N)C2=C1NC=N2 ZPBYVFQJHWLTFB-UHFFFAOYSA-N 0.000 description 4
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 4
- 108700010013 HMGB1 Proteins 0.000 description 4
- 101150021904 HMGB1 gene Proteins 0.000 description 4
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 description 4
- -1 IFN- β Proteins 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 241000712079 Measles morbillivirus Species 0.000 description 4
- 101710127721 Membrane protein Proteins 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 241000711931 Rhabdoviridae Species 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
- 229940075439 smac mimetic Drugs 0.000 description 4
- 230000007502 viral entry Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3MeA Natural products CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 3
- GKKUBLFXKRDMFC-BQBZGAKWSA-N Asn-Pro-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O GKKUBLFXKRDMFC-BQBZGAKWSA-N 0.000 description 3
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 3
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 102100026548 Caspase-8 Human genes 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- 102100030497 Cytochrome c Human genes 0.000 description 3
- 108010075031 Cytochromes c Proteins 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 3
- 101000887051 Homo sapiens Ubiquitin-like-conjugating enzyme ATG3 Proteins 0.000 description 3
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 3
- 241001138401 Kluyveromyces lactis Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091033773 MiR-155 Proteins 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 3
- 101710168567 Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 3
- 102100039930 Ubiquitin-like-conjugating enzyme ATG3 Human genes 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 3
- 108010044940 alanylglutamine Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 210000004957 autophagosome Anatomy 0.000 description 3
- 239000012822 autophagy inhibitor Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000005880 cancer cell killing Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- XGVJWXAYKUHDOO-UHFFFAOYSA-N galanthidine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1=CC(O)C3O XGVJWXAYKUHDOO-UHFFFAOYSA-N 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 108010081551 glycylphenylalanine Proteins 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 3
- 230000006623 intrinsic pathway Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- XGVJWXAYKUHDOO-DANNLKNASA-N lycorine Chemical compound C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2C1=C[C@H](O)[C@H]3O XGVJWXAYKUHDOO-DANNLKNASA-N 0.000 description 3
- KQAOMBGKIWRWNA-UHFFFAOYSA-N lycorine Natural products OC1C=C2CCN3C2C(C1O)c4cc5OCOc5cc34 KQAOMBGKIWRWNA-UHFFFAOYSA-N 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 description 2
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 2
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 2
- BHFOJPDOQPWJRN-XDTLVQLUSA-N Ala-Tyr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(O)=O BHFOJPDOQPWJRN-XDTLVQLUSA-N 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 2
- VJIQPOJMISSUPO-BVSLBCMMSA-N Arg-Trp-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VJIQPOJMISSUPO-BVSLBCMMSA-N 0.000 description 2
- ATHZHGQSAIJHQU-XIRDDKMYSA-N Asn-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ATHZHGQSAIJHQU-XIRDDKMYSA-N 0.000 description 2
- KTDWFWNZLLFEFU-KKUMJFAQSA-N Asn-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O KTDWFWNZLLFEFU-KKUMJFAQSA-N 0.000 description 2
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 2
- NRIFEOUAFLTMFJ-AAEUAGOBSA-N Asp-Gly-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O NRIFEOUAFLTMFJ-AAEUAGOBSA-N 0.000 description 2
- CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 description 2
- ZVGRHIRJLWBWGJ-ACZMJKKPSA-N Asp-Ser-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZVGRHIRJLWBWGJ-ACZMJKKPSA-N 0.000 description 2
- BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 102000001805 Bromodomains Human genes 0.000 description 2
- 108050009021 Bromodomains Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- IIGHQOPGMGKDMT-SRVKXCTJSA-N Cys-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N IIGHQOPGMGKDMT-SRVKXCTJSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- HXOLDXKNWKLDMM-YVNDNENWSA-N Gln-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HXOLDXKNWKLDMM-YVNDNENWSA-N 0.000 description 2
- UQKVUFGUSVYJMQ-IRIUXVKKSA-N Gln-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)N)N)O UQKVUFGUSVYJMQ-IRIUXVKKSA-N 0.000 description 2
- BBFCMGBMYIAGRS-AUTRQRHGSA-N Gln-Val-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BBFCMGBMYIAGRS-AUTRQRHGSA-N 0.000 description 2
- MKRDNSWGJWTBKZ-GVXVVHGQSA-N Gln-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MKRDNSWGJWTBKZ-GVXVVHGQSA-N 0.000 description 2
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 2
- XMVLTPMCUJTJQP-FXQIFTODSA-N Glu-Gln-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N XMVLTPMCUJTJQP-FXQIFTODSA-N 0.000 description 2
- VFZIDQZAEBORGY-GLLZPBPUSA-N Glu-Gln-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VFZIDQZAEBORGY-GLLZPBPUSA-N 0.000 description 2
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 2
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 2
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 2
- VLIJYPMATZSOLL-YUMQZZPRSA-N Gly-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN VLIJYPMATZSOLL-YUMQZZPRSA-N 0.000 description 2
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 2
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 2
- YDIDLLVFCYSXNY-RCOVLWMOSA-N Gly-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN YDIDLLVFCYSXNY-RCOVLWMOSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- 102000000849 HMGB Proteins Human genes 0.000 description 2
- 108010001860 HMGB Proteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- OMNVOTCFQQLEQU-CIUDSAMLSA-N His-Asn-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMNVOTCFQQLEQU-CIUDSAMLSA-N 0.000 description 2
- ORZGPQXISSXQGW-IHRRRGAJSA-N His-His-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O ORZGPQXISSXQGW-IHRRRGAJSA-N 0.000 description 2
- PGRPSOUCWRBWKZ-DLOVCJGASA-N His-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 PGRPSOUCWRBWKZ-DLOVCJGASA-N 0.000 description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 2
- WEWCEPOYKANMGZ-MMWGEVLESA-N Ile-Cys-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N WEWCEPOYKANMGZ-MMWGEVLESA-N 0.000 description 2
- ZDNORQNHCJUVOV-KBIXCLLPSA-N Ile-Gln-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O ZDNORQNHCJUVOV-KBIXCLLPSA-N 0.000 description 2
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 description 2
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 2
- YNMQUIVKEFRCPH-QSFUFRPTSA-N Ile-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O)N YNMQUIVKEFRCPH-QSFUFRPTSA-N 0.000 description 2
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 2
- WIYDLTIBHZSPKY-HJWJTTGWSA-N Ile-Val-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WIYDLTIBHZSPKY-HJWJTTGWSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 description 2
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 2
- QJXHMYMRGDOHRU-NHCYSSNCSA-N Leu-Ile-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O QJXHMYMRGDOHRU-NHCYSSNCSA-N 0.000 description 2
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 description 2
- SYRTUBLKWNDSDK-DKIMLUQUSA-N Leu-Phe-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYRTUBLKWNDSDK-DKIMLUQUSA-N 0.000 description 2
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 2
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 2
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- VSRXPEHZMHSFKU-IUCAKERBSA-N Lys-Gln-Gly Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VSRXPEHZMHSFKU-IUCAKERBSA-N 0.000 description 2
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 2
- UDXSLGLHFUBRRM-OEAJRASXSA-N Lys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N)O UDXSLGLHFUBRRM-OEAJRASXSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- OFNCSQNBSWGGNV-DCAQKATOSA-N Met-Cys-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 OFNCSQNBSWGGNV-DCAQKATOSA-N 0.000 description 2
- RATXDYWHIYNZLE-DCAQKATOSA-N Met-Lys-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N RATXDYWHIYNZLE-DCAQKATOSA-N 0.000 description 2
- WXXNVZMWHOLNRJ-AVGNSLFASA-N Met-Pro-Lys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O WXXNVZMWHOLNRJ-AVGNSLFASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 2
- 108010065395 Neuropep-1 Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 2
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FDINZVJXLPILKV-DCAQKATOSA-N Pro-His-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O FDINZVJXLPILKV-DCAQKATOSA-N 0.000 description 2
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- UBRXAVQWXOWRSJ-ZLUOBGJFSA-N Ser-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)C(=O)N UBRXAVQWXOWRSJ-ZLUOBGJFSA-N 0.000 description 2
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 2
- GRSLLFZTTLBOQX-CIUDSAMLSA-N Ser-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N GRSLLFZTTLBOQX-CIUDSAMLSA-N 0.000 description 2
- YIUWWXVTYLANCJ-NAKRPEOUSA-N Ser-Ile-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YIUWWXVTYLANCJ-NAKRPEOUSA-N 0.000 description 2
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 2
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 2
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 2
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 2
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 2
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 2
- NLWDSYKZUPRMBJ-IEGACIPQSA-N Thr-Trp-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O NLWDSYKZUPRMBJ-IEGACIPQSA-N 0.000 description 2
- UPOGHWJJZAZNSW-XIRDDKMYSA-N Trp-His-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O UPOGHWJJZAZNSW-XIRDDKMYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- GHUNBABNQPIETG-MELADBBJSA-N Tyr-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O GHUNBABNQPIETG-MELADBBJSA-N 0.000 description 2
- BXPOOVDVGWEXDU-WZLNRYEVSA-N Tyr-Ile-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BXPOOVDVGWEXDU-WZLNRYEVSA-N 0.000 description 2
- ZZDYJFVIKVSUFA-WLTAIBSBSA-N Tyr-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ZZDYJFVIKVSUFA-WLTAIBSBSA-N 0.000 description 2
- VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 2
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 2
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 2
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 2
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 2
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 2
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 2
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 2
- NGXQOQNXSGOYOI-BQFCYCMXSA-N Val-Trp-Gln Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 NGXQOQNXSGOYOI-BQFCYCMXSA-N 0.000 description 2
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 241000235015 Yarrowia lipolytica Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 2
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 2
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 2
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 2
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000006667 mitochondrial pathway Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009979 protective mechanism Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 101150034092 ATG4 gene Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- DVWVZSJAYIJZFI-FXQIFTODSA-N Ala-Arg-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DVWVZSJAYIJZFI-FXQIFTODSA-N 0.000 description 1
- YWWATNIVMOCSAV-UBHSHLNASA-N Ala-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YWWATNIVMOCSAV-UBHSHLNASA-N 0.000 description 1
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 1
- YIGLXQRFQVWFEY-NRPADANISA-N Ala-Gln-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O YIGLXQRFQVWFEY-NRPADANISA-N 0.000 description 1
- UHMQKOBNPRAZGB-CIUDSAMLSA-N Ala-Glu-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N UHMQKOBNPRAZGB-CIUDSAMLSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 1
- ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 description 1
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 description 1
- NUBPTCMEOCKWDO-DCAQKATOSA-N Arg-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N NUBPTCMEOCKWDO-DCAQKATOSA-N 0.000 description 1
- BBYTXXRNSFUOOX-IHRRRGAJSA-N Arg-Cys-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BBYTXXRNSFUOOX-IHRRRGAJSA-N 0.000 description 1
- JCAISGGAOQXEHJ-ZPFDUUQYSA-N Arg-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N JCAISGGAOQXEHJ-ZPFDUUQYSA-N 0.000 description 1
- XLWSGICNBZGYTA-CIUDSAMLSA-N Arg-Glu-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XLWSGICNBZGYTA-CIUDSAMLSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- YVTHEZNOKSAWRW-DCAQKATOSA-N Arg-Lys-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O YVTHEZNOKSAWRW-DCAQKATOSA-N 0.000 description 1
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 1
- INOIAEUXVVNJKA-XGEHTFHBSA-N Arg-Thr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O INOIAEUXVVNJKA-XGEHTFHBSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 1
- QTAIIXQCOPUNBQ-QXEWZRGKSA-N Arg-Val-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QTAIIXQCOPUNBQ-QXEWZRGKSA-N 0.000 description 1
- BZWRLDPIWKOVKB-ZPFDUUQYSA-N Asn-Leu-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BZWRLDPIWKOVKB-ZPFDUUQYSA-N 0.000 description 1
- NJSNXIOKBHPFMB-GMOBBJLQSA-N Asn-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)N)N NJSNXIOKBHPFMB-GMOBBJLQSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 1
- KQBVNNAPIURMPD-PEFMBERDSA-N Asp-Ile-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O KQBVNNAPIURMPD-PEFMBERDSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 1
- CTWCFPWFIGRAEP-CIUDSAMLSA-N Asp-Lys-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O CTWCFPWFIGRAEP-CIUDSAMLSA-N 0.000 description 1
- XXAMCEGRCZQGEM-ZLUOBGJFSA-N Asp-Ser-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O XXAMCEGRCZQGEM-ZLUOBGJFSA-N 0.000 description 1
- XOASPVGNFAMYBD-WFBYXXMGSA-N Asp-Trp-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O XOASPVGNFAMYBD-WFBYXXMGSA-N 0.000 description 1
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 102100021251 Beclin-1 Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100028226 COUP transcription factor 2 Human genes 0.000 description 1
- 101710188750 COUP transcription factor 2 Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 240000002112 Carya glabra Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100033211 Centromere protein W Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- RRIJEABIXPKSGP-FXQIFTODSA-N Cys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CS RRIJEABIXPKSGP-FXQIFTODSA-N 0.000 description 1
- YZFCGHIBLBDZDA-ZLUOBGJFSA-N Cys-Asp-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YZFCGHIBLBDZDA-ZLUOBGJFSA-N 0.000 description 1
- MBILEVLLOHJZMG-FXQIFTODSA-N Cys-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N MBILEVLLOHJZMG-FXQIFTODSA-N 0.000 description 1
- MFMDKTLJCUBQIC-MXAVVETBSA-N Cys-Phe-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MFMDKTLJCUBQIC-MXAVVETBSA-N 0.000 description 1
- MBRWOKXNHTUJMB-CIUDSAMLSA-N Cys-Pro-Glu Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O MBRWOKXNHTUJMB-CIUDSAMLSA-N 0.000 description 1
- QQAYIVHVRFJICE-AEJSXWLSSA-N Cys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N QQAYIVHVRFJICE-AEJSXWLSSA-N 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 1
- UVAOVENCIONMJP-GUBZILKMSA-N Gln-Cys-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O UVAOVENCIONMJP-GUBZILKMSA-N 0.000 description 1
- MCAVASRGVBVPMX-FXQIFTODSA-N Gln-Glu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MCAVASRGVBVPMX-FXQIFTODSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- DRDSQGHKTLSNEA-GLLZPBPUSA-N Gln-Glu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRDSQGHKTLSNEA-GLLZPBPUSA-N 0.000 description 1
- JHPFPROFOAJRFN-IHRRRGAJSA-N Gln-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O JHPFPROFOAJRFN-IHRRRGAJSA-N 0.000 description 1
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- CELXWPDNIGWCJN-WDCWCFNPSA-N Gln-Lys-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CELXWPDNIGWCJN-WDCWCFNPSA-N 0.000 description 1
- ARYKRXHBIPLULY-XKBZYTNZSA-N Gln-Thr-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ARYKRXHBIPLULY-XKBZYTNZSA-N 0.000 description 1
- STHSGOZLFLFGSS-SUSMZKCASA-N Gln-Thr-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STHSGOZLFLFGSS-SUSMZKCASA-N 0.000 description 1
- CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 1
- VTTSANCGJWLPNC-ZPFDUUQYSA-N Glu-Arg-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VTTSANCGJWLPNC-ZPFDUUQYSA-N 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 1
- OWVURWCRZZMAOZ-XHNCKOQMSA-N Glu-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)N)C(=O)O OWVURWCRZZMAOZ-XHNCKOQMSA-N 0.000 description 1
- XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 1
- GGJOGFJIPPGNRK-JSGCOSHPSA-N Glu-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 GGJOGFJIPPGNRK-JSGCOSHPSA-N 0.000 description 1
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 1
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 1
- KXTAGESXNQEZKB-DZKIICNBSA-N Glu-Phe-Val Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 description 1
- TWYSSILQABLLME-HJGDQZAQSA-N Glu-Thr-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYSSILQABLLME-HJGDQZAQSA-N 0.000 description 1
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 1
- CAQXJMUDOLSBPF-SUSMZKCASA-N Glu-Thr-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAQXJMUDOLSBPF-SUSMZKCASA-N 0.000 description 1
- UUTGYDAKPISJAO-JYJNAYRXSA-N Glu-Tyr-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 UUTGYDAKPISJAO-JYJNAYRXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- MHHUEAIBJZWDBH-YUMQZZPRSA-N Gly-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN MHHUEAIBJZWDBH-YUMQZZPRSA-N 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 1
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 1
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 1
- XVYKMNXXJXQKME-XEGUGMAKSA-N Gly-Ile-Tyr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XVYKMNXXJXQKME-XEGUGMAKSA-N 0.000 description 1
- YIFUFYZELCMPJP-YUMQZZPRSA-N Gly-Leu-Cys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O YIFUFYZELCMPJP-YUMQZZPRSA-N 0.000 description 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- PCPOYRCAHPJXII-UWVGGRQHSA-N Gly-Lys-Met Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O PCPOYRCAHPJXII-UWVGGRQHSA-N 0.000 description 1
- FXLVSYVJDPCIHH-STQMWFEESA-N Gly-Phe-Arg Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FXLVSYVJDPCIHH-STQMWFEESA-N 0.000 description 1
- IGOYNRWLWHWAQO-JTQLQIEISA-N Gly-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IGOYNRWLWHWAQO-JTQLQIEISA-N 0.000 description 1
- SCJJPCQUJYPHRZ-BQBZGAKWSA-N Gly-Pro-Asn Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O SCJJPCQUJYPHRZ-BQBZGAKWSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- UMRIXLHPZZIOML-OALUTQOASA-N Gly-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CN UMRIXLHPZZIOML-OALUTQOASA-N 0.000 description 1
- GJHWILMUOANXTG-WPRPVWTQSA-N Gly-Val-Arg Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GJHWILMUOANXTG-WPRPVWTQSA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- COZMNNJEGNPDED-HOCLYGCPSA-N Gly-Val-Trp Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O COZMNNJEGNPDED-HOCLYGCPSA-N 0.000 description 1
- 241000035314 Henipavirus Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- QAMFAYSMNZBNCA-UWVGGRQHSA-N His-Gly-Met Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O QAMFAYSMNZBNCA-UWVGGRQHSA-N 0.000 description 1
- WJGSTIMGSIWHJX-HVTMNAMFSA-N His-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N WJGSTIMGSIWHJX-HVTMNAMFSA-N 0.000 description 1
- LVXFNTIIGOQBMD-SRVKXCTJSA-N His-Leu-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O LVXFNTIIGOQBMD-SRVKXCTJSA-N 0.000 description 1
- XIGFLVCAVQQGNS-IHRRRGAJSA-N His-Pro-His Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XIGFLVCAVQQGNS-IHRRRGAJSA-N 0.000 description 1
- JVEKQAYXFGIISZ-HOCLYGCPSA-N His-Trp-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CN=CN1 JVEKQAYXFGIISZ-HOCLYGCPSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000894649 Homo sapiens Beclin-1 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000944447 Homo sapiens Centromere protein W Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
- 101001052512 Homo sapiens Microtubule-associated proteins 1A/1B light chain 3B Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 1
- YKRYHWJRQUSTKG-KBIXCLLPSA-N Ile-Ala-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKRYHWJRQUSTKG-KBIXCLLPSA-N 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- DMHGKBGOUAJRHU-RVMXOQNASA-N Ile-Arg-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N DMHGKBGOUAJRHU-RVMXOQNASA-N 0.000 description 1
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 1
- UAVQIQOOBXFKRC-BYULHYEWSA-N Ile-Asn-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O UAVQIQOOBXFKRC-BYULHYEWSA-N 0.000 description 1
- GECLQMBTZCPAFY-PEFMBERDSA-N Ile-Gln-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GECLQMBTZCPAFY-PEFMBERDSA-N 0.000 description 1
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
- TVSPLSZTKTUYLV-ZPFDUUQYSA-N Ile-Glu-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O TVSPLSZTKTUYLV-ZPFDUUQYSA-N 0.000 description 1
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 1
- WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 1
- NGKPIPCGMLWHBX-WZLNRYEVSA-N Ile-Tyr-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NGKPIPCGMLWHBX-WZLNRYEVSA-N 0.000 description 1
- 241001481495 Indiana vesiculovirus Species 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- GRZSCTXVCDUIPO-SRVKXCTJSA-N Leu-Arg-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRZSCTXVCDUIPO-SRVKXCTJSA-N 0.000 description 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
- DUBAVOVZNZKEQQ-AVGNSLFASA-N Leu-Arg-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CCCN=C(N)N DUBAVOVZNZKEQQ-AVGNSLFASA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 1
- PPTAQBNUFKTJKA-BJDJZHNGSA-N Leu-Cys-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PPTAQBNUFKTJKA-BJDJZHNGSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 1
- SEMUSFOBZGKBGW-YTFOTSKYSA-N Leu-Ile-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SEMUSFOBZGKBGW-YTFOTSKYSA-N 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- ZDBMWELMUCLUPL-QEJZJMRPSA-N Leu-Phe-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ZDBMWELMUCLUPL-QEJZJMRPSA-N 0.000 description 1
- MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- YUTNOGOMBNYPFH-XUXIUFHCSA-N Leu-Pro-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YUTNOGOMBNYPFH-XUXIUFHCSA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- LSLUTXRANSUGFY-XIRDDKMYSA-N Leu-Trp-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(O)=O LSLUTXRANSUGFY-XIRDDKMYSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- JCFYLFOCALSNLQ-GUBZILKMSA-N Lys-Ala-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JCFYLFOCALSNLQ-GUBZILKMSA-N 0.000 description 1
- PNPYKQFJGRFYJE-GUBZILKMSA-N Lys-Ala-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNPYKQFJGRFYJE-GUBZILKMSA-N 0.000 description 1
- NTEVEUCLFMWSND-SRVKXCTJSA-N Lys-Arg-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O NTEVEUCLFMWSND-SRVKXCTJSA-N 0.000 description 1
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 1
- GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
- GTAXSKOXPIISBW-AVGNSLFASA-N Lys-His-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N GTAXSKOXPIISBW-AVGNSLFASA-N 0.000 description 1
- HQXSFFSLXFHWOX-IXOXFDKPSA-N Lys-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCCN)N)O HQXSFFSLXFHWOX-IXOXFDKPSA-N 0.000 description 1
- CTBMEDOQJFGNMI-IHPCNDPISA-N Lys-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCCN)N CTBMEDOQJFGNMI-IHPCNDPISA-N 0.000 description 1
- MXMDJEJWERYPMO-XUXIUFHCSA-N Lys-Ile-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MXMDJEJWERYPMO-XUXIUFHCSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- GOVDTWNJCBRRBJ-DCAQKATOSA-N Lys-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N GOVDTWNJCBRRBJ-DCAQKATOSA-N 0.000 description 1
- WKUXWMWQTOYTFI-SRVKXCTJSA-N Lys-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N WKUXWMWQTOYTFI-SRVKXCTJSA-N 0.000 description 1
- AEIIJFBQVGYVEV-YESZJQIVSA-N Lys-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCN)N)C(=O)O AEIIJFBQVGYVEV-YESZJQIVSA-N 0.000 description 1
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 description 1
- UWHCKWNPWKTMBM-WDCWCFNPSA-N Lys-Thr-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O UWHCKWNPWKTMBM-WDCWCFNPSA-N 0.000 description 1
- LMMBAXJRYSXCOQ-ACRUOGEOSA-N Lys-Tyr-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O LMMBAXJRYSXCOQ-ACRUOGEOSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 1
- VHGIWFGJIHTASW-FXQIFTODSA-N Met-Ala-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O VHGIWFGJIHTASW-FXQIFTODSA-N 0.000 description 1
- SBSIKVMCCJUCBZ-GUBZILKMSA-N Met-Asn-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N SBSIKVMCCJUCBZ-GUBZILKMSA-N 0.000 description 1
- XMMWDTUFTZMQFD-GMOBBJLQSA-N Met-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC XMMWDTUFTZMQFD-GMOBBJLQSA-N 0.000 description 1
- QMIXOTQHYHOUJP-KKUMJFAQSA-N Met-Gln-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N QMIXOTQHYHOUJP-KKUMJFAQSA-N 0.000 description 1
- GETCJHFFECHWHI-QXEWZRGKSA-N Met-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCSC)N GETCJHFFECHWHI-QXEWZRGKSA-N 0.000 description 1
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 1
- UROWNMBTQGGTHB-DCAQKATOSA-N Met-Leu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UROWNMBTQGGTHB-DCAQKATOSA-N 0.000 description 1
- GMMLGMFBYCFCCX-KZVJFYERSA-N Met-Thr-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMMLGMFBYCFCCX-KZVJFYERSA-N 0.000 description 1
- GWADARYJIJDYRC-XGEHTFHBSA-N Met-Thr-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GWADARYJIJDYRC-XGEHTFHBSA-N 0.000 description 1
- CQRGINSEMFBACV-WPRPVWTQSA-N Met-Val-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O CQRGINSEMFBACV-WPRPVWTQSA-N 0.000 description 1
- 102100024177 Microtubule-associated proteins 1A/1B light chain 3B Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100271280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cpr-1 gene Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
- NOFBJKKOPKJDCO-KKXDTOCCSA-N Phe-Ala-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NOFBJKKOPKJDCO-KKXDTOCCSA-N 0.000 description 1
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
- HPECNYCQLSVCHH-BZSNNMDCSA-N Phe-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N HPECNYCQLSVCHH-BZSNNMDCSA-N 0.000 description 1
- AKJAKCBHLJGRBU-JYJNAYRXSA-N Phe-Glu-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N AKJAKCBHLJGRBU-JYJNAYRXSA-N 0.000 description 1
- XXAOSEUPEMQJOF-KKUMJFAQSA-N Phe-Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 XXAOSEUPEMQJOF-KKUMJFAQSA-N 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- INHMISZWLJZQGH-ULQDDVLXSA-N Phe-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 INHMISZWLJZQGH-ULQDDVLXSA-N 0.000 description 1
- PEFJUUYFEGBXFA-BZSNNMDCSA-N Phe-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 PEFJUUYFEGBXFA-BZSNNMDCSA-N 0.000 description 1
- IWZRODDWOSIXPZ-IRXDYDNUSA-N Phe-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 IWZRODDWOSIXPZ-IRXDYDNUSA-N 0.000 description 1
- GPLWGAYGROGDEN-BZSNNMDCSA-N Phe-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GPLWGAYGROGDEN-BZSNNMDCSA-N 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- BONHGTUEEPIMPM-AVGNSLFASA-N Phe-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O BONHGTUEEPIMPM-AVGNSLFASA-N 0.000 description 1
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- YUPRIZTWANWWHK-DZKIICNBSA-N Phe-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N YUPRIZTWANWWHK-DZKIICNBSA-N 0.000 description 1
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 1
- BFXZQMWKTYWGCF-PYJNHQTQSA-N Pro-His-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BFXZQMWKTYWGCF-PYJNHQTQSA-N 0.000 description 1
- AQSMZTIEJMZQEC-DCAQKATOSA-N Pro-His-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)O AQSMZTIEJMZQEC-DCAQKATOSA-N 0.000 description 1
- IBGCFJDLCYTKPW-NAKRPEOUSA-N Pro-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 IBGCFJDLCYTKPW-NAKRPEOUSA-N 0.000 description 1
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 1
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 1
- UREQLMJCKFLLHM-NAKRPEOUSA-N Pro-Ile-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UREQLMJCKFLLHM-NAKRPEOUSA-N 0.000 description 1
- CPRLKHJUFAXVTD-ULQDDVLXSA-N Pro-Leu-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CPRLKHJUFAXVTD-ULQDDVLXSA-N 0.000 description 1
- FZXSYIPVAFVYBH-KKUMJFAQSA-N Pro-Tyr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O FZXSYIPVAFVYBH-KKUMJFAQSA-N 0.000 description 1
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- RZUOXAKGNHXZTB-GUBZILKMSA-N Ser-Arg-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O RZUOXAKGNHXZTB-GUBZILKMSA-N 0.000 description 1
- ICHZYBVODUVUKN-SRVKXCTJSA-N Ser-Asn-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ICHZYBVODUVUKN-SRVKXCTJSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- OJPHFSOMBZKQKQ-GUBZILKMSA-N Ser-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO OJPHFSOMBZKQKQ-GUBZILKMSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- SRKMDKACHDVPMD-SRVKXCTJSA-N Ser-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N SRKMDKACHDVPMD-SRVKXCTJSA-N 0.000 description 1
- LRWBCWGEUCKDTN-BJDJZHNGSA-N Ser-Lys-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LRWBCWGEUCKDTN-BJDJZHNGSA-N 0.000 description 1
- KJKQUQXDEKMPDK-FXQIFTODSA-N Ser-Met-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O KJKQUQXDEKMPDK-FXQIFTODSA-N 0.000 description 1
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- XPVIVVLLLOFBRH-XIRDDKMYSA-N Ser-Trp-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CO)C(O)=O XPVIVVLLLOFBRH-XIRDDKMYSA-N 0.000 description 1
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 1
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- UNURFMVMXLENAZ-KJEVXHAQSA-N Thr-Arg-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UNURFMVMXLENAZ-KJEVXHAQSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 1
- GMXIJHCBTZDAPD-QPHKQPEJSA-N Thr-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N GMXIJHCBTZDAPD-QPHKQPEJSA-N 0.000 description 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 1
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- WKGAAMOJPMBBMC-IXOXFDKPSA-N Thr-Ser-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WKGAAMOJPMBBMC-IXOXFDKPSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 1
- CSZFFQBUTMGHAH-UAXMHLISSA-N Thr-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O CSZFFQBUTMGHAH-UAXMHLISSA-N 0.000 description 1
- IJKNKFJZOJCKRR-GBALPHGKSA-N Thr-Trp-Ser Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 IJKNKFJZOJCKRR-GBALPHGKSA-N 0.000 description 1
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100037357 Thymidylate kinase Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- VZBWRZGNEPBRDE-HZUKXOBISA-N Trp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N VZBWRZGNEPBRDE-HZUKXOBISA-N 0.000 description 1
- VEYXZZGMIBKXCN-UBHSHLNASA-N Trp-Asp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VEYXZZGMIBKXCN-UBHSHLNASA-N 0.000 description 1
- HABYQJRYDKEVOI-IHPCNDPISA-N Trp-His-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CCCCN)C(=O)O)N HABYQJRYDKEVOI-IHPCNDPISA-N 0.000 description 1
- RWAYYYOZMHMEGD-XIRDDKMYSA-N Trp-Leu-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 RWAYYYOZMHMEGD-XIRDDKMYSA-N 0.000 description 1
- ULHASJWZGUEUNN-XIRDDKMYSA-N Trp-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O ULHASJWZGUEUNN-XIRDDKMYSA-N 0.000 description 1
- MICFJCRQBFSKPA-UMPQAUOISA-N Trp-Met-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)=CNC2=C1 MICFJCRQBFSKPA-UMPQAUOISA-N 0.000 description 1
- YTVJTXJTNRWJCR-JBACZVJFSA-N Trp-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N YTVJTXJTNRWJCR-JBACZVJFSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- TVOGEPLDNYTAHD-CQDKDKBSSA-N Tyr-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TVOGEPLDNYTAHD-CQDKDKBSSA-N 0.000 description 1
- FFCRCJZJARTYCG-KKUMJFAQSA-N Tyr-Cys-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N)O FFCRCJZJARTYCG-KKUMJFAQSA-N 0.000 description 1
- KOVXHANYYYMBRF-IRIUXVKKSA-N Tyr-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KOVXHANYYYMBRF-IRIUXVKKSA-N 0.000 description 1
- PJWCWGXAVIVXQC-STECZYCISA-N Tyr-Ile-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PJWCWGXAVIVXQC-STECZYCISA-N 0.000 description 1
- AVIQBBOOTZENLH-KKUMJFAQSA-N Tyr-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N AVIQBBOOTZENLH-KKUMJFAQSA-N 0.000 description 1
- CWVHKVVKAQIJKY-ACRUOGEOSA-N Tyr-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=C(C=C2)O)N CWVHKVVKAQIJKY-ACRUOGEOSA-N 0.000 description 1
- CYTJBBNFJIWKGH-STECZYCISA-N Tyr-Met-Ile Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CYTJBBNFJIWKGH-STECZYCISA-N 0.000 description 1
- WTTRJMAZPDHPGS-KKXDTOCCSA-N Tyr-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O WTTRJMAZPDHPGS-KKXDTOCCSA-N 0.000 description 1
- LRHBBGDMBLFYGL-FHWLQOOXSA-N Tyr-Phe-Glu Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LRHBBGDMBLFYGL-FHWLQOOXSA-N 0.000 description 1
- UUBKSZNKJUJQEJ-JRQIVUDYSA-N Tyr-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O UUBKSZNKJUJQEJ-JRQIVUDYSA-N 0.000 description 1
- CLEGSEJVGBYZBJ-MEYUZBJRSA-N Tyr-Thr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CLEGSEJVGBYZBJ-MEYUZBJRSA-N 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- UEOOXDLMQZBPFR-ZKWXMUAHSA-N Val-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N UEOOXDLMQZBPFR-ZKWXMUAHSA-N 0.000 description 1
- XLDYBRXERHITNH-QSFUFRPTSA-N Val-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)C(C)C XLDYBRXERHITNH-QSFUFRPTSA-N 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 1
- FXVDGDZRYLFQKY-WPRPVWTQSA-N Val-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C FXVDGDZRYLFQKY-WPRPVWTQSA-N 0.000 description 1
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- YLRAFVVWZRSZQC-DZKIICNBSA-N Val-Phe-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N YLRAFVVWZRSZQC-DZKIICNBSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 108010000742 dTMP kinase Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010059898 glycyl-tyrosyl-lysine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 102000048253 human DIABLO Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 208000010655 oral cavity squamous cell carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20041—Use of virus, viral particle or viral elements as a vector
- C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
公开了重组病毒载体,所述重组病毒载体包含编码被插入在RNA病毒基因组内的第二线粒体衍生的胱天蛋白酶激活剂(Smac)蛋白的核酸,其中Smac蛋白特异性地结合至凋亡抑制蛋白(IAP)的至少一部分。还公开了使用所公开的载体治疗癌症的方法。
Description
相关申请的交叉引用
本申请要求于2017年5月19日提交的美国临时申请号62/508,430的权益,该申请特此通过引用以其整体并入本文。
背景
自噬是溶酶体中捕获、降解和回收细胞内蛋白质和细胞器的存活促进途径。自噬在癌症中具有双重作用,充当通过防止受损的蛋白质和细胞器的积累的肿瘤抑制因子和充当可以促进建立的肿瘤的生长的细胞存活的机制两者。存在大量证据指示,自噬在癌症生物学中起着核心作用(Lippai,M.和Z.Szatmari,Cell Biol Toxicol,2017 33(2):145-168)。一方面,正常细胞的自噬可以抑制肿瘤发生。癌症的突变可以导致自噬功能的丧失。可选择地,自噬也可以使得肿瘤细胞对抗癌药物的治疗耐受。自噬和凋亡之间的交叉对话(cross-talk)在癌症生物学中也是关键的,但是该两个途径之间的关系是复杂的。需要破坏自噬的保护机制的方法,因此凋亡可以更容易地被诱导。
概述
本文公开了重组病毒载体,该重组病毒载体包含编码被插入在溶瘤病毒基因组内的治疗基因的核酸,其中治疗基因在病毒感染期间的表达引起肿瘤细胞的死亡。特别地,本文公开了重组病毒载体,该重组病毒载体包含编码第二线粒体衍生的胱天蛋白酶激活剂(Smac)蛋白(也被称为DIABLO)的核酸,该第二线粒体衍生的胱天蛋白酶激活剂(Smac)蛋白特异性地结合至凋亡抑制蛋白(IAP)的至少一部分。编码Smac的核酸作为基因盒被插入在RNA病毒基因组内,以在病毒感染期间表达Smac蛋白。在一些情况下,Smac蛋白是全长Smac蛋白。在一些情况下,Smac蛋白缺乏线粒体靶向序列(Δ55Smac)。在一些情况下,RNA病毒基因组还包含表达微RNA-155的盒。
在一些实施方案中,病毒是非节段负链RNA病毒(NNSV)。在一些实施方案中,病毒是在哺乳动物中传播的单股负链病毒目(order of Mononegavirales)中的任何病毒。
在一些实施方案中,病毒是在哺乳动物中传播的弹状病毒科(family ofrhabdoviridae)中的任何病毒。例如,在一些实施方案中,病毒是水疱病毒属(Vesiculovirus)中的任何病毒。在一些情况下,病毒包含水疱性口炎病毒(VSV)(印第安纳水疱病毒(Indiana vesiculovirus))。
在一些实施方案中,病毒是在哺乳动物中传播的副粘病毒科(family ofparamyxoviridae)中的任何病毒。例如,在一些实施方案中,病毒是亨尼帕病毒属(Henipavirus)中的任何病毒。在一些实施方案中,病毒是麻疹病毒属(Morbillivirus)中的任何病毒。在一些实施方案中,病毒是呼吸道病毒属(Respirovirus)中的任何病毒。在一些实施方案中,病毒是腮腺炎病毒属(Rubulavirus)中的任何病毒。
在一些情况下,溶瘤病毒包含水疱性口炎病毒(VSV)。在一些情况下,病毒包含麻疹病毒(MV)。在一些情况下,病毒包含流感病毒(IFV)。在一些实施方案中,病毒是正链RNA病毒(PSV),诸如小核糖核酸病毒(picornavirus)或α病毒(alphaviruses)。在一些情况下,病毒包含脊髓灰质炎病毒(PV)。在一些情况下,病毒包含柯萨奇病毒(CV)。在一些情况下,病毒包含辛德比斯病毒(Sindbis virus)(SINV)。
smac基因可以被插入病毒基因组中的任何地方,只要它被表达。在优选的实施方案中,smac基因被插入,使得其表达被延迟直到病毒复制之后。VSV基因组包含核蛋白(N)基因、磷蛋白(P)基因、基质蛋白(M)基因、糖蛋白(G)基因和大(L)聚合酶蛋白。VSV基因的mRNA水平在VSV感染中从N基因(接近3’末端)下降至L基因(接近5’末端)。N蛋白和P蛋白是用于支持病毒复制所需的,而M蛋白是用于病毒组装所需的。因此,在一些实施方案中,smac基因在N基因、P基因和M基因之后被插入到VSV基因组中,使得Smac仅当病毒产生被良好地建立时达到显著水平。在一些情况下,smac基因被插入在来自单股负链病毒目的病毒中的M基因之后。其他病毒基因组内的可比位置可以被确定并且被用于所公开的载体中。
在一些实施方案中,Smac蛋白包含全长Smac蛋白。例如,在一些实施方案中,Smac蛋白包含氨基酸序列SEQ ID NO:1,或其保守变体,所述保守变体特异性地结合IAP。在其他实施方案中,Smac蛋白缺乏线粒体靶向序列。例如,在一些实施方案中,Smac蛋白包含氨基酸序列SEQ ID NO:2,或其变体,所述变体特异性地结合IAP。
当病毒在病毒进入期间被暴露于内体中的低pH时,VSV糖蛋白(G)负责附着至宿主受体并且诱导膜融合。在一些实施方案中,靶向结构域被插入到G蛋白中,使得修饰的G蛋白可以将VSV靶向癌症。例如,靶向蛋白质结构域可以是长度为六个氨基酸或更少的蛋白质序列,该蛋白质序列可以选择性地结合在癌细胞的表面上显示的蛋白质。αv整联蛋白和整联蛋白a5β1识别其相应的配体上的RGD序列。因此,在一些实施方案中,靶向序列包含结合整联蛋白(integrin protein)的RGD序列。因此,在一些实施方案中,VSV G蛋白具有氨基酸序列SEQ ID NO:6。
在一些实施方案中,重组载体包含核酸序列SEQ ID NO:8、9、10、或11,或者其变体,该变体产生在癌细胞中感染的病毒颗粒并且产生结合IAP的Smac蛋白。
还公开了细胞,所述细胞包含所公开的重组载体。还公开了重组病毒颗粒,所述重组病毒颗粒包含所公开的重组载体。还公开了组合物,所述组合物包含在药学上可接受的赋形剂中的所公开的重组病毒颗粒。
本文还公开了治疗患有肿瘤的受试者的方法,所述方法包括向受试者施用有效量的包含所公开的重组病毒颗粒的组合物。所公开的方法可以用于治疗多种肿瘤,包括卵巢肿瘤、肝脏肿瘤、胰腺肿瘤、乳腺肿瘤、肺肿瘤、胃肿瘤和脑肿瘤。
本发明的一种或更多种实施方案的细节在以下的附图和描述中阐述。本发明的其他特征、目标和优点将从说明书和附图,以及从权利要求而明显。
附图说明
图1A是示出了Smac插入物在最初编码五个病毒基因的VSV基因组中的位置的图。图1B示出了用于侧接Smac插入物的序列(示出了第一Met和终止密码子)。CT在3’末端处作为另外的基因连接被添加。
图2示出了在HeLa细胞中生长至相似的滴度(MOI=0.01)的wt VSV和VSV-S。
图3示出了VSV-S和wt VSV感染的HeLa细胞的蛋白印迹分析。
图4A示出了,在感染24小时之后,大多数T-47D细胞被表达mCherryP的wt VSV感染(红色荧光,右上图),但是没有死亡。图4B示出了,在感染48小时之后,超过60%的T-47D细胞被VSV-S杀死,而大多数细胞从被wt VSV感染中存活。
图5A描绘了Panc02模型中的肿瘤生长。图5B描绘了在9天结束时肿瘤重量的差异。
图6A示出了犬肛门囊癌的wt VSV(红色)感染的组织的成像。(B)PARP的裂解产物(绿色染色)示出了,与wt VSV相比,VSV-S诱导增强的凋亡。
图7A示出了G表达的蛋白印迹分析。图7B包含示出G诱导的细胞合胞体的图像。将核用DAPI染色。
详细描述
定义
术语“癌症”或“恶性赘生物”指的是显示出不受控制的生长、对相邻组织的侵袭以及经常转移至身体的其他部位的细胞。
术语“肿瘤”指的是含有赘生性细胞的异常组织块。
术语“转移”指的是恶性肿瘤细胞从一个器官或部分扩散到另一个不相邻的器官或部分。癌细胞可以从原发性肿瘤中“脱离”、“泄漏”或“溢出”,进入淋巴管和血管,通过血流循环,并且在身体中的其他地方的正常组织内安定下来生长。当肿瘤细胞转移时,新的肿瘤被称为继发性或转移性癌症或肿瘤。
如本文中所使用的,术语“载体”指的是被设计成用于转导/转染一种或更多种细胞类型的多核苷酸构建体。载体可以是,例如,被设计成用于分离、繁殖和复制所插入的核苷酸的“克隆载体”,被设计成用于在宿主细胞中表达核苷酸序列的“表达载体”,或被设计成导致产生重组病毒或病毒样颗粒的“病毒载体”,或者包含多于一种类型的载体的属性的“穿梭载体”。
在本文中可互换使用的术语“多核苷酸”和“核酸”指的是任何长度的核苷酸的聚合形式,核糖核苷酸或脱氧核糖核苷酸。
术语“受试者”指的是作为施用或治疗的靶的任何个体。受试者可以是脊椎动物,例如哺乳动物。因此,受试者可以是人类或兽医患者。术语“患者”指的是在临床医师例如内科医师的治疗下的受试者。
术语“治疗有效”指的是所使用的组合物的量是改善疾病或紊乱的一种或更多种病因或症状的足够量。这样的改善只需要减少或改变,不一定消除。
术语“药学上可接受的”指的是在合理的医疗判断的范围内,适合用于与人类和动物的组织接触而没有过度的毒性、刺激、过敏响应或与合理的益处/风险比相称的其他问题或并发症的那些化合物、材料、组合物和/或剂型。
术语“载体”意指当与化合物或组合物组合时,有助于或有利于化合物或组合物的制备、储存、施用、递送、有效性、选择性或任何其他特征以用于其预期的用途或目的的化合物、组合物、物质或结构。例如,载体可以被选择成使活性成分的任何降解最小化并且使受试者的任何不利副作用最小化。
术语“治疗”指的是意图治愈、改善、稳定或预防疾病、病理学状况或紊乱而对患者的医疗管理。该术语包括积极治疗,即专门针对疾病、病理学状况或紊乱的改善的治疗,并且还包括病因治疗,即针对相关的疾病、病理学状况或紊乱的病因的消除的治疗。此外,该术语包括姑息治疗,即被设计成用于缓解症状而不是治愈疾病、病理学状况或紊乱的治疗;预防性治疗,即旨在最小化或者部分地或完全地抑制相关的疾病、病理学状况或紊乱的发展的治疗;以及支持性治疗,即用于补充针对相关的疾病、病理学状况或紊乱的改善的另一种特定疗法的治疗。
术语“抑制”指的是活性、响应、状况、疾病或其他生物学参数的降低。这可以包括但不限于活性、响应、状况或疾病的完全消除。这还可以包括,例如,与天然水平或对照水平相比,活性、响应、状况或疾病的10%降低。因此,与天然水平或对照水平相比,降低可以是10%、20%、30%、40%、50%、60%、70%、80%、90%、100%,或其间的任何降低量。
术语“变体”指的是具有保守氨基酸取代、非保守氨基酸取代(即简并变体)、编码氨基酸的每个密码子(即DNA和RNA)的摆动位置内的取代、添加至肽的C-末端的氨基酸、或与参考序列具有60%、70%、80%、90%、95%、96%、97%、98%或99%序列同一性的肽的氨基酸或肽序列。
如本文中所使用的,术语“重组”指的是已经通过基因工程、通过对在病毒中发现的遗传材料的修饰或操纵被改变使得其与天然存在的病毒或病毒的天然存在的变体不同的病毒。
重组载体
本文公开了重组病毒载体,所述重组病毒载体包含编码被插入在RNA病毒基因组内的第二线粒体衍生的胱天蛋白酶激活剂(smac)蛋白的核酸(Smac基因)。
第二线粒体衍生的胱天蛋白酶激活剂(Smac)
在一些实施方案中,由所公开的病毒载体编码的Smac蛋白可以是Smac的任何天然、突变体或片段,该Smac特异性地结合至凋亡抑制蛋白(IAP)的至少一部分。
在一些实施方案中,Smac蛋白是全长天然蛋白,诸如人Smac。因此,在一些实施方案中,Smac蛋白具有氨基酸序列
MAALKSWLSRSVTSFFRYRQCLCVPVVANFKKRCFSELIRPWHKTVTIGFGVTLCAVPIAQKSEPHSLSSEALMRRAVSLVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKMNSEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED(SEQ ID NO:1),或其保守变体,所述保守变体特异性地结合IAP。
在其他实施方案中,Smac蛋白缺乏线粒体靶向序列(MTS),例如全长Smac的N-末端55个氨基酸。因此,在一些实施方案中,Smac蛋白包含氨基酸序列
AVPIAQKSEPHSLSSEALMRRAVSLVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKMNSEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED(SEQ ID NO:2),或其保守变体,所述保守变体特异性地结合IAP。
Smac的共有IAP结合基序例如在Alnemri的US 2002/0160975中被描述,US 2002/0160975通过引用关于结合IAP的氨基酸序列的教导被并入。因此,在一些实施方案中,Smac蛋白包含至少IAP结合基序,该IAP结合基序具有氨基酸序列Ala-Xaa1-Xaa2-Xaa3(SEQ IDNO:3),其中Xaa1是Val、Thr、或Ile;Xaa2是Pro或Ala;以及Xaa3是非极性氨基酸残基或不带电荷的极性氨基酸残基(例如Gly、Ala、Val、Leu、Ile、Pro、Ser、Thr、Cys、Met、Asn、或Gln)。
微RNA-155
在一些情况下,RNA病毒基因组还包含表达微RNA-155的盒。在抗肿瘤免疫中,树突状细胞(DC)捕获、加工肿瘤抗原并将肿瘤抗原呈递至T细胞,这引发杀肿瘤响应。然而,DC由于其暴露于肿瘤微环境(TME)而经常功能失调,这导致肿瘤逃脱免疫监视。加强微RNA-155(miR-155)的表达可以显著地改善基于DC的免疫疗法对乳腺癌的功效。在一些实施方案中,miR-155盒被放置在Smac和G之间。在一些实施方案中,用于人miR-155的核酸序列是CTGTTAATGCTAATCGTGATAGGGGTTTTTGCCTCCAACTGACTCCTACATATTAGCATTAACAG(SEQ ID NO:7)。
RNA病毒
在一些实施方案中,所公开的病毒可以是能够在分裂细胞(例如癌细胞)中更有选择性的复制而在非分裂细胞(例如正常细胞)中复制更少或不复制的任何天然的或修饰的病毒。由于所感染的分裂细胞通过裂解被破坏,所以它们可以在一些情况下释放新的感染性病毒颗粒以感染周围的分裂细胞。许多病毒(包括腺病毒、呼肠孤病毒、麻疹、单纯疱疹、新城疫病毒(NDV)、水疱性口炎病毒、脊髓灰质炎病毒、柯萨奇病毒和牛痘)现在已经作为溶瘤剂被临床测试。
一些病毒是天然溶瘤的(诸如呼肠孤病毒和塞内卡谷小核糖核酸病毒(Senecavalley picornavirus)),而其他病毒通过修饰病毒基因组被工程化用于肿瘤选择性。这样的修饰包括必需病毒基因的功能缺失,使用肿瘤特异性启动子或组织特异性启动子来控制病毒基因表达,以及趋向性修饰以将病毒重定向至癌细胞表面。
水疱性口炎病毒(VSV)
在一些实施方案中,病毒从水疱性口炎病毒(VSV)中获得。重组VSV例如在Russell等人的美国专利号9,428,736中被描述,该专利通过引用关于制备和使用VSV载体和颗粒的方法的教导被并入。
VSV是仅包含5个基因的负链病毒,其优先地在永生化细胞和恶性细胞中复制,最终诱导凋亡。VSV在肿瘤细胞或恶性细胞中繁殖的能力已经被报道部分地发生于有缺陷的干扰素(IFN)系统。由于IFN系统在正常细胞中是功能性的,所以阻止了作为IFN-敏感的病毒的VSV的有效复制。基于体外观察结果和体内观察结果,已经证实VSV有效地在感染的癌细胞中复制并且裂解感染的癌细胞,同时使正常细胞相对地不受影响。
与目前在肿瘤疗法中使用的其他病毒递送系统诸如腺病毒和逆转录病毒相比,使用VSV作为溶瘤剂具有若干个优点。首先,VSV没有已知的转化能力。VSV不是基因减毒的,这影响复制并且因此影响溶瘤的抗肿瘤活性。VSV的包膜糖蛋白(G)对许多细胞类型是高度趋向性的,并且应该有效靶向体内的多种组织。VSV似乎能够在各种各样的致瘤细胞中复制,而不仅仅例如在选择性肿瘤抑制基因诸如p53有缺陷的细胞中复制。VSV能够在具有Ras、Myc和p53途径的缺陷的肿瘤中有效地发挥其溶瘤活性,在所有肿瘤的超过90%中发生细胞畸变。VSV可以通过基因工程被修饰,以包含被设计成增加VSV的抗肿瘤活性的免疫调节和/或自杀盒。
VSV(弹状病毒科(Rhabdoviridae family)的成员)是负链病毒,该负链病毒在感染的细胞的细胞质中复制,不经历基因重组或重配,没有已知的转化潜力,并且不将其基因组的任何部分整合到宿主内。VSV包含约11千碱基基因组,该基因组编码五种蛋白质,该五种蛋白质被称为核衣壳蛋白(N)、聚合酶蛋白(L)和聚合酶蛋白(P)、表面糖蛋白(G)和外周基质蛋白(M)。基因组被紧密地包裹在核衣壳蛋白(N)中,并且还包含聚合酶蛋白(L)和聚合酶蛋白(P)。在细胞的感染之后,聚合酶蛋白启动来自编码病毒蛋白的负链基因组(negative-sense genome)的五个亚基因组病毒mRNA的转录。聚合酶蛋白也负责被包装成子代病毒体的全长病毒基因组的复制。基质(M)蛋白与RNA基因组/核衣壳芯(RNP)结合,并且还与糖基化的(G)蛋白结合,该糖基化的(G)蛋白从外表面以一系列尖峰样突起延伸,并且负责与细胞表面受体结合并启动感染过程。
在VSV通过(G)蛋白附着至宿主表面上的受体之后,病毒穿透宿主并且脱壳(uncoat)以释放RNP颗粒。病毒随身携带的聚合酶蛋白结合至基因组的3’末端,并且依次合成编码N、P、M、G和L的个体mRNA,随后是负链子代基因组。新合成的N蛋白、P蛋白和L蛋白在细胞质中缔合并且形成RNP芯,该RNP芯结合至富含M蛋白和G蛋白两者的质膜的区域。病毒颗粒形成,并且接着发生子代病毒的出芽(budding)或释放。
当病毒在病毒进入期间被暴露于内体中的低pH时,VSV糖基化的(G)蛋白负责附着至宿主受体并且诱导膜融合。因此,在一些实施方案中,靶向结构域被插入到G蛋白中,使得修饰的G可以将VSV靶向癌症。已经针对融合前(中性pH)形式和融合后(低pH)形式两者确定了G蛋白的晶体结构。NJ品系的191(IND品系的190)处的位点允许插入六个氨基酸肽。因此,在一些实施方案中,靶向结构域被插入在G蛋白的此位点处。该位点在C-末端侧具有Gly。因此,在一些实施方案中,将柔性接头(linker)添加至N-末端侧,以允许更大的柔性。
在一些实施方案中,靶向蛋白质结构域是长度为六个氨基酸或更少的任何蛋白质序列,该蛋白质序列可以选择性地结合在癌细胞的表面上显示的蛋白质。RGD是以高亲和力结合整联蛋白诸如整联蛋白αvβ3的序列,并且它可以例如用合适的接头被插入在IND G蛋白的190位点处。在一些实施方案中,靶向蛋白质结构域是长度为六个氨基酸或更少的任何蛋白质序列,该蛋白质序列包含RGD氨基酸序列。在一些实施方案中,插入在G蛋白中的靶向蛋白质结构域是GRGDS(SEQ ID NO:4)。
VSV G蛋白可以具有氨基酸序列:
MKCLLYLAFLFIGVNCKFTIVFPHNRKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKSHKAIQADGWMCHASKWVTTCDFRWYGPEYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAAIVQVTPHHVLVDEYTGEWVDSQFINGKCSNDICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGDKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPVFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDETLFFGDTGLSKNPIEFVEGWFSSWKSSIASFCFIIGLIIGLFLVLRVGIYLCIKLKHTKKRQIYTDIEMNRLGK(SEQ ID NO:5)。
因此,在一些实施方案中,使用了修饰的VSV G蛋白,该修饰的VSV G蛋白具有氨基酸序列:
MKCLLYLAFLFIGVNCKFTIVFPHNRKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKSHKAIQADGWMCHASKWVTTCDFRWYGPEYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAAIVQVTPHHVLVDEYTGEWVDSQFINGKCSNDICPTVHNSTTWHSDYKVKGRGDSGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGDKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPVFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDETLFFGDTGLSKNPIEFVEGWFSSWKSSIASFCFIIGLIIGLFLVLRVGIYLCIKLKHTKKRQIYTDIEMNRLGK(SEQ IDNO:6)。
任何VSV的品系(包括VSV的突变体)可以用于所公开的载体中。VSV基因组的完整核苷酸和推断的蛋白质序列是已知的,并且作为Genbank VSVCG可获得,登录号JO2428;NCBI Seq ID 335873;并且被公布在Rose和Schubert,1987,in The Viruses:TheRhabdoviruses,Plenum Press,NY.第129-166页。VSV品系的完整序列在美国专利号6,168,943中示出。VSV新泽西品系从美国典型培养物保藏中心(the American Type CultureCollection)(ATCC)可获得,并且具有ATCC登录号VR-159。VSV印第安纳品系从ATCC可获得,并且具有ATCC登录号VR-1421。
在一些实施方案中,重组病毒载体包含核酸序列
acgaagacaaacaaaccattattatcattaaaaggctcaggagaaactttaacagtaatcaaaatgtctgttacagtcaagagaatcattgacaacacagtcatagttccaaaacttcctgcaaatgaggatccagtggaatacccggcagattacttcagaaaatcaaaggagattcctctttacatcaatactacaaaaagtttgtcagatctaagaggatatgtctaccaaggcctcaaatccggaaatgtatcaatcatacatgtcaacagctacttgtatggagcattaaaggacatccggggtaagttggataaagattggtcaagtttcggaataaacatcgggaaagcaggggatacaatcggaatatttgaccttgtatccttgaaagccctggacggcgtacttccagatggagtatcggatgcttccagaaccagcgcagatgacaaatggttgcctttgtatctacttggcttatacagagtgggcagaacacaaatgcctgaatacagaaaaaagctcatggatgggctgacaaatcaatgcaaaatgatcaatgaacagtttgaacctcttgtgccagaaggtcgtgacatttttgatgtgtggggaaatgacagtaattacacaaaaattgtcgctgcagtggacatgttcttccacatgttcaaaaaacatgaatgtgcctcgttcagatacggaactattgtttccagattcaaagattgtgctgcattggcaacatttggacacctctgcaaaataaccggaatgtctacagaagatgtaacgacctggatcttgaaccgagaagttgcagatgaaatggtccaaatgatgcttccaggccaagaaattgacaaggccgattcatacatgccttatttgatcgactttggattgtcttctaagtctccatattcttccgtcaaaaaccctgccttccacttctgggggcaattgacagctcttctgctcagatccaccagagcaaggaatgcccgacagcctgatgacattgaGTATACatctcttactacagcaggtttgttgtacgcttatgcagtaggatcctctgccgacttggcacaacagttttgtgttggagataacaaatacactccagatgatagtaccggaggattgacgactaatgcaccgccacaaggcagagatgtggtcgaatggctcggatggtttgaagatcaaaacagaaaaccgactcctgatatgatgcagtatgcgaaaagagcagtcatgtcactgcaaggcctaagagagaagacaattggcaagtatgctaagtcagaatttgacaaatgaccctataattctcagatcacctattatatattatgctacatatgaaaaaaactaacagatatcatggataatctcacaaaagttcgtgagtatctcaagtcctactctcgtctagatcaggcggtaggagagatagatgagatcgaagcacaacgagctgaaaagtccaattatgagttgttccaagaggacggagtggaagagcatactaggccctcttattttcaggcagcagatgattctgacacagaatctgaaccagaaattgaagacaatcaaggcttgtatgtaccagatccggaagctgagcaagttgaaggctttatacaggggcctttagatgactatgcagatgaggacgtggatgttgtattcacttcggactggaaacagcctgagcttgaatccgacgagcatggaaagaccttacggttgacattgccagagggtttaagtggagagcagaaatcccagtggcttttgacgattaaagcagtcgttcaaagtgccaaacactggaatctggcagagtgcacatttgaagcatcgggagaaggggtcatcataaaaaagcgccagataactccggatgtatataaggtcactccagtgatgaacacacatccgtaccaatcagaagccgtatcagatgtttggtctctctcaaagacatccatgactttccaacccaagaaagcaagtcttcagcctctcaccatatccttggatgaattgttctcatctagaggagaattcatctctgtcggaggtaacggacgaatgtctcataaagaggccatcctgctcggtctgaggtacaaaaagttgtacaatcaggcgagagtcaaatattctctgtagactatgaaaaaaagtaacagatatcacaatctaagtgttatcccaatccattcatcatgagttccttaaagaagattctcggtctgaaggggaaaggtaagaaatctaagaaattagggatcgcaccacccccttatgaagaggacactagcatggagtatgctccgagcgctccaattgacaaatcctattttggagttgacgagatggacacctatgatccgaatcaattaagatatgagaaattcttctttacagtgaaaatgacggttagatctaatcgtccgttcagaacatactcagatgtggcagccgctgtatcccattgggatcacatgtacatcggaatggcagggaaacgtcccttctacaaaatcttggcttttttgggttcttctaatctaaaggccactccagcggtattggcagatcaaggtcaaccagagtatcacgctcactgcgaaggcagggcttatttgccacataggatggggaagacccctcccatgctcaatgtaccagagcacttcagaagaccattcaatataggtctttacaagggaacgattgagctcacaatgaccatctacgatgatgagtcactggaagcagctcctatgatctgggatcatttcaattcttccaaattttctgatttcagagagaaggccttaatgtttggcctgattgtcgagaaaaaggcatctggagcgtgggtcctggattctatcagccacttcaaatgagctagtctagcttccagcttctgaacaatccccggtttactcagtctctcctaattccagcctttcgaacaactaatatcctgtcttttctATCCCTATGAAAAAAACTAACAGATCTCGAGATGgcggctctgaagagttggctgtcgcgcagcgtaacttcattcttcaggtacagacagtgtttgtgtgttcctgttgtggctaactttaagaagcggtgtttctcagaattgataagaccatggcacaaaactgtgacgattggctttggagtaaccctgtgtGCGGTTCCTATTGCACAGAAATCAGAGCCTCATTCCCTTAGTAGTGAAGCATTGATGAGGAGAGCAGTGTCTTTGGTAACAGATAGCACCTCTACCTTTCTCTCTCAGACCACATATGCGTTGATTGAAGCTATTACTGAATATACTAAGGCTGTTTATACCTTAACTTCTCTTTACCGACAATATACAAGTTTACTTGGGAAAATGAATTCAGAGGAGGAAGATGAAGTGTGGCAGGTGATCATAGGAGCCAGAGCTGAGATGACTTCAAAACACCAAGAGTACTTGAAGCTGGAAACCACTTGGATGACTGCAGTTGGTCTTTCAGAGATGGCAGCAGAAGCTGCATATCAAACTGGCGCAGATCAGGCCTCTATAACCGCCAGGAATCACATTCAGCTGGTGAAACTGCAGGTGGAAGAGGTGCACCAGCTCTCCCGGAAAGCAGAAACCAAGCTGGCAGAAGCACAGATAGAAGAGCTCCGTCAGAAAACACAGGAGGAAGGGGAGGAGCGGGCTGAGTCGGAGCAGGAGGCCTACCTGCGTGAGGATTGACTCGAGTATATTTTAATTTTTAATTTTTATGAAAAAAACTAacagagatcgatctgtttccttgacaccatgaagtgccttttgtacttagcttttttattcatcggggtgaattgcaagttcaccatagtttttccacacaaccgaaaaggaaactggaaaaatgttccttccaattaccattattgcccgtcaagctcagatttaaattggcataatgacttaataggcacagccttacaagtcaaaatgcccaagagtcacaaggctattcaagcagacggttggatgtgtcatgcttccaaatgggtcactacttgtgatttccgctggtacggaccggagtatataacacattccatccgatccttcactccatctgtagaacaatgcaaggaaagcattgaacaaacgaaacaaggaacttggctgaatccaggcttccctcctcaaagttgtggatatgcaactgtgacggatgctgaagcagcgattgtccaggtgactcctcaccatgtgcttgttgatgaatacacaggagaatgggttgattcacagttcatcaacggaaaatgcagcaatgacatatgccccactgtccataactccacaacctggcattccgactataaggtcaaagggctatgtgattctaacctcatttccatggacatcaccttcttctcagaggacggagagctatcatcCCTAGGaaaggagggcacagggttcagaagtaactactttgcttatgaaactggagacaaggcctgcaaaatgcagtactgcaagcattggggagtcagactcccatcaggtgtctggttcgagatggctgataaggatctctttgctgcagccagattccctgaatgcccagaagggtcaagtatctctgctccatctcagacctcagtggatgtaagtctcattcaggacgttgagaggatcttggattattccctctgccaagaaacctggagcaaaatcagagcgggtcttcccatctctccagtggatctcagctatcttgctcctaaaaacccaggaaccggtcctgtctttaccataatcaatggtaccctaaaatactttgagaccagatacatcagagtcgatattgctgctccaatcctctcaagaatggtcggaatgatcagtggaactaccacagaaagggaactgtgggatgactgggctccatatgaagacgtggaaattggacccaatggagttctgaggaccagttcaggatataagtttcctttatatatgattggacatggtatgttggactccgatcttcatcttagctcaaaggctcaggtgtttgaacatcctcacattcaagacgctgcttcgcagcttcctgatgatgagactttattttttggtgatactgggctatccaaaaatccaatcgagtttgtagaaggttggttcagtagttggaagagctctattgcctctttttgctttatcatagggttaatcattggactattcttggttctccgagttggtatttatctttgcattaaattaaagcacaccaagaaaagacagatttatacagacatagagatgaaccgacttggaaagtaactcaaatcctgcacaacagattcttcatgtttgaaccaaatcaacttgtgatatcatgctcaaagaggccttaattatattttaatttttaatttttatgaaaaaaactaacagcaatcatggaagtccacgattttgagaccgacgagttcaatgatttcaatgaagatgactatgccacaagagaattcctgaatcccgatgagcgcatgacgtacttgaatcatgctgattacaatttgaattctcctctaattagtgatgatattgacaatttgatcaggaaattcaattctcttccgattccctcgatgtgggatagtaagaactgggatggagttcttgagatgttaacatcatgtcaagccaatcccatctcaacatctcagatgcataaatggatgggaagttggttaatgtctgataatcatgatgccagtcaagggtatagttttttacatgaagtggacaaagaggcagaaataacatttgacgtggtggagaccttcatccgcggctggggcaacaaaccaattgaatacatcaaaaaggaaagatggactgactcattcaaaattctcgcttatttgtgtcaaaagtttttggacttacacaagttgacattaatcttaaatgctgtctctgaggtggaattgctcaacttggcgaggactttcaaaggcaaagtcagaagaagttctcatggaacgaacatatgcaggattagggttcccagcttgggtcctacttttatttcagaaggatgggcttacttcaagaaacttgatattctaatggaccgaaactttctgttaatggtcaaagatgtgattatagggaggatgcaaacggtgctatccatggtatgtagaatagacaacctgttctcagagcaagacatcttctcccttctaaatatctacagaattggagataaaattgtggagaggcagggaaatttttcttatgacttgattaaaatggtggaaccgatatgcaacttgaagctgatgaaattagcaagagaatcaaggcctttagtcccacaattccctcattttgaaaatcatatcaagacttctgttgatgaaggggcaaaaattgaccgaggtataagattcctccatgatcagataatgagtgtgaaaacagtggatctcacactggtgatttatggatcgttcagacattggggtcatccttttatagattattacactggactagaaaaattacattcccaagtaaccatgaagaaagatattgatgtgtcatatgcaaaagcacttgcaagtgatttagctcggattgttctatttcaacagttcaatgatcataaaaagtggttcgtgaatggagacttgctccctcatgatcatccctttaaaagtcatgttaaagaaaatacatggcccacagctgctcaagttcaagattttggagataaatggcatgaacttccgctgattaaatgttttgaaatacccgacttactagacccatcgataatatactctgacaaaagtcattcaatgaataggtcagaggtgttgaaacatgtccgaatgaatccgaacactcctatccctagtaaaaaggtgttgcagactatgttggacacaaaggctaccaattggaaagaatttcttaaagagattgatgagaagggcttagatgatgatgatctaattattggtcttaaaggaaaggagagggaactgaagttggcaggtagatttttctccctaatgtcttggaaattgcgagaatactttgtaattaccgaatatttgataaagactcatttcgtccctatgtttaaaggcctgacaatggcggacgatctaactgcagtcattaaaaagatgttagattcctcatccggccaaggattgaagtcatatgaggcaatttgcatagccaatcacattgattacgaaaaatggaataaccaccaaaggaagttatcaaacggcccagtgttccgagttatgggccagttcttaggttatccatccttaatcgagagaactcatgaattttttgagaaaagtcttatatactacaatggaagaccagacttgatgcgtgttcacaacaacacactgatcaattcaacctcccaacgagtttgttggcaaggacaagagggtggactggaaggtctacggcaaaaaggatggagtatcctcaatctactggttattcaaagagaggctaaaatcagaaacactgctgtcaaagtcttggcacaaggtgataatcaagttatttgcacacagtataaaacgaagaaatcgagaaacgttgtagaattacagggtgctctcaatcaaatggtttctaataatgagaaaattatgactgcaatcaaaatagggacagggaagttaggacttttgataaatgacgatgagactatgcaatctgcagattacttgaattatggaaaaataccgattttccgtggagtgattagagggttagagaccaagagatggtcacgagtgacttgtgtcaccaatgaccaaatacccacttgtgctaatataatgagctcagtttccacaaatgctctcaccgtagctcattttgctgagaacccaatcaatgccatgatacagtacaattattttgggacatttgctagactcttgttgatgatgcatgatcctgctcttcgtcaatcattgtatgaagttcaagataagataccgggcttgcacagttctactttcaaatacgccatgttgtatttggacccttccattggaggagtgtcgggcatgtctttgtccaggtttttgattagagccttcccagatcccgtaacagaaagtctctcattctggagattcatccatgtacatgctcgaagtgagcatctgaaggagatgagtgcagtatttggaaaccccgagatagccaagtttcgaataactcacatagacaagctagtagaagatccaacctctctgaacatcgctatgggaatgagtccagcgaacttgttaaagactgaggttaaaaaatgcttaatcgaatcaagacaaaccatcaggaaccaggtgattaaggatgcaaccatatatttgtatcatgaagaggatcggctcagaagtttcttatggtcaataaatcctctgttccctagatttttaagtgaattcaaatcaggcacttttttgggagtcgcagacgggctcatcagtctatttcaaaattctcgtactattcggaactcctttaagaaaaagtatcatagggaattggatgatttgattgtgaggagtgaggtatcctctttgacacatttagggaaacttcatttgagaaggggatcatgtaaaatgtggacatgttcagctactcatgctgacacattaagatacaaatcctggggccgtacagttattgggacaactgtaccccatccattagaaatgttgggtccacaacatcgaaaagagactccttgtgcaccatgtaacacatcagggttcaattatgtttctgtgcattgtccagacgggatccatgacgtctttagttcacggggaccattgcctgcttatctagggtctaaaacatctgaatctacatctattttgcagccttgggaaagggaaagcaaagtcccactgattaaaagagctacacgtcttagagatgctatctcttggtttgttgaacccgactctaaactagcaatgactatactttctaacatccactctttaacaggcgaagaatggaccaaaaggcagcatgggttcaaaagaacagggtctgcccttcataggttttcgacatctcggatgagccatggtgggttcgcatctcagagcactgcagcattgaccaggttgatggcaactacagacaccatgagggatctgggagatcagaatttcgactttttattccaagcaacgttgctctatgctcaaattaccaccactgttgcaagagacggatggatcaccagttgtacagatcattatcatattgcctgtaagtcctgtttgagacccatagaagagatcaccctggactcaagtatggactacacgcccccagatgtatcccatgtgctgaagacatggaggaatggggaaggttcgtggggacaagagataaaacagatctatcctttagaagggaattggaagaatttagcacctgctgagcaatcctatcaagtcggcagatgtataggttttctatatggagacttggcgtatagaaaatctactcatgccgaggacagttctctatttcctctatctatacaaggtcgtattagaggtcgaggtttcttaaaagggttgctagacggattaatgagagcaagttgctgccaagtaatacaccggagaagtctggctcatttgaagaggccggccaacgcagtgtacggaggtttgatttacttgattgataaattgagtgtatcacctccattcctttctcttactagatcaggacctattagagacgaattagaaacgattccccacaagatcccaacctcctatccgacaagcaaccgtgatatgggggtgattgtcagaaattacttcaaataccaatgccgtctaattgaaaagggaaaatacagatcacattattcacaattatggttattctcagatgtcttatccatagacttcattggaccattctctatttccaccaccctcttgcaaatcctatacaagccatttttatctgggaaagataagaatgagttgagagagctggcaaatctttcttcattgctaagatcaggagaggggtgggaagacatacatgtgaaattcttcaccaaggacatattattgtgtccagaggaaatcagacatgcttgcaagttcgggattgctaaggataataataaagacatgagctatcccccttggggaagggaatccagagggacaattacaacaatccctgtttattatacgaccaccccttacccaaagatgctagagatgcctccaagaatccaaaatcccctgctgtccggaatcaggttgggccaattaccaactggcgctcattataaaattcggagtatattacatggaatgggaatccattacagggacttcttgagttgtggagacggctccggagggatgactgctgcattactacgagaaaatgtgcatagcagaggaatattcaatagtctgttagaattatcagggtcagtcatgcgaggcgcctctcctgagccccccagtgccctagaaactttaggaggagataaatcgagatgtgtaaatggtgaaacatgttgggaatatccatctgacttatgtgacccaaggacttgggactatttcctccgactcaaagcaggcttggggcttcaaattgatttaattgtaatggatatggaagttcgggattcttctactagcctgaaaattgagacgaatgttagaaattatgtgcaccggattttggatgagcaaggagttttaatctacaagacttatggaacatatatttgtgagagcgaaaagaatgcagtaacaatccttggtcccatgttcaagacggtcgacttagttcaaacagaatttagtagttctcaaacgtctgaagtatatatggtatgtaaaggtttgaagaaattaatcgatgaacccaatcccgattggtcttccatcaatgaatcctggaaaaacctgtacgcattccagtcatcagaacaggaatttgccagagcaaagaaggttagtacatactttaccttgacaggtattccctcccaattcattcctgatccttttgtaaacattgagactatgctacaaatattcggagtacccacgggtgtgtctcatgcggctgccttaaaatcatctgatagacctgcagatttattgaccattagccttttttatatggcgattatatcgtattataacatcaatcatatcagagtaggaccgatacctccgaaccccccatcagatggaattgcacaaaatgtggggatcgctataactggtataagcttttggctgagtttgatggagaaagacattccactatatcaacagtgtttggcagttatccagcaatcatttccgattaggtgggaggctatttcagtaaaaggaggatacaagcagaagtggagtactagaggtgatgggctcccaaaagatacccgaatttcagactccttggccccaatcgggaactggatcagatctttggaattggtccgaaaccaagttcgtctaaatccattcaataagatcttgttcaatcagctatgtcgtacagtggataatcatttgaagtggtcaaatttgcgaaaaaacacaggaatgattgaatggatcaatgggcgaatttcaaaagaagaccggtctatactgatgttgaagagtgacctacatgaggaaaactcttggagagattaaaaaatcaggaggagactccaaactttaagtatgaaaaaaactttgatccttaagaccctcttgtggtttttattttttatctggttttgtggtcttcgt(VSV-Smac,SEQ ID NO:8)。
在一些实施方案中,重组病毒载体包含核酸序列:
acgaagacaaacaaaccattattatcattaaaaggctcaggagaaactttaacagtaatcaaaatgtctgttacagtcaagagaatcattgacaacacagtcatagttccaaaacttcctgcaaatgaggatccagtggaatacccggcagattacttcagaaaatcaaaggagattcctctttacatcaatactacaaaaagtttgtcagatctaagaggatatgtctaccaaggcctcaaatccggaaatgtatcaatcatacatgtcaacagctacttgtatggagcattaaaggacatccggggtaagttggataaagattggtcaagtttcggaataaacatcgggaaagcaggggatacaatcggaatatttgaccttgtatccttgaaagccctggacggcgtacttccagatggagtatcggatgcttccagaaccagcgcagatgacaaatggttgcctttgtatctacttggcttatacagagtgggcagaacacaaatgcctgaatacagaaaaaagctcatggatgggctgacaaatcaatgcaaaatgatcaatgaacagtttgaacctcttgtgccagaaggtcgtgacatttttgatgtgtggggaaatgacagtaattacacaaaaattgtcgctgcagtggacatgttcttccacatgttcaaaaaacatgaatgtgcctcgttcagatacggaactattgtttccagattcaaagattgtgctgcattggcaacatttggacacctctgcaaaataaccggaatgtctacagaagatgtaacgacctggatcttgaaccgagaagttgcagatgaaatggtccaaatgatgcttccaggccaagaaattgacaaggccgattcatacatgccttatttgatcgactttggattgtcttctaagtctccatattcttccgtcaaaaaccctgccttccacttctgggggcaattgacagctcttctgctcagatccaccagagcaaggaatgcccgacagcctgatgacattgaGTATACatctcttactacagcaggtttgttgtacgcttatgcagtaggatcctctgccgacttggcacaacagttttgtgttggagataacaaatacactccagatgatagtaccggaggattgacgactaatgcaccgccacaaggcagagatgtggtcgaatggctcggatggtttgaagatcaaaacagaaaaccgactcctgatatgatgcagtatgcgaaaagagcagtcatgtcactgcaaggcctaagagagaagacaattggcaagtatgctaagtcagaatttgacaaatgaccctataattctcagatcacctattatatattatgctacatatgaaaaaaactaacagatatcatggataatctcacaaaagttcgtgagtatctcaagtcctactctcgtctagatcaggcggtaggagagatagatgagatcgaagcacaacgagctgaaaagtccaattatgagttgttccaagaggacggagtggaagagcatactaggccctcttattttcaggcagcagatgattctgacacagaatctgaaccagaaattgaagacaatcaaggcttgtatgtaccagatccggaagctgagcaagttgaaggctttatacaggggcctttagatgactatgcagatgaggacgtggatgttgtattcacttcggactggaaacagcctgagcttgaatccgacgagcatggaaagaccttacggttgacattgccagagggtttaagtggagagcagaaatcccagtggcttttgacgattaaagcagtcgttcaaagtgccaaacactggaatctggcagagtgcacatttgaagcatcgggagaaggggtcatcataaaaaagcgccagataactccggatgtatataaggtcactccagtgatgaacacacatccgtaccaatcagaagccgtatcagatgtttggtctctctcaaagacatccatgactttccaacccaagaaagcaagtcttcagcctctcaccatatccttggatgaattgttctcatctagaggagaattcatctctgtcggaggtaacggacgaatgtctcataaagaggccatcctgctcggtctgaggtacaaaaagttgtacaatcaggcgagagtcaaatattctctgtagactatgaaaaaaagtaacagatatcacaatctaagtgttatcccaatccattcatcatgagttccttaaagaagattctcggtctgaaggggaaaggtaagaaatctaagaaattagggatcgcaccacccccttatgaagaggacactagcatggagtatgctccgagcgctccaattgacaaatcctattttggagttgacgagatggacacctatgatccgaatcaattaagatatgagaaattcttctttacagtgaaaatgacggttagatctaatcgtccgttcagaacatactcagatgtggcagccgctgtatcccattgggatcacatgtacatcggaatggcagggaaacgtcccttctacaaaatcttggcttttttgggttcttctaatctaaaggccactccagcggtattggcagatcaaggtcaaccagagtatcacgctcactgcgaaggcagggcttatttgccacataggatggggaagacccctcccatgctcaatgtaccagagcacttcagaagaccattcaatataggtctttacaagggaacgattgagctcacaatgaccatctacgatgatgagtcactggaagcagctcctatgatctgggatcatttcaattcttccaaattttctgatttcagagagaaggccttaatgtttggcctgattgtcgagaaaaaggcatctggagcgtgggtcctggattctatcagccacttcaaatgagctagtctagcttccagcttctgaacaatccccggtttactcagtctctcctaattccagcctttcgaacaactaatatcctgtcttttctATCCCTATGAAAAAAACTAACAGATCTCGAGATGGCGGTTCCTATTGCACAGAAATCAGAGCCTCATTCCCTTAGTAGTGAAGCATTGATGAGGAGAGCAGTGTCTTTGGTAACAGATAGCACCTCTACCTTTCTCTCTCAGACCACATATGCGTTGATTGAAGCTATTACTGAATATACTAAGGCTGTTTATACCTTAACTTCTCTTTACCGACAATATACAAGTTTACTTGGGAAAATGAATTCAGAGGAGGAAGATGAAGTGTGGCAGGTGATCATAGGAGCCAGAGCTGAGATGACTTCAAAACACCAAGAGTACTTGAAGCTGGAAACCACTTGGATGACTGCAGTTGGTCTTTCAGAGATGGCAGCAGAAGCTGCATATCAAACTGGCGCAGATCAGGCCTCTATAACCGCCAGGAATCACATTCAGCTGGTGAAACTGCAGGTGGAAGAGGTGCACCAGCTCTCCCGGAAAGCAGAAACCAAGCTGGCAGAAGCACAGATAGAAGAGCTCCGTCAGAAAACACAGGAGGAAGGGGAGGAGCGGGCTGAGTCGGAGCAGGAGGCCTACCTGCGTGAGGATTGACTCGAGTATATTTTAATTTTTAATTTTTATGAAAAAAACTAacagagatcgatctgtttccttgacaccatgaagtgccttttgtacttagcttttttattcatcggggtgaattgcaagttcaccatagtttttccacacaaccgaaaaggaaactggaaaaatgttccttccaattaccattattgcccgtcaagctcagatttaaattggcataatgacttaataggcacagccttacaagtcaaaatgcccaagagtcacaaggctattcaagcagacggttggatgtgtcatgcttccaaatgggtcactacttgtgatttccgctggtacggaccggagtatataacacattccatccgatccttcactccatctgtagaacaatgcaaggaaagcattgaacaaacgaaacaaggaacttggctgaatccaggcttccctcctcaaagttgtggatatgcaactgtgacggatgctgaagcagcgattgtccaggtgactcctcaccatgtgcttgttgatgaatacacaggagaatgggttgattcacagttcatcaacggaaaatgcagcaatgacatatgccccactgtccataactccacaacctggcattccgactataaggtcaaagggctatgtgattctaacctcatttccatggacatcaccttcttctcagaggacggagagctatcatcCCTAGGaaaggagggcacagggttcagaagtaactactttgcttatgaaactggagacaaggcctgcaaaatgcagtactgcaagcattggggagtcagactcccatcaggtgtctggttcgagatggctgataaggatctctttgctgcagccagattccctgaatgcccagaagggtcaagtatctctgctccatctcagacctcagtggatgtaagtctcattcaggacgttgagaggatcttggattattccctctgccaagaaacctggagcaaaatcagagcgggtcttcccatctctccagtggatctcagctatcttgctcctaaaaacccaggaaccggtcctgtctttaccataatcaatggtaccctaaaatactttgagaccagatacatcagagtcgatattgctgctccaatcctctcaagaatggtcggaatgatcagtggaactaccacagaaagggaactgtgggatgactgggctccatatgaagacgtggaaattggacccaatggagttctgaggaccagttcaggatataagtttcctttatatatgattggacatggtatgttggactccgatcttcatcttagctcaaaggctcaggtgtttgaacatcctcacattcaagacgctgcttcgcagcttcctgatgatgagactttattttttggtgatactgggctatccaaaaatccaatcgagtttgtagaaggttggttcagtagttggaagagctctattgcctctttttgctttatcatagggttaatcattggactattcttggttctccgagttggtatttatctttgcattaaattaaagcacaccaagaaaagacagatttatacagacatagagatgaaccgacttggaaagtaactcaaatcctgcacaacagattcttcatgtttgaaccaaatcaacttgtgatatcatgctcaaagaggccttaattatattttaatttttaatttttatgaaaaaaactaacagcaatcatggaagtccacgattttgagaccgacgagttcaatgatttcaatgaagatgactatgccacaagagaattcctgaatcccgatgagcgcatgacgtacttgaatcatgctgattacaatttgaattctcctctaattagtgatgatattgacaatttgatcaggaaattcaattctcttccgattccctcgatgtgggatagtaagaactgggatggagttcttgagatgttaacatcatgtcaagccaatcccatctcaacatctcagatgcataaatggatgggaagttggttaatgtctgataatcatgatgccagtcaagggtatagttttttacatgaagtggacaaagaggcagaaataacatttgacgtggtggagaccttcatccgcggctggggcaacaaaccaattgaatacatcaaaaaggaaagatggactgactcattcaaaattctcgcttatttgtgtcaaaagtttttggacttacacaagttgacattaatcttaaatgctgtctctgaggtggaattgctcaacttggcgaggactttcaaaggcaaagtcagaagaagttctcatggaacgaacatatgcaggattagggttcccagcttgggtcctacttttatttcagaaggatgggcttacttcaagaaacttgatattctaatggaccgaaactttctgttaatggtcaaagatgtgattatagggaggatgcaaacggtgctatccatggtatgtagaatagacaacctgttctcagagcaagacatcttctcccttctaaatatctacagaattggagataaaattgtggagaggcagggaaatttttcttatgacttgattaaaatggtggaaccgatatgcaacttgaagctgatgaaattagcaagagaatcaaggcctttagtcccacaattccctcattttgaaaatcatatcaagacttctgttgatgaaggggcaaaaattgaccgaggtataagattcctccatgatcagataatgagtgtgaaaacagtggatctcacactggtgatttatggatcgttcagacattggggtcatccttttatagattattacactggactagaaaaattacattcccaagtaaccatgaagaaagatattgatgtgtcatatgcaaaagcacttgcaagtgatttagctcggattgttctatttcaacagttcaatgatcataaaaagtggttcgtgaatggagacttgctccctcatgatcatccctttaaaagtcatgttaaagaaaatacatggcccacagctgctcaagttcaagattttggagataaatggcatgaacttccgctgattaaatgttttgaaatacccgacttactagacccatcgataatatactctgacaaaagtcattcaatgaataggtcagaggtgttgaaacatgtccgaatgaatccgaacactcctatccctagtaaaaaggtgttgcagactatgttggacacaaaggctaccaattggaaagaatttcttaaagagattgatgagaagggcttagatgatgatgatctaattattggtcttaaaggaaaggagagggaactgaagttggcaggtagatttttctccctaatgtcttggaaattgcgagaatactttgtaattaccgaatatttgataaagactcatttcgtccctatgtttaaaggcctgacaatggcggacgatctaactgcagtcattaaaaagatgttagattcctcatccggccaaggattgaagtcatatgaggcaatttgcatagccaatcacattgattacgaaaaatggaataaccaccaaaggaagttatcaaacggcccagtgttccgagttatgggccagttcttaggttatccatccttaatcgagagaactcatgaattttttgagaaaagtcttatatactacaatggaagaccagacttgatgcgtgttcacaacaacacactgatcaattcaacctcccaacgagtttgttggcaaggacaagagggtggactggaaggtctacggcaaaaaggatggagtatcctcaatctactggttattcaaagagaggctaaaatcagaaacactgctgtcaaagtcttggcacaaggtgataatcaagttatttgcacacagtataaaacgaagaaatcgagaaacgttgtagaattacagggtgctctcaatcaaatggtttctaataatgagaaaattatgactgcaatcaaaatagggacagggaagttaggacttttgataaatgacgatgagactatgcaatctgcagattacttgaattatggaaaaataccgattttccgtggagtgattagagggttagagaccaagagatggtcacgagtgacttgtgtcaccaatgaccaaatacccacttgtgctaatataatgagctcagtttccacaaatgctctcaccgtagctcattttgctgagaacccaatcaatgccatgatacagtacaattattttgggacatttgctagactcttgttgatgatgcatgatcctgctcttcgtcaatcattgtatgaagttcaagataagataccgggcttgcacagttctactttcaaatacgccatgttgtatttggacccttccattggaggagtgtcgggcatgtctttgtccaggtttttgattagagccttcccagatcccgtaacagaaagtctctcattctggagattcatccatgtacatgctcgaagtgagcatctgaaggagatgagtgcagtatttggaaaccccgagatagccaagtttcgaataactcacatagacaagctagtagaagatccaacctctctgaacatcgctatgggaatgagtccagcgaacttgttaaagactgaggttaaaaaatgcttaatcgaatcaagacaaaccatcaggaaccaggtgattaaggatgcaaccatatatttgtatcatgaagaggatcggctcagaagtttcttatggtcaataaatcctctgttccctagatttttaagtgaattcaaatcaggcacttttttgggagtcgcagacgggctcatcagtctatttcaaaattctcgtactattcggaactcctttaagaaaaagtatcatagggaattggatgatttgattgtgaggagtgaggtatcctctttgacacatttagggaaacttcatttgagaaggggatcatgtaaaatgtggacatgttcagctactcatgctgacacattaagatacaaatcctggggccgtacagttattgggacaactgtaccccatccattagaaatgttgggtccacaacatcgaaaagagactccttgtgcaccatgtaacacatcagggttcaattatgtttctgtgcattgtccagacgggatccatgacgtctttagttcacggggaccattgcctgcttatctagggtctaaaacatctgaatctacatctattttgcagccttgggaaagggaaagcaaagtcccactgattaaaagagctacacgtcttagagatgctatctcttggtttgttgaacccgactctaaactagcaatgactatactttctaacatccactctttaacaggcgaagaatggaccaaaaggcagcatgggttcaaaagaacagggtctgcccttcataggttttcgacatctcggatgagccatggtgggttcgcatctcagagcactgcagcattgaccaggttgatggcaactacagacaccatgagggatctgggagatcagaatttcgactttttattccaagcaacgttgctctatgctcaaattaccaccactgttgcaagagacggatggatcaccagttgtacagatcattatcatattgcctgtaagtcctgtttgagacccatagaagagatcaccctggactcaagtatggactacacgcccccagatgtatcccatgtgctgaagacatggaggaatggggaaggttcgtggggacaagagataaaacagatctatcctttagaagggaattggaagaatttagcacctgctgagcaatcctatcaagtcggcagatgtataggttttctatatggagacttggcgtatagaaaatctactcatgccgaggacagttctctatttcctctatctatacaaggtcgtattagaggtcgaggtttcttaaaagggttgctagacggattaatgagagcaagttgctgccaagtaatacaccggagaagtctggctcatttgaagaggccggccaacgcagtgtacggaggtttgatttacttgattgataaattgagtgtatcacctccattcctttctcttactagatcaggacctattagagacgaattagaaacgattccccacaagatcccaacctcctatccgacaagcaaccgtgatatgggggtgattgtcagaaattacttcaaataccaatgccgtctaattgaaaagggaaaatacagatcacattattcacaattatggttattctcagatgtcttatccatagacttcattggaccattctctatttccaccaccctcttgcaaatcctatacaagccatttttatctgggaaagataagaatgagttgagagagctggcaaatctttcttcattgctaagatcaggagaggggtgggaagacatacatgtgaaattcttcaccaaggacatattattgtgtccagaggaaatcagacatgcttgcaagttcgggattgctaaggataataataaagacatgagctatcccccttggggaagggaatccagagggacaattacaacaatccctgtttattatacgaccaccccttacccaaagatgctagagatgcctccaagaatccaaaatcccctgctgtccggaatcaggttgggccaattaccaactggcgctcattataaaattcggagtatattacatggaatgggaatccattacagggacttcttgagttgtggagacggctccggagggatgactgctgcattactacgagaaaatgtgcatagcagaggaatattcaatagtctgttagaattatcagggtcagtcatgcgaggcgcctctcctgagccccccagtgccctagaaactttaggaggagataaatcgagatgtgtaaatggtgaaacatgttgggaatatccatctgacttatgtgacccaaggacttgggactatttcctccgactcaaagcaggcttggggcttcaaattgatttaattgtaatggatatggaagttcgggattcttctactagcctgaaaattgagacgaatgttagaaattatgtgcaccggattttggatgagcaaggagttttaatctacaagacttatggaacatatatttgtgagagcgaaaagaatgcagtaacaatccttggtcccatgttcaagacggtcgacttagttcaaacagaatttagtagttctcaaacgtctgaagtatatatggtatgtaaaggtttgaagaaattaatcgatgaacccaatcccgattggtcttccatcaatgaatcctggaaaaacctgtacgcattccagtcatcagaacaggaatttgccagagcaaagaaggttagtacatactttaccttgacaggtattccctcccaattcattcctgatccttttgtaaacattgagactatgctacaaatattcggagtacccacgggtgtgtctcatgcggctgccttaaaatcatctgatagacctgcagatttattgaccattagccttttttatatggcgattatatcgtattataacatcaatcatatcagagtaggaccgatacctccgaaccccccatcagatggaattgcacaaaatgtggggatcgctataactggtataagcttttggctgagtttgatggagaaagacattccactatatcaacagtgtttggcagttatccagcaatcatttccgattaggtgggaggctatttcagtaaaaggaggatacaagcagaagtggagtactagaggtgatgggctcccaaaagatacccgaatttcagactccttggccccaatcgggaactggatcagatctttggaattggtccgaaaccaagttcgtctaaatccattcaataagatcttgttcaatcagctatgtcgtacagtggataatcatttgaagtggtcaaatttgcgaaaaaacacaggaatgattgaatggatcaatgggcgaatttcaaaagaagaccggtctatactgatgttgaagagtgacctacatgaggaaaactcttggagagattaaaaaatcaggaggagactccaaactttaagtatgaaaaaaactttgatccttaagaccctcttgtggtttttattttttatctggttttgtggtcttcgt(VSV-SmacΔ55,SEQ ID NO:9)。
在一些实施方案中,重组病毒载体包含核酸序列:
acgaagacaaacaaaccattattatcattaaaaggctcaggagaaactttaacagtaatcaaaatgtctgttacagtcaagagaatcattgacaacacagtcatagttccaaaacttcctgcaaatgaggatccagtggaatacccggcagattacttcagaaaatcaaaggagattcctctttacatcaatactacaaaaagtttgtcagatctaagaggatatgtctaccaaggcctcaaatccggaaatgtatcaatcatacatgtcaacagctacttgtatggagcattaaaggacatccggggtaagttggataaagattggtcaagtttcggaataaacatcgggaaagcaggggatacaatcggaatatttgaccttgtatccttgaaagccctggacggcgtacttccagatggagtatcggatgcttccagaaccagcgcagatgacaaatggttgcctttgtatctacttggcttatacagagtgggcagaacacaaatgcctgaatacagaaaaaagctcatggatgggctgacaaatcaatgcaaaatgatcaatgaacagtttgaacctcttgtgccagaaggtcgtgacatttttgatgtgtggggaaatgacagtaattacacaaaaattgtcgctgcagtggacatgttcttccacatgttcaaaaaacatgaatgtgcctcgttcagatacggaactattgtttccagattcaaagattgtgctgcattggcaacatttggacacctctgcaaaataaccggaatgtctacagaagatgtaacgacctggatcttgaaccgagaagttgcagatgaaatggtccaaatgatgcttccaggccaagaaattgacaaggccgattcatacatgccttatttgatcgactttggattgtcttctaagtctccatattcttccgtcaaaaaccctgccttccacttctgggggcaattgacagctcttctgctcagatccaccagagcaaggaatgcccgacagcctgatgacattgaGTATACatctcttactacagcaggtttgttgtacgcttatgcagtaggatcctctgccgacttggcacaacagttttgtgttggagataacaaatacactccagatgatagtaccggaggattgacgactaatgcaccgccacaaggcagagatgtggtcgaatggctcggatggtttgaagatcaaaacagaaaaccgactcctgatatgatgcagtatgcgaaaagagcagtcatgtcactgcaaggcctaagagagaagacaattggcaagtatgctaagtcagaatttgacaaatgaccctataattctcagatcacctattatatattatgctacatatgaaaaaaactaacagatatcatggataatctcacaaaagttcgtgagtatctcaagtcctactctcgtctagatcaggcggtaggagagatagatgagatcgaagcacaacgagctgaaaagtccaattatgagttgttccaagaggacggagtggaagagcatactaggccctcttattttcaggcagcagatgattctgacacagaatctgaaccagaaattgaagacaatcaaggcttgtatgtaccagatccggaagctgagcaagttgaaggctttatacaggggcctttagatgactatgcagatgaggacgtggatgttgtattcacttcggactggaaacagcctgagcttgaatccgacgagcatggaaagaccttacggttgacattgccagagggtttaagtggagagcagaaatcccagtggcttttgacgattaaagcagtcgttcaaagtgccaaacactggaatctggcagagtgcacatttgaagcatcgggagaaggggtcatcataaaaaagcgccagataactccggatgtatataaggtcactccagtgatgaacacacatccgtaccaatcagaagccgtatcagatgtttggtctctctcaaagacatccatgactttccaacccaagaaagcaagtcttcagcctctcaccatatccttggatgaattgttctcatctagaggagaattcatctctgtcggaggtaacggacgaatgtctcataaagaggccatcctgctcggtctgaggtacaaaaagttgtacaatcaggcgagagtcaaatattctctgtagactatgaaaaaaagtaacagatatcacaatctaagtgttatcccaatccattcatcatgagttccttaaagaagattctcggtctgaaggggaaaggtaagaaatctaagaaattagggatcgcaccacccccttatgaagaggacactagcatggagtatgctccgagcgctccaattgacaaatcctattttggagttgacgagatggacacctatgatccgaatcaattaagatatgagaaattcttctttacagtgaaaatgacggttagatctaatcgtccgttcagaacatactcagatgtggcagccgctgtatcccattgggatcacatgtacatcggaatggcagggaaacgtcccttctacaaaatcttggcttttttgggttcttctaatctaaaggccactccagcggtattggcagatcaaggtcaaccagagtatcacgctcactgcgaaggcagggcttatttgccacataggatggggaagacccctcccatgctcaatgtaccagagcacttcagaagaccattcaatataggtctttacaagggaacgattgagctcacaatgaccatctacgatgatgagtcactggaagcagctcctatgatctgggatcatttcaattcttccaaattttctgatttcagagagaaggccttaatgtttggcctgattgtcgagaaaaaggcatctggagcgtgggtcctggattctatcagccacttcaaatgagctagtctagcttccagcttctgaacaatccccggtttactcagtctctcctaattccagcctttcgaacaactaatatcctgtcttttctATCCCTATGAAAAAAACTAACAGATCTCGAGATGgcggctctgaagagttggctgtcgcgcagcgtaacttcattcttcaggtacagacagtgtttgtgtgttcctgttgtggctaactttaagaagcggtgtttctcagaattgataagaccatggcacaaaactgtgacgattggctttggagtaaccctgtgtGCGGTTCCTATTGCACAGAAATCAGAGCCTCATTCCCTTAGTAGTGAAGCATTGATGAGGAGAGCAGTGTCTTTGGTAACAGATAGCACCTCTACCTTTCTCTCTCAGACCACATATGCGTTGATTGAAGCTATTACTGAATATACTAAGGCTGTTTATACCTTAACTTCTCTTTACCGACAATATACAAGTTTACTTGGGAAAATGAATTCAGAGGAGGAAGATGAAGTGTGGCAGGTGATCATAGGAGCCAGAGCTGAGATGACTTCAAAACACCAAGAGTACTTGAAGCTGGAAACCACTTGGATGACTGCAGTTGGTCTTTCAGAGATGGCAGCAGAAGCTGCATATCAAACTGGCGCAGATCAGGCCTCTATAACCGCCAGGAATCACATTCAGCTGGTGAAACTGCAGGTGGAAGAGGTGCACCAGCTCTCCCGGAAAGCAGAAACCAAGCTGGCAGAAGCACAGATAGAAGAGCTCCGTCAGAAAACACAGGAGGAAGGGGAGGAGCGGGCTGAGTCGGAGCAGGAGGCCTACCTGCGTGAGGATTGACTCGAGTATATTTTAATTTTTAATTTTTATGAAAAAAACTAacagaTCTCGAGctgttaatgctaatcgtgataggggtttttgcctccaactgactcctacatattagcattaacagCTCGAGTATATTTTAATTTTTAATTTTTATGAAAAAAACTAacagagatcgatctgtttccttgacaccatgaagtgccttttgtacttagcttttttattcatcggggtgaattgcaagttcaccatagtttttccacacaaccgaaaaggaaactggaaaaatgttccttccaattaccattattgcccgtcaagctcagatttaaattggcataatgacttaataggcacagccttacaagtcaaaatgcccaagagtcacaaggctattcaagcagacggttggatgtgtcatgcttccaaatgggtcactacttgtgatttccgctggtacggaccggagtatataacacattccatccgatccttcactccatctgtagaacaatgcaaggaaagcattgaacaaacgaaacaaggaacttggctgaatccaggcttccctcctcaaagttgtggatatgcaactgtgacggatgctgaagcagcgattgtccaggtgactcctcaccatgtgcttgttgatgaatacacaggagaatgggttgattcacagttcatcaacggaaaatgcagcaatgacatatgccccactgtccataactccacaacctggcattccgactataaggtcaaagggctatgtgattctaacctcatttccatggacatcaccttcttctcagaggacggagagctatcatcCCTAGGaaaggagggcacagggttcagaagtaactactttgcttatgaaactggagacaaggcctgcaaaatgcagtactgcaagcattggggagtcagactcccatcaggtgtctggttcgagatggctgataaggatctctttgctgcagccagattccctgaatgcccagaagggtcaagtatctctgctccatctcagacctcagtggatgtaagtctcattcaggacgttgagaggatcttggattattccctctgccaagaaacctggagcaaaatcagagcgggtcttcccatctctccagtggatctcagctatcttgctcctaaaaacccaggaaccggtcctgtctttaccataatcaatggtaccctaaaatactttgagaccagatacatcagagtcgatattgctgctccaatcctctcaagaatggtcggaatgatcagtggaactaccacagaaagggaactgtgggatgactgggctccatatgaagacgtggaaattggacccaatggagttctgaggaccagttcaggatataagtttcctttatatatgattggacatggtatgttggactccgatcttcatcttagctcaaaggctcaggtgtttgaacatcctcacattcaagacgctgcttcgcagcttcctgatgatgagactttattttttggtgatactgggctatccaaaaatccaatcgagtttgtagaaggttggttcagtagttggaagagctctattgcctctttttgctttatcatagggttaatcattggactattcttggttctccgagttggtatttatctttgcattaaattaaagcacaccaagaaaagacagatttatacagacatagagatgaaccgacttggaaagtaactcaaatcctgcacaacagattcttcatgtttgaaccaaatcaacttgtgatatcatgctcaaagaggccttaattatattttaatttttaatttttatgaaaaaaactaacagcaatcatggaagtccacgattttgagaccgacgagttcaatgatttcaatgaagatgactatgccacaagagaattcctgaatcccgatgagcgcatgacgtacttgaatcatgctgattacaatttgaattctcctctaattagtgatgatattgacaatttgatcaggaaattcaattctcttccgattccctcgatgtgggatagtaagaactgggatggagttcttgagatgttaacatcatgtcaagccaatcccatctcaacatctcagatgcataaatggatgggaagttggttaatgtctgataatcatgatgccagtcaagggtatagttttttacatgaagtggacaaagaggcagaaataacatttgacgtggtggagaccttcatccgcggctggggcaacaaaccaattgaatacatcaaaaaggaaagatggactgactcattcaaaattctcgcttatttgtgtcaaaagtttttggacttacacaagttgacattaatcttaaatgctgtctctgaggtggaattgctcaacttggcgaggactttcaaaggcaaagtcagaagaagttctcatggaacgaacatatgcaggattagggttcccagcttgggtcctacttttatttcagaaggatgggcttacttcaagaaacttgatattctaatggaccgaaactttctgttaatggtcaaagatgtgattatagggaggatgcaaacggtgctatccatggtatgtagaatagacaacctgttctcagagcaagacatcttctcccttctaaatatctacagaattggagataaaattgtggagaggcagggaaatttttcttatgacttgattaaaatggtggaaccgatatgcaacttgaagctgatgaaattagcaagagaatcaaggcctttagtcccacaattccctcattttgaaaatcatatcaagacttctgttgatgaaggggcaaaaattgaccgaggtataagattcctccatgatcagataatgagtgtgaaaacagtggatctcacactggtgatttatggatcgttcagacattggggtcatccttttatagattattacactggactagaaaaattacattcccaagtaaccatgaagaaagatattgatgtgtcatatgcaaaagcacttgcaagtgatttagctcggattgttctatttcaacagttcaatgatcataaaaagtggttcgtgaatggagacttgctccctcatgatcatccctttaaaagtcatgttaaagaaaatacatggcccacagctgctcaagttcaagattttggagataaatggcatgaacttccgctgattaaatgttttgaaatacccgacttactagacccatcgataatatactctgacaaaagtcattcaatgaataggtcagaggtgttgaaacatgtccgaatgaatccgaacactcctatccctagtaaaaaggtgttgcagactatgttggacacaaaggctaccaattggaaagaatttcttaaagagattgatgagaagggcttagatgatgatgatctaattattggtcttaaaggaaaggagagggaactgaagttggcaggtagatttttctccctaatgtcttggaaattgcgagaatactttgtaattaccgaatatttgataaagactcatttcgtccctatgtttaaaggcctgacaatggcggacgatctaactgcagtcattaaaaagatgttagattcctcatccggccaaggattgaagtcatatgaggcaatttgcatagccaatcacattgattacgaaaaatggaataaccaccaaaggaagttatcaaacggcccagtgttccgagttatgggccagttcttaggttatccatccttaatcgagagaactcatgaattttttgagaaaagtcttatatactacaatggaagaccagacttgatgcgtgttcacaacaacacactgatcaattcaacctcccaacgagtttgttggcaaggacaagagggtggactggaaggtctacggcaaaaaggatggagtatcctcaatctactggttattcaaagagaggctaaaatcagaaacactgctgtcaaagtcttggcacaaggtgataatcaagttatttgcacacagtataaaacgaagaaatcgagaaacgttgtagaattacagggtgctctcaatcaaatggtttctaataatgagaaaattatgactgcaatcaaaatagggacagggaagttaggacttttgataaatgacgatgagactatgcaatctgcagattacttgaattatggaaaaataccgattttccgtggagtgattagagggttagagaccaagagatggtcacgagtgacttgtgtcaccaatgaccaaatacccacttgtgctaatataatgagctcagtttccacaaatgctctcaccgtagctcattttgctgagaacccaatcaatgccatgatacagtacaattattttgggacatttgctagactcttgttgatgatgcatgatcctgctcttcgtcaatcattgtatgaagttcaagataagataccgggcttgcacagttctactttcaaatacgccatgttgtatttggacccttccattggaggagtgtcgggcatgtctttgtccaggtttttgattagagccttcccagatcccgtaacagaaagtctctcattctggagattcatccatgtacatgctcgaagtgagcatctgaaggagatgagtgcagtatttggaaaccccgagatagccaagtttcgaataactcacatagacaagctagtagaagatccaacctctctgaacatcgctatgggaatgagtccagcgaacttgttaaagactgaggttaaaaaatgcttaatcgaatcaagacaaaccatcaggaaccaggtgattaaggatgcaaccatatatttgtatcatgaagaggatcggctcagaagtttcttatggtcaataaatcctctgttccctagatttttaagtgaattcaaatcaggcacttttttgggagtcgcagacgggctcatcagtctatttcaaaattctcgtactattcggaactcctttaagaaaaagtatcatagggaattggatgatttgattgtgaggagtgaggtatcctctttgacacatttagggaaacttcatttgagaaggggatcatgtaaaatgtggacatgttcagctactcatgctgacacattaagatacaaatcctggggccgtacagttattgggacaactgtaccccatccattagaaatgttgggtccacaacatcgaaaagagactccttgtgcaccatgtaacacatcagggttcaattatgtttctgtgcattgtccagacgggatccatgacgtctttagttcacggggaccattgcctgcttatctagggtctaaaacatctgaatctacatctattttgcagccttgggaaagggaaagcaaagtcccactgattaaaagagctacacgtcttagagatgctatctcttggtttgttgaacccgactctaaactagcaatgactatactttctaacatccactctttaacaggcgaagaatggaccaaaaggcagcatgggttcaaaagaacagggtctgcccttcataggttttcgacatctcggatgagccatggtgggttcgcatctcagagcactgcagcattgaccaggttgatggcaactacagacaccatgagggatctgggagatcagaatttcgactttttattccaagcaacgttgctctatgctcaaattaccaccactgttgcaagagacggatggatcaccagttgtacagatcattatcatattgcctgtaagtcctgtttgagacccatagaagagatcaccctggactcaagtatggactacacgcccccagatgtatcccatgtgctgaagacatggaggaatggggaaggttcgtggggacaagagataaaacagatctatcctttagaagggaattggaagaatttagcacctgctgagcaatcctatcaagtcggcagatgtataggttttctatatggagacttggcgtatagaaaatctactcatgccgaggacagttctctatttcctctatctatacaaggtcgtattagaggtcgaggtttcttaaaagggttgctagacggattaatgagagcaagttgctgccaagtaatacaccggagaagtctggctcatttgaagaggccggccaacgcagtgtacggaggtttgatttacttgattgataaattgagtgtatcacctccattcctttctcttactagatcaggacctattagagacgaattagaaacgattccccacaagatcccaacctcctatccgacaagcaaccgtgatatgggggtgattgtcagaaattacttcaaataccaatgccgtctaattgaaaagggaaaatacagatcacattattcacaattatggttattctcagatgtcttatccatagacttcattggaccattctctatttccaccaccctcttgcaaatcctatacaagccatttttatctgggaaagataagaatgagttgagagagctggcaaatctttcttcattgctaagatcaggagaggggtgggaagacatacatgtgaaattcttcaccaaggacatattattgtgtccagaggaaatcagacatgcttgcaagttcgggattgctaaggataataataaagacatgagctatcccccttggggaagggaatccagagggacaattacaacaatccctgtttattatacgaccaccccttacccaaagatgctagagatgcctccaagaatccaaaatcccctgctgtccggaatcaggttgggccaattaccaactggcgctcattataaaattcggagtatattacatggaatgggaatccattacagggacttcttgagttgtggagacggctccggagggatgactgctgcattactacgagaaaatgtgcatagcagaggaatattcaatagtctgttagaattatcagggtcagtcatgcgaggcgcctctcctgagccccccagtgccctagaaactttaggaggagataaatcgagatgtgtaaatggtgaaacatgttgggaatatccatctgacttatgtgacccaaggacttgggactatttcctccgactcaaagcaggcttggggcttcaaattgatttaattgtaatggatatggaagttcgggattcttctactagcctgaaaattgagacgaatgttagaaattatgtgcaccggattttggatgagcaaggagttttaatctacaagacttatggaacatatatttgtgagagcgaaaagaatgcagtaacaatccttggtcccatgttcaagacggtcgacttagttcaaacagaatttagtagttctcaaacgtctgaagtatatatggtatgtaaaggtttgaagaaattaatcgatgaacccaatcccgattggtcttccatcaatgaatcctggaaaaacctgtacgcattccagtcatcagaacaggaatttgccagagcaaagaaggttagtacatactttaccttgacaggtattccctcccaattcattcctgatccttttgtaaacattgagactatgctacaaatattcggagtacccacgggtgtgtctcatgcggctgccttaaaatcatctgatagacctgcagatttattgaccattagccttttttatatggcgattatatcgtattataacatcaatcatatcagagtaggaccgatacctccgaaccccccatcagatggaattgcacaaaatgtggggatcgctataactggtataagcttttggctgagtttgatggagaaagacattccactatatcaacagtgtttggcagttatccagcaatcatttccgattaggtgggaggctatttcagtaaaaggaggatacaagcagaagtggagtactagaggtgatgggctcccaaaagatacccgaatttcagactccttggccccaatcgggaactggatcagatctttggaattggtccgaaaccaagttcgtctaaatccattcaataagatcttgttcaatcagctatgtcgtacagtggataatcatttgaagtggtcaaatttgcgaaaaaacacaggaatgattgaatggatcaatgggcgaatttcaaaagaagaccggtctatactgatgttgaagagtgacctacatgaggaaaactcttggagagattaaaaaatcaggaggagactccaaactttaagtatgaaaaaaactttgatccttaagaccctcttgtggtttttattttttatctggttttgtggtcttcgt(VSV-SmacmiR155,SEQ IDNO:10)。
在一些实施方案中,重组病毒载体包含核酸序列:
acgaagacaaacaaaccattattatcattaaaaggctcaggagaaactttaacagtaatcaaaatgtctgttacagtcaagagaatcattgacaacacagtcatagttccaaaacttcctgcaaatgaggatccagtggaatacccggcagattacttcagaaaatcaaaggagattcctctttacatcaatactacaaaaagtttgtcagatctaagaggatatgtctaccaaggcctcaaatccggaaatgtatcaatcatacatgtcaacagctacttgtatggagcattaaaggacatccggggtaagttggataaagattggtcaagtttcggaataaacatcgggaaagcaggggatacaatcggaatatttgaccttgtatccttgaaagccctggacggcgtacttccagatggagtatcggatgcttccagaaccagcgcagatgacaaatggttgcctttgtatctacttggcttatacagagtgggcagaacacaaatgcctgaatacagaaaaaagctcatggatgggctgacaaatcaatgcaaaatgatcaatgaacagtttgaacctcttgtgccagaaggtcgtgacatttttgatgtgtggggaaatgacagtaattacacaaaaattgtcgctgcagtggacatgttcttccacatgttcaaaaaacatgaatgtgcctcgttcagatacggaactattgtttccagattcaaagattgtgctgcattggcaacatttggacacctctgcaaaataaccggaatgtctacagaagatgtaacgacctggatcttgaaccgagaagttgcagatgaaatggtccaaatgatgcttccaggccaagaaattgacaaggccgattcatacatgccttatttgatcgactttggattgtcttctaagtctccatattcttccgtcaaaaaccctgccttccacttctgggggcaattgacagctcttctgctcagatccaccagagcaaggaatgcccgacagcctgatgacattgaGTATACatctcttactacagcaggtttgttgtacgcttatgcagtaggatcctctgccgacttggcacaacagttttgtgttggagataacaaatacactccagatgatagtaccggaggattgacgactaatgcaccgccacaaggcagagatgtggtcgaatggctcggatggtttgaagatcaaaacagaaaaccgactcctgatatgatgcagtatgcgaaaagagcagtcatgtcactgcaaggcctaagagagaagacaattggcaagtatgctaagtcagaatttgacaaatgaccctataattctcagatcacctattatatattatgctacatatgaaaaaaactaacagatatcatggataatctcacaaaagttcgtgagtatctcaagtcctactctcgtctagatcaggcggtaggagagatagatgagatcgaagcacaacgagctgaaaagtccaattatgagttgttccaagaggacggagtggaagagcatactaggccctcttattttcaggcagcagatgattctgacacagaatctgaaccagaaattgaagacaatcaaggcttgtatgtaccagatccggaagctgagcaagttgaaggctttatacaggggcctttagatgactatgcagatgaggacgtggatgttgtattcacttcggactggaaacagcctgagcttgaatccgacgagcatggaaagaccttacggttgacattgccagagggtttaagtggagagcagaaatcccagtggcttttgacgattaaagcagtcgttcaaagtgccaaacactggaatctggcagagtgcacatttgaagcatcgggagaaggggtcatcataaaaaagcgccagataactccggatgtatataaggtcactccagtgatgaacacacatccgtaccaatcagaagccgtatcagatgtttggtctctctcaaagacatccatgactttccaacccaagaaagcaagtcttcagcctctcaccatatccttggatgaattgttctcatctagaggagaattcatctctgtcggaggtaacggacgaatgtctcataaagaggccatcctgctcggtctgaggtacaaaaagttgtacaatcaggcgagagtcaaatattctctgtagactatgaaaaaaagtaacagatatcacaatctaagtgttatcccaatccattcatcatgagttccttaaagaagattctcggtctgaaggggaaaggtaagaaatctaagaaattagggatcgcaccacccccttatgaagaggacactagcatggagtatgctccgagcgctccaattgacaaatcctattttggagttgacgagatggacacctatgatccgaatcaattaagatatgagaaattcttctttacagtgaaaatgacggttagatctaatcgtccgttcagaacatactcagatgtggcagccgctgtatcccattgggatcacatgtacatcggaatggcagggaaacgtcccttctacaaaatcttggcttttttgggttcttctaatctaaaggccactccagcggtattggcagatcaaggtcaaccagagtatcacgctcactgcgaaggcagggcttatttgccacataggatggggaagacccctcccatgctcaatgtaccagagcacttcagaagaccattcaatataggtctttacaagggaacgattgagctcacaatgaccatctacgatgatgagtcactggaagcagctcctatgatctgggatcatttcaattcttccaaattttctgatttcagagagaaggccttaatgtttggcctgattgtcgagaaaaaggcatctggagcgtgggtcctggattctatcagccacttcaaatgagctagtctagcttccagcttctgaacaatccccggtttactcagtctctcctaattccagcctttcgaacaactaatatcctgtcttttctATCCCTATGAAAAAAACTAACAGATCTCGAGATGGCGGTTCCTATTGCACAGAAATCAGAGCCTCATTCCCTTAGTAGTGAAGCATTGATGAGGAGAGCAGTGTCTTTGGTAACAGATAGCACCTCTACCTTTCTCTCTCAGACCACATATGCGTTGATTGAAGCTATTACTGAATATACTAAGGCTGTTTATACCTTAACTTCTCTTTACCGACAATATACAAGTTTACTTGGGAAAATGAATTCAGAGGAGGAAGATGAAGTGTGGCAGGTGATCATAGGAGCCAGAGCTGAGATGACTTCAAAACACCAAGAGTACTTGAAGCTGGAAACCACTTGGATGACTGCAGTTGGTCTTTCAGAGATGGCAGCAGAAGCTGCATATCAAACTGGCGCAGATCAGGCCTCTATAACCGCCAGGAATCACATTCAGCTGGTGAAACTGCAGGTGGAAGAGGTGCACCAGCTCTCCCGGAAAGCAGAAACCAAGCTGGCAGAAGCACAGATAGAAGAGCTCCGTCAGAAAACACAGGAGGAAGGGGAGGAGCGGGCTGAGTCGGAGCAGGAGGCCTACCTGCGTGAGGATTGACTCGAGTATATTTTAATTTTTAATTTTTATGAAAAAAACTAacagaTCTCGAGctgttaatgctaatcgtgataggggtttttgcctccaactgactcctacatattagcattaacagCTCGAGTATATTTTAATTTTTAATTTTTATGAAAAAAACTAacagagatcgatctgtttccttgacaccatgaagtgccttttgtacttagcttttttattcatcggggtgaattgcaagttcaccatagtttttccacacaaccgaaaaggaaactggaaaaatgttccttccaattaccattattgcccgtcaagctcagatttaaattggcataatgacttaataggcacagccttacaagtcaaaatgcccaagagtcacaaggctattcaagcagacggttggatgtgtcatgcttccaaatgggtcactacttgtgatttccgctggtacggaccggagtatataacacattccatccgatccttcactccatctgtagaacaatgcaaggaaagcattgaacaaacgaaacaaggaacttggctgaatccaggcttccctcctcaaagttgtggatatgcaactgtgacggatgctgaagcagcgattgtccaggtgactcctcaccatgtgcttgttgatgaatacacaggagaatgggttgattcacagttcatcaacggaaaatgcagcaatgacatatgccccactgtccataactccacaacctggcattccgactataaggtcaaagggctatgtgattctaacctcatttccatggacatcaccttcttctcagaggacggagagctatcatcCCTAGGaaaggagggcacagggttcagaagtaactactttgcttatgaaactggagacaaggcctgcaaaatgcagtactgcaagcattggggagtcagactcccatcaggtgtctggttcgagatggctgataaggatctctttgctgcagccagattccctgaatgcccagaagggtcaagtatctctgctccatctcagacctcagtggatgtaagtctcattcaggacgttgagaggatcttggattattccctctgccaagaaacctggagcaaaatcagagcgggtcttcccatctctccagtggatctcagctatcttgctcctaaaaacccaggaaccggtcctgtctttaccataatcaatggtaccctaaaatactttgagaccagatacatcagagtcgatattgctgctccaatcctctcaagaatggtcggaatgatcagtggaactaccacagaaagggaactgtgggatgactgggctccatatgaagacgtggaaattggacccaatggagttctgaggaccagttcaggatataagtttcctttatatatgattggacatggtatgttggactccgatcttcatcttagctcaaaggctcaggtgtttgaacatcctcacattcaagacgctgcttcgcagcttcctgatgatgagactttattttttggtgatactgggctatccaaaaatccaatcgagtttgtagaaggttggttcagtagttggaagagctctattgcctctttttgctttatcatagggttaatcattggactattcttggttctccgagttggtatttatctttgcattaaattaaagcacaccaagaaaagacagatttatacagacatagagatgaaccgacttggaaagtaactcaaatcctgcacaacagattcttcatgtttgaaccaaatcaacttgtgatatcatgctcaaagaggccttaattatattttaatttttaatttttatgaaaaaaactaacagcaatcatggaagtccacgattttgagaccgacgagttcaatgatttcaatgaagatgactatgccacaagagaattcctgaatcccgatgagcgcatgacgtacttgaatcatgctgattacaatttgaattctcctctaattagtgatgatattgacaatttgatcaggaaattcaattctcttccgattccctcgatgtgggatagtaagaactgggatggagttcttgagatgttaacatcatgtcaagccaatcccatctcaacatctcagatgcataaatggatgggaagttggttaatgtctgataatcatgatgccagtcaagggtatagttttttacatgaagtggacaaagaggcagaaataacatttgacgtggtggagaccttcatccgcggctggggcaacaaaccaattgaatacatcaaaaaggaaagatggactgactcattcaaaattctcgcttatttgtgtcaaaagtttttggacttacacaagttgacattaatcttaaatgctgtctctgaggtggaattgctcaacttggcgaggactttcaaaggcaaagtcagaagaagttctcatggaacgaacatatgcaggattagggttcccagcttgggtcctacttttatttcagaaggatgggcttacttcaagaaacttgatattctaatggaccgaaactttctgttaatggtcaaagatgtgattatagggaggatgcaaacggtgctatccatggtatgtagaatagacaacctgttctcagagcaagacatcttctcccttctaaatatctacagaattggagataaaattgtggagaggcagggaaatttttcttatgacttgattaaaatggtggaaccgatatgcaacttgaagctgatgaaattagcaagagaatcaaggcctttagtcccacaattccctcattttgaaaatcatatcaagacttctgttgatgaaggggcaaaaattgaccgaggtataagattcctccatgatcagataatgagtgtgaaaacagtggatctcacactggtgatttatggatcgttcagacattggggtcatccttttatagattattacactggactagaaaaattacattcccaagtaaccatgaagaaagatattgatgtgtcatatgcaaaagcacttgcaagtgatttagctcggattgttctatttcaacagttcaatgatcataaaaagtggttcgtgaatggagacttgctccctcatgatcatccctttaaaagtcatgttaaagaaaatacatggcccacagctgctcaagttcaagattttggagataaatggcatgaacttccgctgattaaatgttttgaaatacccgacttactagacccatcgataatatactctgacaaaagtcattcaatgaataggtcagaggtgttgaaacatgtccgaatgaatccgaacactcctatccctagtaaaaaggtgttgcagactatgttggacacaaaggctaccaattggaaagaatttcttaaagagattgatgagaagggcttagatgatgatgatctaattattggtcttaaaggaaaggagagggaactgaagttggcaggtagatttttctccctaatgtcttggaaattgcgagaatactttgtaattaccgaatatttgataaagactcatttcgtccctatgtttaaaggcctgacaatggcggacgatctaactgcagtcattaaaaagatgttagattcctcatccggccaaggattgaagtcatatgaggcaatttgcatagccaatcacattgattacgaaaaatggaataaccaccaaaggaagttatcaaacggcccagtgttccgagttatgggccagttcttaggttatccatccttaatcgagagaactcatgaattttttgagaaaagtcttatatactacaatggaagaccagacttgatgcgtgttcacaacaacacactgatcaattcaacctcccaacgagtttgttggcaaggacaagagggtggactggaaggtctacggcaaaaaggatggagtatcctcaatctactggttattcaaagagaggctaaaatcagaaacactgctgtcaaagtcttggcacaaggtgataatcaagttatttgcacacagtataaaacgaagaaatcgagaaacgttgtagaattacagggtgctctcaatcaaatggtttctaataatgagaaaattatgactgcaatcaaaatagggacagggaagttaggacttttgataaatgacgatgagactatgcaatctgcagattacttgaattatggaaaaataccgattttccgtggagtgattagagggttagagaccaagagatggtcacgagtgacttgtgtcaccaatgaccaaatacccacttgtgctaatataatgagctcagtttccacaaatgctctcaccgtagctcattttgctgagaacccaatcaatgccatgatacagtacaattattttgggacatttgctagactcttgttgatgatgcatgatcctgctcttcgtcaatcattgtatgaagttcaagataagataccgggcttgcacagttctactttcaaatacgccatgttgtatttggacccttccattggaggagtgtcgggcatgtctttgtccaggtttttgattagagccttcccagatcccgtaacagaaagtctctcattctggagattcatccatgtacatgctcgaagtgagcatctgaaggagatgagtgcagtatttggaaaccccgagatagccaagtttcgaataactcacatagacaagctagtagaagatccaacctctctgaacatcgctatgggaatgagtccagcgaacttgttaaagactgaggttaaaaaatgcttaatcgaatcaagacaaaccatcaggaaccaggtgattaaggatgcaaccatatatttgtatcatgaagaggatcggctcagaagtttcttatggtcaataaatcctctgttccctagatttttaagtgaattcaaatcaggcacttttttgggagtcgcagacgggctcatcagtctatttcaaaattctcgtactattcggaactcctttaagaaaaagtatcatagggaattggatgatttgattgtgaggagtgaggtatcctctttgacacatttagggaaacttcatttgagaaggggatcatgtaaaatgtggacatgttcagctactcatgctgacacattaagatacaaatcctggggccgtacagttattgggacaactgtaccccatccattagaaatgttgggtccacaacatcgaaaagagactccttgtgcaccatgtaacacatcagggttcaattatgtttctgtgcattgtccagacgggatccatgacgtctttagttcacggggaccattgcctgcttatctagggtctaaaacatctgaatctacatctattttgcagccttgggaaagggaaagcaaagtcccactgattaaaagagctacacgtcttagagatgctatctcttggtttgttgaacccgactctaaactagcaatgactatactttctaacatccactctttaacaggcgaagaatggaccaaaaggcagcatgggttcaaaagaacagggtctgcccttcataggttttcgacatctcggatgagccatggtgggttcgcatctcagagcactgcagcattgaccaggttgatggcaactacagacaccatgagggatctgggagatcagaatttcgactttttattccaagcaacgttgctctatgctcaaattaccaccactgttgcaagagacggatggatcaccagttgtacagatcattatcatattgcctgtaagtcctgtttgagacccatagaagagatcaccctggactcaagtatggactacacgcccccagatgtatcccatgtgctgaagacatggaggaatggggaaggttcgtggggacaagagataaaacagatctatcctttagaagggaattggaagaatttagcacctgctgagcaatcctatcaagtcggcagatgtataggttttctatatggagacttggcgtatagaaaatctactcatgccgaggacagttctctatttcctctatctatacaaggtcgtattagaggtcgaggtttcttaaaagggttgctagacggattaatgagagcaagttgctgccaagtaatacaccggagaagtctggctcatttgaagaggccggccaacgcagtgtacggaggtttgatttacttgattgataaattgagtgtatcacctccattcctttctcttactagatcaggacctattagagacgaattagaaacgattccccacaagatcccaacctcctatccgacaagcaaccgtgatatgggggtgattgtcagaaattacttcaaataccaatgccgtctaattgaaaagggaaaatacagatcacattattcacaattatggttattctcagatgtcttatccatagacttcattggaccattctctatttccaccaccctcttgcaaatcctatacaagccatttttatctgggaaagataagaatgagttgagagagctggcaaatctttcttcattgctaagatcaggagaggggtgggaagacatacatgtgaaattcttcaccaaggacatattattgtgtccagaggaaatcagacatgcttgcaagttcgggattgctaaggataataataaagacatgagctatcccccttggggaagggaatccagagggacaattacaacaatccctgtttattatacgaccaccccttacccaaagatgctagagatgcctccaagaatccaaaatcccctgctgtccggaatcaggttgggccaattaccaactggcgctcattataaaattcggagtatattacatggaatgggaatccattacagggacttcttgagttgtggagacggctccggagggatgactgctgcattactacgagaaaatgtgcatagcagaggaatattcaatagtctgttagaattatcagggtcagtcatgcgaggcgcctctcctgagccccccagtgccctagaaactttaggaggagataaatcgagatgtgtaaatggtgaaacatgttgggaatatccatctgacttatgtgacccaaggacttgggactatttcctccgactcaaagcaggcttggggcttcaaattgatttaattgtaatggatatggaagttcgggattcttctactagcctgaaaattgagacgaatgttagaaattatgtgcaccggattttggatgagcaaggagttttaatctacaagacttatggaacatatatttgtgagagcgaaaagaatgcagtaacaatccttggtcccatgttcaagacggtcgacttagttcaaacagaatttagtagttctcaaacgtctgaagtatatatggtatgtaaaggtttgaagaaattaatcgatgaacccaatcccgattggtcttccatcaatgaatcctggaaaaacctgtacgcattccagtcatcagaacaggaatttgccagagcaaagaaggttagtacatactttaccttgacaggtattccctcccaattcattcctgatccttttgtaaacattgagactatgctacaaatattcggagtacccacgggtgtgtctcatgcggctgccttaaaatcatctgatagacctgcagatttattgaccattagccttttttatatggcgattatatcgtattataacatcaatcatatcagagtaggaccgatacctccgaaccccccatcagatggaattgcacaaaatgtggggatcgctataactggtataagcttttggctgagtttgatggagaaagacattccactatatcaacagtgtttggcagttatccagcaatcatttccgattaggtgggaggctatttcagtaaaaggaggatacaagcagaagtggagtactagaggtgatgggctcccaaaagatacccgaatttcagactccttggccccaatcgggaactggatcagatctttggaattggtccgaaaccaagttcgtctaaatccattcaataagatcttgttcaatcagctatgtcgtacagtggataatcatttgaagtggtcaaatttgcgaaaaaacacaggaatgattgaatggatcaatgggcgaatttcaaaagaagaccggtctatactgatgttgaagagtgacctacatgaggaaaactcttggagagattaaaaaatcaggaggagactccaaactttaagtatgaaaaaaactttgatccttaagaccctcttgtggtttttattttttatctggttttgtggtcttcgt(VSV-SmacΔ55-miR155,SEQ ID NO:11)。
突变体VSV溶瘤病毒在WO 2001019380中被描述,其通过引用关于如何制备和使用这些病毒的教导被并入。
插入位置
所公开的组合物和方法涵盖包含病毒载体的表达系统,所述病毒载体包含一个或更多个异源核苷酸序列,诸如编码Smac蛋白的核苷酸序列。smac基因可以被插入病毒基因组中的任何地方,只要它被表达。在优选的实施方案中,smac基因被插入,使得其表达被延迟直到病毒复制之后。VSV基因组包含核蛋白(N)基因、磷蛋白(P)基因、基质蛋白(M)基因、糖蛋白(G)基因和大(L)聚合酶蛋白。VSV基因的mRNA水平在VSV感染中从N基因(接近3’末端)下降至L基因(接近5’末端)。N蛋白和P蛋白是用于支持病毒复制所需的,而M蛋白是用于病毒组装所需的。因此,在一些实施方案中,smac基因在N蛋白、P蛋白和M蛋白之后被插入到VSV基因组中,使得Smac仅当病毒产生被良好地建立时达到显著水平。在一些情况下,smac基因被插入在来自单股负链病毒目的病毒中的M基因之后。其他病毒基因组内的可比位置可以被确定并且被用于所公开的载体中。
治疗基因
在一些实施方案中,病毒进一步表达被插入在病毒基因组中的至少一种治疗基因。在所公开的载体的上下文中可以设想大量的治疗基因,诸如编码可以补偿受试者中有缺陷的或不足的蛋白质的多肽的那些治疗基因,或通过毒性作用起作用以从体内限制或去除有害细胞的那些治疗基因,或者编码免疫赋予多肽的那些治疗基因。在一些情况下,所公开的溶瘤病毒携带治疗基因,所述治疗基因选自由编码自杀基因产物和免疫刺激蛋白的基因组成的组。
术语“自杀基因”指的是编码能够将药物的前体转化成细胞毒性化合物的蛋白质的基因。自杀基因包括但不限于编码具有胞嘧啶脱氨酶活性、胸苷激酶活性、尿嘧啶磷酸核糖转移酶活性、嘌呤核苷磷酸化酶活性和胸苷酸激酶活性的蛋白质的基因。在一些情况下,自杀基因编码具有至少CD酶活性的蛋白质。可选择地或组合地,本发明的病毒可以在其病毒基因组中携带自杀基因,该自杀基因编码具有尿嘧啶磷酸核糖转移酶(UPRT酶)活性的多肽。
“促凋亡产物”指的是当以显著水平存在时诱导细胞凋亡的蛋白质。编码促凋亡蛋白的基因包括但不限于编码肿瘤细胞中的促凋亡细胞因子、fas配体、FADD、胱天蛋白酶-8、胱天蛋白酶-9、胱天蛋白酶-3、Smac/DIABLO、细胞色素c、IFN-β、RANTES、IP-10、TNF-α、CD95配体和TRAIL的基因;激活肿瘤细胞中的肿瘤抑制基因诸如p53的基因;或者激活肿瘤细胞中存在的胱天蛋白酶-8、胱天蛋白酶-9、胱天蛋白酶-3、Smac/DIABLO、细胞色素c的基因。
如本文中所使用的,术语“免疫刺激蛋白”指的是具有以特异性方式或非特异性方式刺激免疫系统的能力的蛋白质。大量的蛋白质因其发挥免疫刺激作用的能力在本领域中是已知的。在本发明的上下文中合适的免疫刺激蛋白的实例包括但不限于细胞因子(其中特别优选白细胞介素(例如IL-2、IL-6、IL-12、IL-15、IL-24))、趋化因子(例如CXCL10、CXCL9、CXCL11)、干扰素(例如IFNγ、IFNα)、肿瘤坏死因子(TNF)、集落刺激因子(例如GM-CSF、C-CSF、M-CSF...)、APC(针对抗原呈递细胞)-暴露的蛋白质(例如,B7.1、B7.2等)、生长因子(转化生长因子TGF、成纤维细胞生长因子FGF、血管内皮生长因子VEGF等)、I类或II类的MHC抗原、凋亡诱导剂或抑制剂(例如,Bax、Bcl2、BclX...)、细胞抑制剂(p21、pl6、Rb...)、免疫毒素、抗原多肽(抗原多肽、表位等)和标志物(β-半乳糖苷酶、荧光素酶....)。在一些癌症中,免疫刺激蛋白是白细胞介素或集落刺激因子,其中特别优选GM-CSF。
除非另外指示,否则所公开的组合物和方法的实践将采用分子生物学(包含重组技术)、微生物学、细胞生物学、生物化学和免疫学的常规技术,这些都在本领域技术人员的范围内。这样的技术在文献中被充分地解释,诸如“Molecular Cloning:A LaboratoryManual”,第二版(Sambrook等人,1989);“Oligonucleotide Synthesis”(M.J.Gait,编著,1984);“Animal Cell Culture”(R.I.Freshney,编著,1987);“Methods in Enzymology”(Academic Press,Inc.);“Handbook of Experimental Immunology”(D.M.Weir和C.C.Blackwell,编著);“Gene Transfer Vectors for Mammalian Cells”(J.M.Miller和M.P.Calos,编著,1987);“Current Protocols in Molecular Biology”(F.M.Ausubel等人,编著,1987);“PCR:The Polymerase Chain Reaction”,(Mullis等人,编著,1994);以及“Current Protocols in Immunology”(J.E.Coligan等人,编著,1991)。
组合物
还公开了包含(即,转化的、转染的或感染的)本文描述的病毒载体或病毒颗粒的宿主细胞。原核宿主细胞和真核宿主细胞(包括昆虫细胞)两者可以被使用,只要在该宿主中用于维持所必需的序列诸如合适的复制起点存在。为了方便,还提供了可选择的标志物。宿主系统是本领域中已知的,并且不需要在本文中详细地描述。原核宿主细胞包括细菌细胞,例如大肠杆菌(E.coli)、枯草芽孢杆菌(B.subtilis)和分枝杆菌。在真核宿主细胞之中的是酵母宿主细胞、昆虫宿主细胞、鸟类宿主细胞、植物宿主细胞、秀丽隐杆线虫(C.Elegans)(或线虫)宿主细胞和哺乳动物宿主细胞。真菌(包括酵母)宿主细胞的实例是酿酒酵母(S.cerevisiae)、乳酸克鲁维酵母(Kluyveromyces lactis)(K.lactis)、念珠菌的物种(包括白色念珠菌(C.albicans)和光滑念珠菌(C.glabrata))、构巢曲霉、粟酒裂殖酵母(Schizosaccharomyces pombe)(S.pombe)、巴斯德毕赤酵母(Pichia pastoris)和解脂耶氏酵母(Yarrowia lipolytica)。哺乳动物细胞的实例是COS细胞、小鼠L细胞、LNCaP细胞、中国仓鼠卵巢(CHO)细胞、人胚胎肾(HEK)细胞和非洲绿猴细胞。也可以使用非洲爪蟾卵母细胞(Xenopus laevis oocyte)或其他两栖动物来源的细胞。
还公开了包含本文描述的病毒载体的组合物,包括药物组合物。这样的组合物可用于体内施用,例如,当测量溶瘤活性对恶性细胞的转导程度和/或有效性时。组合物可以包含病毒载体和合适的溶剂,诸如生理学上可接受的缓冲液。这些是本领域中熟知的。在其他实施方案中,这些组合物还包含药学上可接受的赋形剂。可以在药学上可接受的赋形剂中包含有效量的病毒载体的这些组合物适合于以单位剂型、无菌肠胃外溶液或悬浮液、无菌非肠胃外溶液或口服溶液或悬浮液、水包油乳液或油包水乳液等全身的或局部的施用至个体。用于肠胃外药物递送和非肠胃外药物递送的制剂是本领域中已知的,并且在Remington's Pharmaceutical Sciences,第19版,Mack Publishing(1995)中阐述。组合物还包括本发明的冻干形式和/或重构形式的VSV载体(包括包装成病毒的那些VSV载体)。
还公开了包含本文公开的病毒载体的试剂盒。这些试剂盒可以被用于例如生产用于筛选、测定和生物用途诸如治疗肿瘤的蛋白质。使用这些试剂盒的程序可以由临床实验室、实验实验室、医疗从业者或私营的个体进行。试剂盒可以在合适的包装中包含本文所描述的病毒载体。试剂盒可以任选地提供在该程序中有用的另外的组分,包括但不限于缓冲液、显影试剂、标签、反应表面、用于检测的手段、对照样品、使用说明和解释性信息。试剂盒可以包括用于病毒载体的施用的使用说明。
使用本发明的重组病毒载体的方法
主题病毒载体和病毒颗粒可以被用于各种各样的目的,所述目的将随着期望的结果或预期的结果而变化。
因此,公开了用于在肿瘤细胞中产生溶瘤活性的方法,该方法包括使细胞与重组载体或包含本文公开的载体的病毒颗粒接触的步骤。本文公开了用于抑制肿瘤生长的方法,该方法包括使肿瘤与重组载体或包含本文公开的载体的病毒颗粒接触的步骤。
所公开的方法的癌症可以是受试者中经历不受调节的生长、侵袭或转移的任何细胞。在一些方面,癌症可以是目前对其使用放射疗法的任何赘生物或肿瘤。可选择地,癌症可以是对使用标准方法的放射疗法不足够敏感的赘生物或肿瘤。因此,癌症可以是肉瘤、淋巴瘤、白血病、癌、胚细胞瘤或生殖细胞瘤。所公开的组合物可以用于治疗的癌症的代表性但非限制性的清单包括淋巴瘤,B细胞淋巴瘤,T细胞淋巴瘤,蕈样肉芽肿,霍奇金病,骨髓性白血病,膀胱癌,脑癌,神经系统癌,头颈癌(head and neck cancer),头颈部鳞状细胞癌,肾癌(kidney cancer),肺癌(lung cancer)诸如小细胞肺癌和非小细胞肺癌,成神经细胞瘤/成胶质细胞瘤,卵巢癌,胰腺癌,前列腺癌(prostate cancer),皮肤癌,肝癌,黑素瘤,口腔、咽喉、喉和肺部的鳞状细胞癌,结肠癌,宫颈癌(cervical cancer),宫颈癌(cervicalcarcinoma),乳腺癌,上皮癌,肾癌(renal cancer),泌尿生殖系统癌,肺癌(pulmonarycancer),食道癌,头颈癌(head and neck carcinoma),大肠癌,造血癌;睾丸癌;结肠癌和直肠癌,前列腺癌(prostatic cancer)和胰腺癌。
所公开的重组载体或包含该载体的病毒颗粒可以被施用至有需要的个体。这样的个体可以包含恶性细胞或肿瘤细胞,或者可以处于发展恶性细胞或肿瘤细胞或发展转移性疾病的风险中。所公开的构建体可以用于治疗局部肿瘤或转移性疾病。多种细胞和细胞系(包括卵巢癌细胞、纤维肉瘤、肺癌、黑素瘤、前列腺癌、肺癌和白血病细胞)对通过包括VSV的溶瘤病毒的感染是敏感的。
施用的方法
许多方法可以用于将所公开的载体或病毒颗粒施用到或引入到个体中,包括但不限于口服途径、皮内途径、肌内途径、腹膜内途径、静脉内途径、瘤内途径、皮下途径和鼻内途径。向其施用所公开的载体或病毒颗粒的个体是灵长类动物,或者在其他实例中是哺乳动物,或者在其他实例中是人类,但是也可以是非人类哺乳动物,包括但不限于牛、马、羊、猪、家禽、猫、狗、仓鼠、小鼠和大鼠。在使用所公开的载体或病毒颗粒中,个体可以是其中所公开的载体或病毒能够生长和/或复制的任何动物。本发明涵盖包含所公开的载体或病毒颗粒的组合物,其中所述组合物还可以包含药学上可接受的载体。待施用的载体的量将取决于若干个因素,诸如施用的途径、个体的状况、恶性肿瘤的侵袭性程度以及所采用的特定载体。此外,所公开的载体可以与其他治疗模式结合使用。
如果作为所公开的病毒施用,则从约102直至约108p.f.u.(或TCID50),在其他实例中从约103直至约106p.f.u.(或TCID50),并且在其他实例中从约104直至约105p.f.u.(或TCID50)可以被施用。如果作为多核苷酸构建体(即,未被包装成病毒)施用,则约0.01μg至约100μg的所公开的病毒构建体可以被施用,在其他实例中0.1μg至约500μg,并且在其他实例中约0.5μg至约200μg可以被施用。多于一种病毒载体可以同时或依次被施用。施用通常定期地被给予,同时监测任何响应。施用可以例如瘤内、静脉内或腹膜内被给予。
药学上可接受的载体是本领域中熟知的,并且包括但不限于盐水、缓冲盐水、右旋糖、水、甘油、无菌等渗水性缓冲液、以及它们的组合。这样的可接受的载体的一个实例是包含一种或更多种稳定剂诸如稳定的、水解的蛋白质、乳糖等的生理学上平衡的培养基。载体优选地是无菌的。制剂应该适合施用的模式。
如果需要,组合物还可以包含少量的润湿剂或乳化剂,或pH缓冲剂。组合物可以是液体溶液、悬浮液、乳剂、片剂、丸剂、胶囊、持续释放制剂或粉末。口服制剂可以包括标准载体,诸如药物级别的甘露醇、乳糖、淀粉、硬脂酸镁、糖精钠、纤维素、碳酸镁等。
一般地,各成分单独地供应或以单位剂型混合在一起供应,例如作为在指示活性剂的量的气密密封容器诸如安瓿、瓶或小袋中的干燥冻干粉末、溶液或无水浓缩物。在组合物通过注射施用的情况下,可以提供安瓿的无菌稀释剂使得可以在施用之前将成分混合,或者提供溶液。
在具体实施方案中,本文公开的冻干重组病毒载体被提供在第一容器中;第二容器包含稀释剂,该稀释剂由50%甘油、0.25%苯酚和防腐剂(例如,0.005%亮绿色)的水溶液组成。
待在制剂中使用的病毒载体或病毒颗粒的精确剂量也将取决于施用的途径和患者的性质,并且应该根据从业者的判断和每个患者的情况根据标准临床技术来决定。在给定的制品中使用的病毒载体或病毒颗粒的确切量不是关键的,条件是给出产生溶瘤活性所必需的病毒的最小量。预期剂量范围低至约10微克,多达毫克或更多的量。
具体特征
在回顾以下特征后将更好地理解本公开内容,这些特征不应该与权利要求混淆。
特征1.一种重组病毒载体,包含编码被插入在RNA病毒基因组内的第二线粒体衍生的胱天蛋白酶激活剂(SMAC)蛋白的核酸,其中所述SMAC蛋白特异性地结合至凋亡抑制蛋白(IAP)的至少一部分。
特征2.如特征1所述的重组载体,其中所述病毒是负链RNA病毒(NSV)。
特征3.如特征1所述的重组载体,其中溶瘤病毒是正链RNA病毒(PSV)。
特征4.如特征1所述的重组载体,其中所述病毒是副粘病毒。
特征5.如特征4所述的重组载体,其中所述病毒包含麻疹病毒(MV)。
特征6.如特征1所述的重组载体,其中所述病毒是弹状病毒。
特征7.如特征6所述的重组载体,其中所述病毒包含水疱性口炎病毒(VSV)。
特征8.如任一前述特征所述的重组载体,其中所述病毒基因组包含至少核蛋白(N)基因、磷蛋白(P)基因和基质蛋白(M)基因,其中编码SMAC的核酸被插入在所述M基因之后。
特征9.如特征8所述的重组载体,其中所述病毒基因组包含糖蛋白(G)基因,所述糖蛋白(G)基因编码包含插入的癌症靶向结构域的修饰的G蛋白。
特征10.如特征9所述的重组载体,其中所述靶向结构域包含结合整联蛋白的RGD序列。
特征11.如特征10所述的重组载体,其中所述G蛋白包含氨基酸序列SEQ ID NO:6。
特征12.如特征8至11中任一项所述的重组载体,其中所述SMAC蛋白包含氨基酸序列SEQ ID NO:1,或其保守变体,所述保守变体特异性地结合IAP。
特征13.如任一前述特征所述的重组载体,其中所述SMAC蛋白包含全长SMAC蛋白。
特征14.如任一前述特征所述的重组载体,其中所述SMAC蛋白缺乏线粒体靶向序列。
特征15.如特征14所述的重组载体,其中所述SMAC蛋白包含氨基酸序列SEQ IDNO:2,或其保守变体,所述保守变体特异性地结合IAP。
特征16.如特征1至15中任一项所述的重组载体,其中还包含编码微RNA-155的核酸。
特征17.如特征16所述的重组载体,其中所述编码微RNA-155的核酸具有核酸序列SEQ ID NO:7。
特征18.如任一前述特征所述的重组载体,其中所述重组载体包含核酸序列SEQID NO:8、9、10、或11。
特征19.一种细胞,包含如特征1至18中任一项所述的重组载体。
特征20.一种重组病毒颗粒,包含如特征1至18中任一项所述的重组载体。
特征21.一种组合物,包含在药学上可接受的赋形剂中的如特征20所述的重组病毒颗粒。
特征22.一种治疗患有肿瘤的受试者的方法,包括向所述受试者施用有效量的如特征21所述的组合物。
特征23.如特征22所述的方法,其中所述肿瘤包含乳腺肿瘤。
已描述了本发明的许多实施方案。尽管如此,将理解的是,可以做出各种修改而不偏离本发明的精神和范围。因此,其他实施方案在所附权利要求的范围内。
实施例
实施例1:
自噬是用于细胞维持其存活的必要机制。癌细胞生活在异常的环境中。存在大量证据指示,自噬在癌症生物学中起着核心作用(Lippai,M.和Z.Szatmari,Cell BiolToxicol,2017 33(2):145-168)。一方面,正常细胞的自噬可以抑制肿瘤发生。在最近的出版物中,已经显示癌症,特别是卵巢癌(OV)的突变导致自噬功能的丧失(Delaney,J.R.,等人,Nat Commun,2017 8:14423)。使用癌症基因组图谱(TCGA)数据(Kandoth,C.,等人,Nature,2013 502(7471):333-9),作者发现48%的卵巢肿瘤不包含癌基因或肿瘤抑制因子的突变,除了TP53之外。似乎体细胞拷贝数改变(SCNA)是OV和其他癌症的主要驱动力。通过SCNA最受抑制的途径是跨过所有癌症类型的自噬途径和溶酶体途径(Delaney,J.R.,等人,Nat Commun,2017 8:14423)。MAP1LC3B(LC3)和BECN1被发现为最具影响力的基因。这些数据与先前的出版物一致。
可选择地,自噬也可以使得肿瘤细胞对抗癌药物的治疗耐受。在多发性骨髓瘤(MM)的研究中,示出了基于基因表达谱,高迁移率族蛋白B1(high mobility group box 1)(HMGB1)的较高的表达与MM的差的预后有关(Roy,M.,等人,Theranostics,2016 6(12):2209-2224)。内源性HMGB1是自噬调节剂,当转位到胞质溶胶中时通过结合Beclin-1以替换Bcl-2(Tang,D.,等人,J Cell Biol,2010 190(5):881-92)。在ARH-77细胞、ANBL-6细胞和ARP-1细胞中,将HMGB1的表达升高,并且HMGB1的敲低降低存活率。Beclin-1和LC3的水平与HMGB1的水平相关。自噬抑制剂石蒜碱可以诱导HMGB1的降解,因此抑制Bcl-2从Beclin-1中解离。同时,石蒜碱可以使MM细胞对硼替佐米的治疗敏感。通过石蒜碱抑制自噬使MM对硼替佐米治疗敏感在小鼠异种移植模型中被进一步证实。
自噬和凋亡之间的交叉对话在癌症生物学中也是关键的,但是该两个途径之间的关系是复杂的(Marino,G.,等人,Nat Rev Mol Cell Biol,2014 15(2):81-94);Liu,G.,等人,Int J Mol Sci.2017 18(2))。自噬和凋亡两者可以通过应激被诱导。通常,自噬在凋亡之前开始。当应激被延长持续临界的持续时间或超过强度阈值时,凋亡被激活。同时,自噬的持续激活也可以导致自噬程序性细胞死亡。因此,对于在癌症疗法中如何防止自噬对抗凋亡或指导自噬以促进凋亡存在关注。两个途径之间的关键交叉点之一是Beclin-1与Bcl-2的相互作用。Beclin-1与Bcl-2的结合抑制自噬和凋亡两者。当Bcl-2通过在应激下被激活的JNK1磷酸化时,Beclin-1与Bcl-2解离并且激活自噬。同时,磷酸化的Bcl-2结合线粒体中的Bax以抑制凋亡。在这种情况下,自噬的激活实际上抑制凋亡。
通过自噬的凋亡抑制的另一个重要机制是线粒体自噬(mitophagy)(Kulikov,A.V.,等人,Biochem Biophys Res Commun,2017 482(3):432-439;Youle,R.J.和D.P.Narendra,Nat Rev Mol Cell Biol,2011 12(1):9-14)。线粒体自噬指的是通过自噬选择性降解线粒体。由于内在凋亡通过线粒体外膜的破坏被诱导,所以线粒体自噬将严重地限制凋亡。正常地,因为线粒体膜中的激酶PINK1(PTEN-诱导的推定激酶1)被线粒体膜中的蛋白酶裂解,因此线粒体自噬被阻止。在应激下,PINK1将积累在线粒体的外膜上,并且为线粒体募集另一种蛋白PARKIN(帕金森病蛋白)。PARKIN是E3泛素连接酶,该E3泛素连接酶泛素化线粒体的外膜中的蛋白质。衔接子蛋白p62/A170/SQSTM1识别泛素化蛋白,并且诱导线粒体与LC3II-自噬体的融合。
另一方面,激活的凋亡胱天蛋白酶可以下调自噬以中止其细胞保护功能(Marino,G.,等人,Nat Rev Mol Cell Biol,2014 15(2):81-94)。若干种自噬蛋白被激活的胱天蛋白酶(诸如ATG3、Beclin-1和ATG5)裂解。Beclin-1通过与VPS34和其他蛋白质形成核心复合物,导致分离的膜结构而在自噬的启动中起着核心作用。蛋白质轻链3(LC3)是结合在自噬体的膜中的关键蛋白质。在自噬的激活期间,LC3首先被ATG4裂解为LC3 II。ATG3通过ATG7介导LC3 II与磷脂酰乙醇胺(PE)的缀合。LC3 II/PE结合在自噬体的膜中。通过活性胱天蛋白酶裂解Beclin-1和ATG3终止自噬。同时,由胱天蛋白酶裂解得到的Beclin-1的C-末端结构域结合线粒体,以引起细胞色素c的释放,这进一步激活凋亡。在通过钙蛋白酶裂解的ATG5的N-末端结构域的情况下,也观察到相同的凋亡激活。
自噬和凋亡之间的相互作用比我们简要地讨论的复杂得多。然而,主要关注的是如何操纵这两个途径以便构建用于癌症治疗的有效机制。在大多数情况下,自噬倾向于抑制凋亡。当自噬的保护机制被破坏时,凋亡可以更容易地被诱导。公开了实现后者的策略。
存在许多实例显示,抑制自噬可以使肿瘤细胞对通过抗癌药物的治疗敏感。在对溴结构域和末端外结构域(bromodomain and extraterminal domain)(BET)抑制剂JQ1耐受的急性骨髓性白血病细胞中,将Beclin-1的表达上调,并且自噬被JQ1激活(Jang,J.E.,等人,Autophagy,2017:0;Jang,J.E.,等人,Clin Cancer Res,2016)。通过siRNA敲低BECN1/Beclin-1基因表达或添加自噬抑制剂3-甲基腺嘌呤(3-MA)增加JQ1诱导的耐受细胞的凋亡。在MCF-7乳腺癌细胞中,用蛋白酶体抑制剂硼替佐米治疗也激活自噬(Yao,F.,等人,Mol Med Rep,2012 5(1):84-8)。用硼替佐米处理MCF-7细胞诱导LC3-II的剂量依赖性增加和GFP-LC3点纹(puncta)的时间依赖性积累。当添加3-MA时,硼替佐米对MCF-7增殖的抑制被增强。
当研究溶瘤性水疱性口炎病毒(VSV)时,自噬的抑制增强VSV-诱导的凋亡(Malilas,W.,等人,Int J Oncol,2014 44(4):1177-84)。VSV感染通过内在线粒体途径诱导凋亡(Pearce,A.F.和D.S.Lyles,J Virol,2009 83(18):9102-12;Balachandran,S.,等人,J Virol,2000 74(3):1513-23;Kopecky,S.A.和D.S.Lyles,J Virol,2003 77(8):4658-69)。癌症上调的基因2(CUG2)在许多肿瘤细胞诸如卵巢癌细胞、肝癌细胞、结肠癌细胞和肺癌细胞中被上调,并且在肿瘤发生中起着关键作用(Lee,S.,等人,Biochem BiophysRes Commun,2007 360(3):633-9)。当CUG2被过表达时,它赋予对VSV感染的抗性(Malilas,W.,等人,Cancer Gene Ther,2013 20(2):125-32)。当Beclin-1或ATG5在CUG2-过表达细胞中被siRNA敲低时,这些细胞变得对VSV杀伤敏感,这表明自噬在CUG2-过表达细胞中起着保护作用(Malilas,W.,等人,Int J Oncol,2014 44(4):1177-84)。对于另一种溶瘤病毒新城疫病毒(NDV)也观察到相同的致敏作用,该病毒与VSV属于同一病毒类别,即负链RNA病毒。在富含癌症干细胞的肺癌球状体中,通过NDV的感染诱导自噬,如通过LC3和p62的增加的降解所示出的(Hu,L.,等人,Am J Cancer Res,2015 5(12):3612-23)。用氯喹抑制自噬增强了球状体的3D培养中由NDV感染诱导的凋亡胱天蛋白酶-3加工,而通过自噬诱导剂雷帕霉素的治疗降低了NDV感染中的凋亡。在对顺铂(A549/DDP)或紫杉醇(A549/PTX)耐受的A549肺癌细胞系中也观察到通过自噬诱导剂/抑制剂的相同增强作用(Jiang,K.,等人,BMCCancer,2014 14:551)。对NDV-诱导的凋亡的耐受与线粒体自噬直接相关(Meng,G.,等人,Oncotarget,2014 5(15):6365-74)。在NDV感染的细胞中,LC3和SQSTM1的降解被增加。更重要的是,由NDV诱导的自噬实际上阻断凋亡,如通过胱天蛋白酶9和胱天蛋白酶3的降解所指示的(Meng,G.,等人,Oncotarget,2014 5(15):6365-74)。凋亡的抑制支持病毒复制,并且通过3-MA抑制自噬恢复通过NDV的细胞杀伤。另外的研究显示,SQSTM1介导NDV感染的细胞中的线粒体自噬,如通过线粒体和自噬体的共定位所指示的,这可以减少细胞色素c的释放(Meng,G.,等人,Oncotarget,2014 5(15):6365-74)。因此,自噬可以由溶瘤病毒VSV或NDV的感染诱导,并且自噬的激活可以支持病毒复制(Chakrabarti,A.,等人,J Virol,2012 86(20):11311-21;Richetta,C.,等人,PLoS Pathog,2013 9(9):e1003599)。
然而,癌细胞中自噬的激活似乎通过抑制凋亡而起着细胞保护作用。自噬的抑制可以使癌细胞对通过溶瘤性VSV或NDV的杀伤敏感。一个有趣的观察结果是,当在NDV感染24小时之后添加3-MA以抑制自噬时,实现了增强的细胞杀伤,这进一步表明自噬应该在后期被抑制,以允许有效的病毒复制,以便有效地诱导凋亡(Meng,G.,等人,Oncotarget,2014 5(15):6365-74)。因此,最佳设计可以是在有效的病毒复制之后抑制自噬的机制。本文公开了武装的VSV以便实现该目标。
已经开发了武装的VSV以增强癌细胞的杀伤。在一种情况下,用于干扰素β的基因被插入在G病毒基因和L病毒基因之间(VSV-IFNβ)(Obuchi,M.,等人.J Virol,2003 77(16):8843-56)。IFNβ的表达增强癌细胞杀伤(Willmon,C.L.,等人,Cancer Res,2009 69(19):7713-20;Saloura,V.,等人,Hum Gene Ther,2010 21(1):51-64;Kurisetty,V.V.,等人,Head Neck,2014 36(11):1619-27;Patel,M.R.,等人,Oncotarget,2015 6(32):33165-77)。基于其基质蛋白(M)中的残基51已经被突变以便限制VSV扩散到正常细胞的VSVMΔ51(Goel,A.,等人,Blood,2007 110(7):2342-50),用于干扰素γ的基因被插入在G病毒基因和L病毒基因之间(VSV MΔ51-IFNγ)(Bourgeois-Daigneault,M.C.,等人,Mol TherOncolytics,2016 3:16001)。这种病毒还示出增强的抗肿瘤活性。这些武装的VSV的机制是增强对癌细胞的免疫应答,但是不通过VSV感染直接杀死癌细胞。
该实例的目标是增强VSV对癌细胞的直接杀伤。在TRAIL-耐受的乳腺癌细胞中,Smac/DIABLO的过表达使这些细胞对化学治疗药物(他莫昔芬、多柔比星或紫杉醇)和辐照敏感(Fandy,T.E.,等人,Mol Cancer,2008 7:60)。Smac/DIABLO被示出具有与IAP增强的相互作用。横纹肌肉瘤(RMS)是儿童中最常见的软组织肉瘤。RMS可以对许多治疗耐受,尤其是Smac模拟化合物(SMC,例如LCL161)(Houghton,P.J.,等人,Pediatr Blood Cancer,201258(4):636-9)。然而,VSV VSVMΔ51和SMC LCL161的组合可以根除小鼠模型中的RMS肿瘤,这指示用Smac武装溶瘤性VSV的潜力(Dobson,C.C.,等人,Oncotarget,2017 8(2):3495-3508)。
公开了VSV,其中Smac基因(全长或Δ55)已经被插入在VSV基因组中的M基因和G基因之间(图1)。在M基因和G基因之间插入Smac对病毒复制具有最小影响。Smac表达的水平取决于VSV复制的建立,这意味着Smac诱导的内在凋亡的增强将不由于延迟而显著地限制VSV复制。由于VSV经由线粒体途径诱导凋亡,所以Smac将加强VSV的凋亡活性。此外,内在凋亡的诱导也可以抑制自噬,以消除其细胞保护作用。若干行实验被设计以测试这种病毒。
VSV溶瘤中自噬和凋亡之间的交叉对话。
当将Smac释放到胞质溶胶中时,它将结合IAP以防止其与胱天蛋白酶9缔合,从而促进胱天蛋白酶9的活性,随后是胱天蛋白酶3和凋亡。一些Smac-模拟肽示出强有力的促凋亡活性,但是它们的递送仍然是一个挑战。递送Smac的有效方法之一是通过病毒载体来表达它。因此,将Smac基因(全长或Δ55)作为表达单元插入VSV基因组(VSV-S)中。该单元被插入在VSV的M基因和G基因之间(图1)。VSV基因的mRNA水平在VSV感染中从N基因(接近3’末端)下降至L基因(接近5’末端)(Ball,L.A.,等人,J Virol,1999 73(6):4705-12;Wertz,G.W.,等人,Proc Natl Acad Sci USA,1998 95(7):3501-6)。N蛋白和P蛋白是用于支持病毒复制所需的。通过在M基因之后具有插入的表达单元,Smac仅当病毒复制被良好地建立时达到显著水平。此外,这种延迟也可以帮助实现自噬/线粒体自噬的更好的控制,因为自噬抑制剂的延迟应用在促进通过VSV和新城疫病毒的溶瘤方面具有增强的效果(Malilas,W.,等人,Int J Oncol,2014 44(4):1177-84;Hu,L.,等人,Am J Cancer Res,2015 5(12):3612-23;Jiang,K.,等人,BMC Cancer,2014 14:551;Meng,G.,等人,Oncotarget,2014 5(15):6365-74;Samuel,S.,等人,Mol Ther,2013 21(7):1413-23;Shulak,L.,等人,JVirol,2014 88(5):2927-40)。
VSV-S通过反向遗传学产生(Whelan,S.P.,等人,Proc Natl Acad Sci USA,199592(18):8388-92)。简言之,全长Smac或Δ55Smac的编码序列的侧翼是形成新的ORF加上用于新的基因连接的CT的序列(图1)。该节段通过平端克隆在VSV基因组中被克隆。正确的插入物通过DNA测序来鉴定,并且将该基因组质粒与pN、pP和pL共转染到被表达T7聚合酶的牛痘病毒感染的BHK-21细胞中。在建立稳定的病毒原种之后,将VSV-S的生长曲线与wt VSV的生长曲线进行比较。具有所插入的全长Smac的突变体病毒被拯救。将其在HeLa细胞中的生长曲线与wt VSV的生长曲线进行比较(图2)。VSV-S生长至与wt VSV相似的滴度,这表明Smac的插入不损害VSV复制。检查了根据病毒生长的Smac的表达(图3)。
为了评价杀死癌细胞的潜力,将T-47D乳腺癌细胞接种在12孔板中,并且以MOI=5用VSV-S感染。遵循制造商的方案,使用Promega试剂盒(CellTiter(MTT))来评价细胞死亡(图4)。表达mCherry融合的P蛋白的wt VSV被用作对照。由于T-47D具有高水平的XIAP表达(Foster,F.M.,等人,Breast Cancer Res,2009 11(3):R41),因此wt VSV明显地不能有效地杀死它们。VSV-S能够更有效地杀死T-47D。在感染48小时之后,VSV-S杀死超过60%的T-47D细胞,而wt VSV仅可以杀死少于10%。
在动物模型中测试改善的溶瘤性VSV的功效
简单的动物模型是使用典型的癌细胞系中的一种在裸鼠中的异种移植。VSV-S在T-47D异种移植物中被测试。在建立肿瘤之后,每0.4cm31.0x105PFU的VSV-S或以相等量的VSV对照在每只小鼠中被瘤内注射。监测肿瘤的尺寸,并且将小鼠处死并将肿瘤取下。通常得出结论,当被瘤内注射时,VSV-S可以显著地减小肿瘤异种移植物的尺寸。
实施例2:
为了建立同基因模型,将100万个Panc02细胞皮下注射在C57BL/6小鼠的侧翼中。在12天之后,肿瘤生长至约100-200mm3的尺寸。将在0.1mL中的1x105PFU的VSV-S的剂量瘤内注射到肿瘤中(两只小鼠)。在平行小鼠中注射相同剂量的wt VSV作为对照。监测肿瘤体积持续多达9天(图5)。在研究结束时将小鼠安乐死,并且将肿瘤取下并称重(图5)。数据显示,VSV-S可以比wt VSV更有效地抑制肿瘤生长。在该初步研究中测试的动物的数目少,因为这只是一项试验研究。用更多的受试者(n=12)和更高的剂量重复该实验。
离体活性:收集来自肛门囊癌的组织。将肿瘤组织的切片在DPBS中洗涤三次,并且然后成对放置在24孔托盘中。1x105PFU的VSV-S用于在37℃感染每个孔持续1小时。具有mCherry融合的P蛋白的wt VSV被用作对照,这允许通过红色荧光成像的VSV感染的可视化。在1小时病毒吸收之后,去除病毒接种物并且添加新鲜培养基。在感染后72小时,犬肛门囊癌的肿瘤组织清楚地被wt VSV感染,如图6A中所示出的。通过监测PARP的裂解进行由VSV-S诱导的凋亡的分析(图6B),这示出了VSV-S在诱导凋亡中的稳健性。
作用机制:HeLa细胞用VSV-S和wt VSV对照感染。进行蛋白印迹分析以监测Smac的表达(图6)。由于Smac在病毒感染期间由VSV-S表达,所以存在增加的Smac表达水平。通过感染后24小时,尽管大部分细胞已经死亡,Smac水平仍然是高的,如通过降低的GAPDH水平所指示的。由VSV-S表达的蛋白是全长Smac,该全长Smac被加工成成熟Smac(Δ55Smac)。存在增加的成熟Smac水平,但是大多数VSV-S表达的Smac仍然是全长的。这样的意义可能是通过VSV-S的Smac表达不导致Δ55Smac的过早释放,因此病毒可以在感染细胞的凋亡激活之前继续产生。另一方面,在VSV感染的细胞中,内源性成熟Smac的水平在感染后12小时开始下降,并且在感染后24小时下降检测不到。在VSV感染的细胞中观察到少得多的细胞死亡,如通过恒定水平的GAPDH所指示的。用于VSV耗尽成熟Smac的一种方法是通过诱导线粒体自噬,因为成熟Smac驻留在线粒体的膜间空间中。Smac去除的另一个潜在机制是通过由wtVSV感染激活的Smac泛素化(Hao,Y.,等人,Nat Cell Biol,2004 6(9):849-60)。
为了检查凋亡,将MDA-MB 231乳腺癌细胞以MOI=10用VSV-S感染。wt VSV被包括用于比较。基于PARP、胱天蛋白酶-9和胱天蛋白酶-3的裂解产物,存在由VSV-S感染诱导的大量凋亡。另一方面,wt VSV在一定程度上基于PAPR的裂解诱导凋亡。然而,没有观察到胱天蛋白酶-9和胱天蛋白酶-3的裂解。这与其中减少内源性Δ55Smac使得内在途径未被激活的结果一致。在T-47D细胞的VSV-S感染中也观察到类似的胱天蛋白酶裂解模式。为了证实内在途径负责由VSV-S感染诱导的程序性细胞死亡,在各种胱天蛋白酶抑制剂的存在下重复VSV-S感染。胱天蛋白酶-9和胱天蛋白酶-3的抑制剂能够保护细胞免受VSV-S诱导的程序性细胞死亡,这证实内在途径是针对VSV-S诱导的凋亡的主要途径,因为胱天蛋白酶-8抑制剂不能保护细胞免受VSV-S感染。在T-47D细胞的VSV-S感染中也观察到类似的胱天蛋白酶裂解模式。
实施例3:
VSV G蛋白使用LDL受体或其家族成员作为用于病毒进入的宿主受体(Finkelshtein,D.,等人,Proc Natl Acad Sci USA,2013 110(18):7306-11)。由于该受体家族在许多细胞类型中被表达,所以wt VSV可以感染几乎所有的人类细胞。为了使VSV特异性地靶向肿瘤,VSV G中的靶特异性蛋白结构域被插入。整联蛋白αvβ3是这样的候选物,因为它在肿瘤血管的内皮细胞中被高度表达(Demircioglu,F.,等人,Curr Opin Cell Biol,2016 42:121-127;Atkinson,S.J.,等人,Biochem Soc Trans,2014 42(6):1590-5)。
实验设计
靶向VSV G的肿瘤的设计。当病毒在病毒进入期间被暴露于内体中的低pH时,VSV的G蛋白负责附着至宿主受体并且诱导膜融合。靶向结构域被插入在G蛋白中,因此修饰的G将VSV靶向癌症。第一步骤是选择插入的位点。对于融合前(中性pH)形式和融合后(低pH)形式两者,已经确定G蛋白的晶体结构(Roche,S.,等人,Science,2007 315(5813):843-8;Roche,S.,等人,Science,2006 313(5784):187-91)。191处的位点已经被示出允许插入六个氨基酸肽(Schlehuber,L.D.,等人,J Virol,2004 78(10):5079-87)。因此,这是用于插入靶向结构域的良好的位点。该位点在C-末端侧具有Gly。还可以将柔性接头添加至N-末端侧,以允许更大的柔性。
下一步骤是选择靶向蛋白质结构域。RGD是以高亲和力结合整联蛋白αvβ3的序列(Kapp,T.G.,等人,Sci Rep,2017 7:39805)。它可以用合适的接头被插入在191位点处(例如GRGDS(SEQ ID NO:4))。
为了验证RGD的插入不改变VSV G结合其受体和介导膜融合的能力,修饰的VSV G和wt VSV G使用载体pCAGGS表达。将质粒用聚乙烯亚胺转染到293T细胞中。在24h之后,细胞通过4%多聚甲醛被固定。一种用0.2%Triton X-100透化持续5min,另一种不透化。在含有5%山羊血清的PBS中封闭持续1h之后,所有细胞与多克隆抗VSV G在4℃孵育过夜。然后,在与Alexa488-缀合的山羊抗兔第二抗体在37℃孵育持续1h之后,用PBS洗涤细胞。在洗涤之后,将细胞用DAPI染色持续10min,并且然后安装到显微镜载玻片上。载玻片通过Keyence成像系统成像。该实验是确保靶向结构域的插入不阻碍细胞膜的表达和有效转运。下一个实验是测试修饰的VSV G诱导膜融合的能力。遵循在(Schlehuber,L.D.,等人,JVirol,2004 78(10):5079-87)中的方案,将表达G蛋白的细胞暴露于pH 5.2持续1min,并且稍后再暴露1h。功能性G蛋白诱导细胞-细胞融合和合胞体形成。
VSV G和RGD插入的G(RGD G)被克隆到pCAGGS中。在转染到293T细胞中之后,使用针对VSV G的mAb通过蛋白印迹来检测这些蛋白的表达(图7A和图7B)。RGD G示出与wt VSVG相同的表达水平。为了证明RGD G的融合活性,进行细胞的酸处理,并且将核用DAPI染色(图7B)。该研究证实,在191位点处插入GRGDS(SEQ ID NO:4)序列不破坏G蛋白的表达和促融合性质。含有Smac插入物和RGD G的重组VSV已经被拯救。
除非另外定义,否则本文使用的所有技术术语和科学术语具有与所公开的本发明所属领域的技术人员通常理解的相同的含义。本文中引用的出版物及它们引用的材料通过引用具体地并入。
本领域技术人员将认识到,或能够使用不超过常规的实验确定,本文描述的本发明的具体实施方案的许多等同物。这样的等同物意图被所附的权利要求涵盖。
序列表
<110> 佐治亚州立大学研究基金会公司
<120> 重组溶瘤病毒
<130> 220702-2910
<150> US 62/508,430
<151> 2017-05-19
<160> 11
<170> PatentIn version 3.5
<210> 1
<211> 239
<212> PRT
<213> 智人
<400> 1
Met Ala Ala Leu Lys Ser Trp Leu Ser Arg Ser Val Thr Ser Phe Phe
1 5 10 15
Arg Tyr Arg Gln Cys Leu Cys Val Pro Val Val Ala Asn Phe Lys Lys
20 25 30
Arg Cys Phe Ser Glu Leu Ile Arg Pro Trp His Lys Thr Val Thr Ile
35 40 45
Gly Phe Gly Val Thr Leu Cys Ala Val Pro Ile Ala Gln Lys Ser Glu
50 55 60
Pro His Ser Leu Ser Ser Glu Ala Leu Met Arg Arg Ala Val Ser Leu
65 70 75 80
Val Thr Asp Ser Thr Ser Thr Phe Leu Ser Gln Thr Thr Tyr Ala Leu
85 90 95
Ile Glu Ala Ile Thr Glu Tyr Thr Lys Ala Val Tyr Thr Leu Thr Ser
100 105 110
Leu Tyr Arg Gln Tyr Thr Ser Leu Leu Gly Lys Met Asn Ser Glu Glu
115 120 125
Glu Asp Glu Val Trp Gln Val Ile Ile Gly Ala Arg Ala Glu Met Thr
130 135 140
Ser Lys His Gln Glu Tyr Leu Lys Leu Glu Thr Thr Trp Met Thr Ala
145 150 155 160
Val Gly Leu Ser Glu Met Ala Ala Glu Ala Ala Tyr Gln Thr Gly Ala
165 170 175
Asp Gln Ala Ser Ile Thr Ala Arg Asn His Ile Gln Leu Val Lys Leu
180 185 190
Gln Val Glu Glu Val His Gln Leu Ser Arg Lys Ala Glu Thr Lys Leu
195 200 205
Ala Glu Ala Gln Ile Glu Glu Leu Arg Gln Lys Thr Gln Glu Glu Gly
210 215 220
Glu Glu Arg Ala Glu Ser Glu Gln Glu Ala Tyr Leu Arg Glu Asp
225 230 235
<210> 2
<211> 184
<212> PRT
<213> 人工序列
<220>
<223> 合成构建体
<400> 2
Ala Val Pro Ile Ala Gln Lys Ser Glu Pro His Ser Leu Ser Ser Glu
1 5 10 15
Ala Leu Met Arg Arg Ala Val Ser Leu Val Thr Asp Ser Thr Ser Thr
20 25 30
Phe Leu Ser Gln Thr Thr Tyr Ala Leu Ile Glu Ala Ile Thr Glu Tyr
35 40 45
Thr Lys Ala Val Tyr Thr Leu Thr Ser Leu Tyr Arg Gln Tyr Thr Ser
50 55 60
Leu Leu Gly Lys Met Asn Ser Glu Glu Glu Asp Glu Val Trp Gln Val
65 70 75 80
Ile Ile Gly Ala Arg Ala Glu Met Thr Ser Lys His Gln Glu Tyr Leu
85 90 95
Lys Leu Glu Thr Thr Trp Met Thr Ala Val Gly Leu Ser Glu Met Ala
100 105 110
Ala Glu Ala Ala Tyr Gln Thr Gly Ala Asp Gln Ala Ser Ile Thr Ala
115 120 125
Arg Asn His Ile Gln Leu Val Lys Leu Gln Val Glu Glu Val His Gln
130 135 140
Leu Ser Arg Lys Ala Glu Thr Lys Leu Ala Glu Ala Gln Ile Glu Glu
145 150 155 160
Leu Arg Gln Lys Thr Gln Glu Glu Gly Glu Glu Arg Ala Glu Ser Glu
165 170 175
Gln Glu Ala Tyr Leu Arg Glu Asp
180
<210> 3
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 合成构建体
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa 是Val、Thr、或Ile
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa是Pro或Ala
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa是 Gly、Ala、Val、Leu、Ile、Pro、Ser、Thr、Cys、Met、Asn、或
Gln
<400> 3
Ala Xaa Xaa Xaa
1
<210> 4
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成构建体
<400> 4
Gly Arg Gly Asp Ser
1 5
<210> 5
<211> 511
<212> PRT
<213> 智人
<400> 5
Met Lys Cys Leu Leu Tyr Leu Ala Phe Leu Phe Ile Gly Val Asn Cys
1 5 10 15
Lys Phe Thr Ile Val Phe Pro His Asn Arg Lys Gly Asn Trp Lys Asn
20 25 30
Val Pro Ser Asn Tyr His Tyr Cys Pro Ser Ser Ser Asp Leu Asn Trp
35 40 45
His Asn Asp Leu Ile Gly Thr Ala Leu Gln Val Lys Met Pro Lys Ser
50 55 60
His Lys Ala Ile Gln Ala Asp Gly Trp Met Cys His Ala Ser Lys Trp
65 70 75 80
Val Thr Thr Cys Asp Phe Arg Trp Tyr Gly Pro Glu Tyr Ile Thr His
85 90 95
Ser Ile Arg Ser Phe Thr Pro Ser Val Glu Gln Cys Lys Glu Ser Ile
100 105 110
Glu Gln Thr Lys Gln Gly Thr Trp Leu Asn Pro Gly Phe Pro Pro Gln
115 120 125
Ser Cys Gly Tyr Ala Thr Val Thr Asp Ala Glu Ala Ala Ile Val Gln
130 135 140
Val Thr Pro His His Val Leu Val Asp Glu Tyr Thr Gly Glu Trp Val
145 150 155 160
Asp Ser Gln Phe Ile Asn Gly Lys Cys Ser Asn Asp Ile Cys Pro Thr
165 170 175
Val His Asn Ser Thr Thr Trp His Ser Asp Tyr Lys Val Lys Gly Leu
180 185 190
Cys Asp Ser Asn Leu Ile Ser Met Asp Ile Thr Phe Phe Ser Glu Asp
195 200 205
Gly Glu Leu Ser Ser Leu Gly Lys Glu Gly Thr Gly Phe Arg Ser Asn
210 215 220
Tyr Phe Ala Tyr Glu Thr Gly Asp Lys Ala Cys Lys Met Gln Tyr Cys
225 230 235 240
Lys His Trp Gly Val Arg Leu Pro Ser Gly Val Trp Phe Glu Met Ala
245 250 255
Asp Lys Asp Leu Phe Ala Ala Ala Arg Phe Pro Glu Cys Pro Glu Gly
260 265 270
Ser Ser Ile Ser Ala Pro Ser Gln Thr Ser Val Asp Val Ser Leu Ile
275 280 285
Gln Asp Val Glu Arg Ile Leu Asp Tyr Ser Leu Cys Gln Glu Thr Trp
290 295 300
Ser Lys Ile Arg Ala Gly Leu Pro Ile Ser Pro Val Asp Leu Ser Tyr
305 310 315 320
Leu Ala Pro Lys Asn Pro Gly Thr Gly Pro Val Phe Thr Ile Ile Asn
325 330 335
Gly Thr Leu Lys Tyr Phe Glu Thr Arg Tyr Ile Arg Val Asp Ile Ala
340 345 350
Ala Pro Ile Leu Ser Arg Met Val Gly Met Ile Ser Gly Thr Thr Thr
355 360 365
Glu Arg Glu Leu Trp Asp Asp Trp Ala Pro Tyr Glu Asp Val Glu Ile
370 375 380
Gly Pro Asn Gly Val Leu Arg Thr Ser Ser Gly Tyr Lys Phe Pro Leu
385 390 395 400
Tyr Met Ile Gly His Gly Met Leu Asp Ser Asp Leu His Leu Ser Ser
405 410 415
Lys Ala Gln Val Phe Glu His Pro His Ile Gln Asp Ala Ala Ser Gln
420 425 430
Leu Pro Asp Asp Glu Thr Leu Phe Phe Gly Asp Thr Gly Leu Ser Lys
435 440 445
Asn Pro Ile Glu Phe Val Glu Gly Trp Phe Ser Ser Trp Lys Ser Ser
450 455 460
Ile Ala Ser Phe Cys Phe Ile Ile Gly Leu Ile Ile Gly Leu Phe Leu
465 470 475 480
Val Leu Arg Val Gly Ile Tyr Leu Cys Ile Lys Leu Lys His Thr Lys
485 490 495
Lys Arg Gln Ile Tyr Thr Asp Ile Glu Met Asn Arg Leu Gly Lys
500 505 510
<210> 6
<211> 516
<212> PRT
<213> 人工序列
<220>
<223> 合成构建体
<400> 6
Met Lys Cys Leu Leu Tyr Leu Ala Phe Leu Phe Ile Gly Val Asn Cys
1 5 10 15
Lys Phe Thr Ile Val Phe Pro His Asn Arg Lys Gly Asn Trp Lys Asn
20 25 30
Val Pro Ser Asn Tyr His Tyr Cys Pro Ser Ser Ser Asp Leu Asn Trp
35 40 45
His Asn Asp Leu Ile Gly Thr Ala Leu Gln Val Lys Met Pro Lys Ser
50 55 60
His Lys Ala Ile Gln Ala Asp Gly Trp Met Cys His Ala Ser Lys Trp
65 70 75 80
Val Thr Thr Cys Asp Phe Arg Trp Tyr Gly Pro Glu Tyr Ile Thr His
85 90 95
Ser Ile Arg Ser Phe Thr Pro Ser Val Glu Gln Cys Lys Glu Ser Ile
100 105 110
Glu Gln Thr Lys Gln Gly Thr Trp Leu Asn Pro Gly Phe Pro Pro Gln
115 120 125
Ser Cys Gly Tyr Ala Thr Val Thr Asp Ala Glu Ala Ala Ile Val Gln
130 135 140
Val Thr Pro His His Val Leu Val Asp Glu Tyr Thr Gly Glu Trp Val
145 150 155 160
Asp Ser Gln Phe Ile Asn Gly Lys Cys Ser Asn Asp Ile Cys Pro Thr
165 170 175
Val His Asn Ser Thr Thr Trp His Ser Asp Tyr Lys Val Lys Gly Arg
180 185 190
Gly Asp Ser Gly Leu Cys Asp Ser Asn Leu Ile Ser Met Asp Ile Thr
195 200 205
Phe Phe Ser Glu Asp Gly Glu Leu Ser Ser Leu Gly Lys Glu Gly Thr
210 215 220
Gly Phe Arg Ser Asn Tyr Phe Ala Tyr Glu Thr Gly Asp Lys Ala Cys
225 230 235 240
Lys Met Gln Tyr Cys Lys His Trp Gly Val Arg Leu Pro Ser Gly Val
245 250 255
Trp Phe Glu Met Ala Asp Lys Asp Leu Phe Ala Ala Ala Arg Phe Pro
260 265 270
Glu Cys Pro Glu Gly Ser Ser Ile Ser Ala Pro Ser Gln Thr Ser Val
275 280 285
Asp Val Ser Leu Ile Gln Asp Val Glu Arg Ile Leu Asp Tyr Ser Leu
290 295 300
Cys Gln Glu Thr Trp Ser Lys Ile Arg Ala Gly Leu Pro Ile Ser Pro
305 310 315 320
Val Asp Leu Ser Tyr Leu Ala Pro Lys Asn Pro Gly Thr Gly Pro Val
325 330 335
Phe Thr Ile Ile Asn Gly Thr Leu Lys Tyr Phe Glu Thr Arg Tyr Ile
340 345 350
Arg Val Asp Ile Ala Ala Pro Ile Leu Ser Arg Met Val Gly Met Ile
355 360 365
Ser Gly Thr Thr Thr Glu Arg Glu Leu Trp Asp Asp Trp Ala Pro Tyr
370 375 380
Glu Asp Val Glu Ile Gly Pro Asn Gly Val Leu Arg Thr Ser Ser Gly
385 390 395 400
Tyr Lys Phe Pro Leu Tyr Met Ile Gly His Gly Met Leu Asp Ser Asp
405 410 415
Leu His Leu Ser Ser Lys Ala Gln Val Phe Glu His Pro His Ile Gln
420 425 430
Asp Ala Ala Ser Gln Leu Pro Asp Asp Glu Thr Leu Phe Phe Gly Asp
435 440 445
Thr Gly Leu Ser Lys Asn Pro Ile Glu Phe Val Glu Gly Trp Phe Ser
450 455 460
Ser Trp Lys Ser Ser Ile Ala Ser Phe Cys Phe Ile Ile Gly Leu Ile
465 470 475 480
Ile Gly Leu Phe Leu Val Leu Arg Val Gly Ile Tyr Leu Cys Ile Lys
485 490 495
Leu Lys His Thr Lys Lys Arg Gln Ile Tyr Thr Asp Ile Glu Met Asn
500 505 510
Arg Leu Gly Lys
515
<210> 7
<211> 65
<212> DNA
<213> 人工序列
<220>
<223> 合成构建体
<400> 7
ctgttaatgc taatcgtgat aggggttttt gcctccaact gactcctaca tattagcatt 60
aacag 65
<210> 8
<211> 11934
<212> DNA
<213> 人工序列
<220>
<223> 合成构建体
<400> 8
acgaagacaa acaaaccatt attatcatta aaaggctcag gagaaacttt aacagtaatc 60
aaaatgtctg ttacagtcaa gagaatcatt gacaacacag tcatagttcc aaaacttcct 120
gcaaatgagg atccagtgga atacccggca gattacttca gaaaatcaaa ggagattcct 180
ctttacatca atactacaaa aagtttgtca gatctaagag gatatgtcta ccaaggcctc 240
aaatccggaa atgtatcaat catacatgtc aacagctact tgtatggagc attaaaggac 300
atccggggta agttggataa agattggtca agtttcggaa taaacatcgg gaaagcaggg 360
gatacaatcg gaatatttga ccttgtatcc ttgaaagccc tggacggcgt acttccagat 420
ggagtatcgg atgcttccag aaccagcgca gatgacaaat ggttgccttt gtatctactt 480
ggcttataca gagtgggcag aacacaaatg cctgaataca gaaaaaagct catggatggg 540
ctgacaaatc aatgcaaaat gatcaatgaa cagtttgaac ctcttgtgcc agaaggtcgt 600
gacatttttg atgtgtgggg aaatgacagt aattacacaa aaattgtcgc tgcagtggac 660
atgttcttcc acatgttcaa aaaacatgaa tgtgcctcgt tcagatacgg aactattgtt 720
tccagattca aagattgtgc tgcattggca acatttggac acctctgcaa aataaccgga 780
atgtctacag aagatgtaac gacctggatc ttgaaccgag aagttgcaga tgaaatggtc 840
caaatgatgc ttccaggcca agaaattgac aaggccgatt catacatgcc ttatttgatc 900
gactttggat tgtcttctaa gtctccatat tcttccgtca aaaaccctgc cttccacttc 960
tgggggcaat tgacagctct tctgctcaga tccaccagag caaggaatgc ccgacagcct 1020
gatgacattg agtatacatc tcttactaca gcaggtttgt tgtacgctta tgcagtagga 1080
tcctctgccg acttggcaca acagttttgt gttggagata acaaatacac tccagatgat 1140
agtaccggag gattgacgac taatgcaccg ccacaaggca gagatgtggt cgaatggctc 1200
ggatggtttg aagatcaaaa cagaaaaccg actcctgata tgatgcagta tgcgaaaaga 1260
gcagtcatgt cactgcaagg cctaagagag aagacaattg gcaagtatgc taagtcagaa 1320
tttgacaaat gaccctataa ttctcagatc acctattata tattatgcta catatgaaaa 1380
aaactaacag atatcatgga taatctcaca aaagttcgtg agtatctcaa gtcctactct 1440
cgtctagatc aggcggtagg agagatagat gagatcgaag cacaacgagc tgaaaagtcc 1500
aattatgagt tgttccaaga ggacggagtg gaagagcata ctaggccctc ttattttcag 1560
gcagcagatg attctgacac agaatctgaa ccagaaattg aagacaatca aggcttgtat 1620
gtaccagatc cggaagctga gcaagttgaa ggctttatac aggggccttt agatgactat 1680
gcagatgagg acgtggatgt tgtattcact tcggactgga aacagcctga gcttgaatcc 1740
gacgagcatg gaaagacctt acggttgaca ttgccagagg gtttaagtgg agagcagaaa 1800
tcccagtggc ttttgacgat taaagcagtc gttcaaagtg ccaaacactg gaatctggca 1860
gagtgcacat ttgaagcatc gggagaaggg gtcatcataa aaaagcgcca gataactccg 1920
gatgtatata aggtcactcc agtgatgaac acacatccgt accaatcaga agccgtatca 1980
gatgtttggt ctctctcaaa gacatccatg actttccaac ccaagaaagc aagtcttcag 2040
cctctcacca tatccttgga tgaattgttc tcatctagag gagaattcat ctctgtcgga 2100
ggtaacggac gaatgtctca taaagaggcc atcctgctcg gtctgaggta caaaaagttg 2160
tacaatcagg cgagagtcaa atattctctg tagactatga aaaaaagtaa cagatatcac 2220
aatctaagtg ttatcccaat ccattcatca tgagttcctt aaagaagatt ctcggtctga 2280
aggggaaagg taagaaatct aagaaattag ggatcgcacc acccccttat gaagaggaca 2340
ctagcatgga gtatgctccg agcgctccaa ttgacaaatc ctattttgga gttgacgaga 2400
tggacaccta tgatccgaat caattaagat atgagaaatt cttctttaca gtgaaaatga 2460
cggttagatc taatcgtccg ttcagaacat actcagatgt ggcagccgct gtatcccatt 2520
gggatcacat gtacatcgga atggcaggga aacgtccctt ctacaaaatc ttggcttttt 2580
tgggttcttc taatctaaag gccactccag cggtattggc agatcaaggt caaccagagt 2640
atcacgctca ctgcgaaggc agggcttatt tgccacatag gatggggaag acccctccca 2700
tgctcaatgt accagagcac ttcagaagac cattcaatat aggtctttac aagggaacga 2760
ttgagctcac aatgaccatc tacgatgatg agtcactgga agcagctcct atgatctggg 2820
atcatttcaa ttcttccaaa ttttctgatt tcagagagaa ggccttaatg tttggcctga 2880
ttgtcgagaa aaaggcatct ggagcgtggg tcctggattc tatcagccac ttcaaatgag 2940
ctagtctagc ttccagcttc tgaacaatcc ccggtttact cagtctctcc taattccagc 3000
ctttcgaaca actaatatcc tgtcttttct atccctatga aaaaaactaa cagatctcga 3060
gatggcggct ctgaagagtt ggctgtcgcg cagcgtaact tcattcttca ggtacagaca 3120
gtgtttgtgt gttcctgttg tggctaactt taagaagcgg tgtttctcag aattgataag 3180
accatggcac aaaactgtga cgattggctt tggagtaacc ctgtgtgcgg ttcctattgc 3240
acagaaatca gagcctcatt cccttagtag tgaagcattg atgaggagag cagtgtcttt 3300
ggtaacagat agcacctcta cctttctctc tcagaccaca tatgcgttga ttgaagctat 3360
tactgaatat actaaggctg tttatacctt aacttctctt taccgacaat atacaagttt 3420
acttgggaaa atgaattcag aggaggaaga tgaagtgtgg caggtgatca taggagccag 3480
agctgagatg acttcaaaac accaagagta cttgaagctg gaaaccactt ggatgactgc 3540
agttggtctt tcagagatgg cagcagaagc tgcatatcaa actggcgcag atcaggcctc 3600
tataaccgcc aggaatcaca ttcagctggt gaaactgcag gtggaagagg tgcaccagct 3660
ctcccggaaa gcagaaacca agctggcaga agcacagata gaagagctcc gtcagaaaac 3720
acaggaggaa ggggaggagc gggctgagtc ggagcaggag gcctacctgc gtgaggattg 3780
actcgagtat attttaattt ttaattttta tgaaaaaaac taacagagat cgatctgttt 3840
ccttgacacc atgaagtgcc ttttgtactt agctttttta ttcatcgggg tgaattgcaa 3900
gttcaccata gtttttccac acaaccgaaa aggaaactgg aaaaatgttc cttccaatta 3960
ccattattgc ccgtcaagct cagatttaaa ttggcataat gacttaatag gcacagcctt 4020
acaagtcaaa atgcccaaga gtcacaaggc tattcaagca gacggttgga tgtgtcatgc 4080
ttccaaatgg gtcactactt gtgatttccg ctggtacgga ccggagtata taacacattc 4140
catccgatcc ttcactccat ctgtagaaca atgcaaggaa agcattgaac aaacgaaaca 4200
aggaacttgg ctgaatccag gcttccctcc tcaaagttgt ggatatgcaa ctgtgacgga 4260
tgctgaagca gcgattgtcc aggtgactcc tcaccatgtg cttgttgatg aatacacagg 4320
agaatgggtt gattcacagt tcatcaacgg aaaatgcagc aatgacatat gccccactgt 4380
ccataactcc acaacctggc attccgacta taaggtcaaa gggctatgtg attctaacct 4440
catttccatg gacatcacct tcttctcaga ggacggagag ctatcatccc taggaaagga 4500
gggcacaggg ttcagaagta actactttgc ttatgaaact ggagacaagg cctgcaaaat 4560
gcagtactgc aagcattggg gagtcagact cccatcaggt gtctggttcg agatggctga 4620
taaggatctc tttgctgcag ccagattccc tgaatgccca gaagggtcaa gtatctctgc 4680
tccatctcag acctcagtgg atgtaagtct cattcaggac gttgagagga tcttggatta 4740
ttccctctgc caagaaacct ggagcaaaat cagagcgggt cttcccatct ctccagtgga 4800
tctcagctat cttgctccta aaaacccagg aaccggtcct gtctttacca taatcaatgg 4860
taccctaaaa tactttgaga ccagatacat cagagtcgat attgctgctc caatcctctc 4920
aagaatggtc ggaatgatca gtggaactac cacagaaagg gaactgtggg atgactgggc 4980
tccatatgaa gacgtggaaa ttggacccaa tggagttctg aggaccagtt caggatataa 5040
gtttccttta tatatgattg gacatggtat gttggactcc gatcttcatc ttagctcaaa 5100
ggctcaggtg tttgaacatc ctcacattca agacgctgct tcgcagcttc ctgatgatga 5160
gactttattt tttggtgata ctgggctatc caaaaatcca atcgagtttg tagaaggttg 5220
gttcagtagt tggaagagct ctattgcctc tttttgcttt atcatagggt taatcattgg 5280
actattcttg gttctccgag ttggtattta tctttgcatt aaattaaagc acaccaagaa 5340
aagacagatt tatacagaca tagagatgaa ccgacttgga aagtaactca aatcctgcac 5400
aacagattct tcatgtttga accaaatcaa cttgtgatat catgctcaaa gaggccttaa 5460
ttatatttta atttttaatt tttatgaaaa aaactaacag caatcatgga agtccacgat 5520
tttgagaccg acgagttcaa tgatttcaat gaagatgact atgccacaag agaattcctg 5580
aatcccgatg agcgcatgac gtacttgaat catgctgatt acaatttgaa ttctcctcta 5640
attagtgatg atattgacaa tttgatcagg aaattcaatt ctcttccgat tccctcgatg 5700
tgggatagta agaactggga tggagttctt gagatgttaa catcatgtca agccaatccc 5760
atctcaacat ctcagatgca taaatggatg ggaagttggt taatgtctga taatcatgat 5820
gccagtcaag ggtatagttt tttacatgaa gtggacaaag aggcagaaat aacatttgac 5880
gtggtggaga ccttcatccg cggctggggc aacaaaccaa ttgaatacat caaaaaggaa 5940
agatggactg actcattcaa aattctcgct tatttgtgtc aaaagttttt ggacttacac 6000
aagttgacat taatcttaaa tgctgtctct gaggtggaat tgctcaactt ggcgaggact 6060
ttcaaaggca aagtcagaag aagttctcat ggaacgaaca tatgcaggat tagggttccc 6120
agcttgggtc ctacttttat ttcagaagga tgggcttact tcaagaaact tgatattcta 6180
atggaccgaa actttctgtt aatggtcaaa gatgtgatta tagggaggat gcaaacggtg 6240
ctatccatgg tatgtagaat agacaacctg ttctcagagc aagacatctt ctcccttcta 6300
aatatctaca gaattggaga taaaattgtg gagaggcagg gaaatttttc ttatgacttg 6360
attaaaatgg tggaaccgat atgcaacttg aagctgatga aattagcaag agaatcaagg 6420
cctttagtcc cacaattccc tcattttgaa aatcatatca agacttctgt tgatgaaggg 6480
gcaaaaattg accgaggtat aagattcctc catgatcaga taatgagtgt gaaaacagtg 6540
gatctcacac tggtgattta tggatcgttc agacattggg gtcatccttt tatagattat 6600
tacactggac tagaaaaatt acattcccaa gtaaccatga agaaagatat tgatgtgtca 6660
tatgcaaaag cacttgcaag tgatttagct cggattgttc tatttcaaca gttcaatgat 6720
cataaaaagt ggttcgtgaa tggagacttg ctccctcatg atcatccctt taaaagtcat 6780
gttaaagaaa atacatggcc cacagctgct caagttcaag attttggaga taaatggcat 6840
gaacttccgc tgattaaatg ttttgaaata cccgacttac tagacccatc gataatatac 6900
tctgacaaaa gtcattcaat gaataggtca gaggtgttga aacatgtccg aatgaatccg 6960
aacactccta tccctagtaa aaaggtgttg cagactatgt tggacacaaa ggctaccaat 7020
tggaaagaat ttcttaaaga gattgatgag aagggcttag atgatgatga tctaattatt 7080
ggtcttaaag gaaaggagag ggaactgaag ttggcaggta gatttttctc cctaatgtct 7140
tggaaattgc gagaatactt tgtaattacc gaatatttga taaagactca tttcgtccct 7200
atgtttaaag gcctgacaat ggcggacgat ctaactgcag tcattaaaaa gatgttagat 7260
tcctcatccg gccaaggatt gaagtcatat gaggcaattt gcatagccaa tcacattgat 7320
tacgaaaaat ggaataacca ccaaaggaag ttatcaaacg gcccagtgtt ccgagttatg 7380
ggccagttct taggttatcc atccttaatc gagagaactc atgaattttt tgagaaaagt 7440
cttatatact acaatggaag accagacttg atgcgtgttc acaacaacac actgatcaat 7500
tcaacctccc aacgagtttg ttggcaagga caagagggtg gactggaagg tctacggcaa 7560
aaaggatgga gtatcctcaa tctactggtt attcaaagag aggctaaaat cagaaacact 7620
gctgtcaaag tcttggcaca aggtgataat caagttattt gcacacagta taaaacgaag 7680
aaatcgagaa acgttgtaga attacagggt gctctcaatc aaatggtttc taataatgag 7740
aaaattatga ctgcaatcaa aatagggaca gggaagttag gacttttgat aaatgacgat 7800
gagactatgc aatctgcaga ttacttgaat tatggaaaaa taccgatttt ccgtggagtg 7860
attagagggt tagagaccaa gagatggtca cgagtgactt gtgtcaccaa tgaccaaata 7920
cccacttgtg ctaatataat gagctcagtt tccacaaatg ctctcaccgt agctcatttt 7980
gctgagaacc caatcaatgc catgatacag tacaattatt ttgggacatt tgctagactc 8040
ttgttgatga tgcatgatcc tgctcttcgt caatcattgt atgaagttca agataagata 8100
ccgggcttgc acagttctac tttcaaatac gccatgttgt atttggaccc ttccattgga 8160
ggagtgtcgg gcatgtcttt gtccaggttt ttgattagag ccttcccaga tcccgtaaca 8220
gaaagtctct cattctggag attcatccat gtacatgctc gaagtgagca tctgaaggag 8280
atgagtgcag tatttggaaa ccccgagata gccaagtttc gaataactca catagacaag 8340
ctagtagaag atccaacctc tctgaacatc gctatgggaa tgagtccagc gaacttgtta 8400
aagactgagg ttaaaaaatg cttaatcgaa tcaagacaaa ccatcaggaa ccaggtgatt 8460
aaggatgcaa ccatatattt gtatcatgaa gaggatcggc tcagaagttt cttatggtca 8520
ataaatcctc tgttccctag atttttaagt gaattcaaat caggcacttt tttgggagtc 8580
gcagacgggc tcatcagtct atttcaaaat tctcgtacta ttcggaactc ctttaagaaa 8640
aagtatcata gggaattgga tgatttgatt gtgaggagtg aggtatcctc tttgacacat 8700
ttagggaaac ttcatttgag aaggggatca tgtaaaatgt ggacatgttc agctactcat 8760
gctgacacat taagatacaa atcctggggc cgtacagtta ttgggacaac tgtaccccat 8820
ccattagaaa tgttgggtcc acaacatcga aaagagactc cttgtgcacc atgtaacaca 8880
tcagggttca attatgtttc tgtgcattgt ccagacggga tccatgacgt ctttagttca 8940
cggggaccat tgcctgctta tctagggtct aaaacatctg aatctacatc tattttgcag 9000
ccttgggaaa gggaaagcaa agtcccactg attaaaagag ctacacgtct tagagatgct 9060
atctcttggt ttgttgaacc cgactctaaa ctagcaatga ctatactttc taacatccac 9120
tctttaacag gcgaagaatg gaccaaaagg cagcatgggt tcaaaagaac agggtctgcc 9180
cttcataggt tttcgacatc tcggatgagc catggtgggt tcgcatctca gagcactgca 9240
gcattgacca ggttgatggc aactacagac accatgaggg atctgggaga tcagaatttc 9300
gactttttat tccaagcaac gttgctctat gctcaaatta ccaccactgt tgcaagagac 9360
ggatggatca ccagttgtac agatcattat catattgcct gtaagtcctg tttgagaccc 9420
atagaagaga tcaccctgga ctcaagtatg gactacacgc ccccagatgt atcccatgtg 9480
ctgaagacat ggaggaatgg ggaaggttcg tggggacaag agataaaaca gatctatcct 9540
ttagaaggga attggaagaa tttagcacct gctgagcaat cctatcaagt cggcagatgt 9600
ataggttttc tatatggaga cttggcgtat agaaaatcta ctcatgccga ggacagttct 9660
ctatttcctc tatctataca aggtcgtatt agaggtcgag gtttcttaaa agggttgcta 9720
gacggattaa tgagagcaag ttgctgccaa gtaatacacc ggagaagtct ggctcatttg 9780
aagaggccgg ccaacgcagt gtacggaggt ttgatttact tgattgataa attgagtgta 9840
tcacctccat tcctttctct tactagatca ggacctatta gagacgaatt agaaacgatt 9900
ccccacaaga tcccaacctc ctatccgaca agcaaccgtg atatgggggt gattgtcaga 9960
aattacttca aataccaatg ccgtctaatt gaaaagggaa aatacagatc acattattca 10020
caattatggt tattctcaga tgtcttatcc atagacttca ttggaccatt ctctatttcc 10080
accaccctct tgcaaatcct atacaagcca tttttatctg ggaaagataa gaatgagttg 10140
agagagctgg caaatctttc ttcattgcta agatcaggag aggggtggga agacatacat 10200
gtgaaattct tcaccaagga catattattg tgtccagagg aaatcagaca tgcttgcaag 10260
ttcgggattg ctaaggataa taataaagac atgagctatc ccccttgggg aagggaatcc 10320
agagggacaa ttacaacaat ccctgtttat tatacgacca ccccttaccc aaagatgcta 10380
gagatgcctc caagaatcca aaatcccctg ctgtccggaa tcaggttggg ccaattacca 10440
actggcgctc attataaaat tcggagtata ttacatggaa tgggaatcca ttacagggac 10500
ttcttgagtt gtggagacgg ctccggaggg atgactgctg cattactacg agaaaatgtg 10560
catagcagag gaatattcaa tagtctgtta gaattatcag ggtcagtcat gcgaggcgcc 10620
tctcctgagc cccccagtgc cctagaaact ttaggaggag ataaatcgag atgtgtaaat 10680
ggtgaaacat gttgggaata tccatctgac ttatgtgacc caaggacttg ggactatttc 10740
ctccgactca aagcaggctt ggggcttcaa attgatttaa ttgtaatgga tatggaagtt 10800
cgggattctt ctactagcct gaaaattgag acgaatgtta gaaattatgt gcaccggatt 10860
ttggatgagc aaggagtttt aatctacaag acttatggaa catatatttg tgagagcgaa 10920
aagaatgcag taacaatcct tggtcccatg ttcaagacgg tcgacttagt tcaaacagaa 10980
tttagtagtt ctcaaacgtc tgaagtatat atggtatgta aaggtttgaa gaaattaatc 11040
gatgaaccca atcccgattg gtcttccatc aatgaatcct ggaaaaacct gtacgcattc 11100
cagtcatcag aacaggaatt tgccagagca aagaaggtta gtacatactt taccttgaca 11160
ggtattccct cccaattcat tcctgatcct tttgtaaaca ttgagactat gctacaaata 11220
ttcggagtac ccacgggtgt gtctcatgcg gctgccttaa aatcatctga tagacctgca 11280
gatttattga ccattagcct tttttatatg gcgattatat cgtattataa catcaatcat 11340
atcagagtag gaccgatacc tccgaacccc ccatcagatg gaattgcaca aaatgtgggg 11400
atcgctataa ctggtataag cttttggctg agtttgatgg agaaagacat tccactatat 11460
caacagtgtt tggcagttat ccagcaatca tttccgatta ggtgggaggc tatttcagta 11520
aaaggaggat acaagcagaa gtggagtact agaggtgatg ggctcccaaa agatacccga 11580
atttcagact ccttggcccc aatcgggaac tggatcagat ctttggaatt ggtccgaaac 11640
caagttcgtc taaatccatt caataagatc ttgttcaatc agctatgtcg tacagtggat 11700
aatcatttga agtggtcaaa tttgcgaaaa aacacaggaa tgattgaatg gatcaatggg 11760
cgaatttcaa aagaagaccg gtctatactg atgttgaaga gtgacctaca tgaggaaaac 11820
tcttggagag attaaaaaat caggaggaga ctccaaactt taagtatgaa aaaaactttg 11880
atccttaaga ccctcttgtg gtttttattt tttatctggt tttgtggtct tcgt 11934
<210> 9
<211> 11772
<212> DNA
<213> 人工序列
<220>
<223> 合成构建体
<400> 9
acgaagacaa acaaaccatt attatcatta aaaggctcag gagaaacttt aacagtaatc 60
aaaatgtctg ttacagtcaa gagaatcatt gacaacacag tcatagttcc aaaacttcct 120
gcaaatgagg atccagtgga atacccggca gattacttca gaaaatcaaa ggagattcct 180
ctttacatca atactacaaa aagtttgtca gatctaagag gatatgtcta ccaaggcctc 240
aaatccggaa atgtatcaat catacatgtc aacagctact tgtatggagc attaaaggac 300
atccggggta agttggataa agattggtca agtttcggaa taaacatcgg gaaagcaggg 360
gatacaatcg gaatatttga ccttgtatcc ttgaaagccc tggacggcgt acttccagat 420
ggagtatcgg atgcttccag aaccagcgca gatgacaaat ggttgccttt gtatctactt 480
ggcttataca gagtgggcag aacacaaatg cctgaataca gaaaaaagct catggatggg 540
ctgacaaatc aatgcaaaat gatcaatgaa cagtttgaac ctcttgtgcc agaaggtcgt 600
gacatttttg atgtgtgggg aaatgacagt aattacacaa aaattgtcgc tgcagtggac 660
atgttcttcc acatgttcaa aaaacatgaa tgtgcctcgt tcagatacgg aactattgtt 720
tccagattca aagattgtgc tgcattggca acatttggac acctctgcaa aataaccgga 780
atgtctacag aagatgtaac gacctggatc ttgaaccgag aagttgcaga tgaaatggtc 840
caaatgatgc ttccaggcca agaaattgac aaggccgatt catacatgcc ttatttgatc 900
gactttggat tgtcttctaa gtctccatat tcttccgtca aaaaccctgc cttccacttc 960
tgggggcaat tgacagctct tctgctcaga tccaccagag caaggaatgc ccgacagcct 1020
gatgacattg agtatacatc tcttactaca gcaggtttgt tgtacgctta tgcagtagga 1080
tcctctgccg acttggcaca acagttttgt gttggagata acaaatacac tccagatgat 1140
agtaccggag gattgacgac taatgcaccg ccacaaggca gagatgtggt cgaatggctc 1200
ggatggtttg aagatcaaaa cagaaaaccg actcctgata tgatgcagta tgcgaaaaga 1260
gcagtcatgt cactgcaagg cctaagagag aagacaattg gcaagtatgc taagtcagaa 1320
tttgacaaat gaccctataa ttctcagatc acctattata tattatgcta catatgaaaa 1380
aaactaacag atatcatgga taatctcaca aaagttcgtg agtatctcaa gtcctactct 1440
cgtctagatc aggcggtagg agagatagat gagatcgaag cacaacgagc tgaaaagtcc 1500
aattatgagt tgttccaaga ggacggagtg gaagagcata ctaggccctc ttattttcag 1560
gcagcagatg attctgacac agaatctgaa ccagaaattg aagacaatca aggcttgtat 1620
gtaccagatc cggaagctga gcaagttgaa ggctttatac aggggccttt agatgactat 1680
gcagatgagg acgtggatgt tgtattcact tcggactgga aacagcctga gcttgaatcc 1740
gacgagcatg gaaagacctt acggttgaca ttgccagagg gtttaagtgg agagcagaaa 1800
tcccagtggc ttttgacgat taaagcagtc gttcaaagtg ccaaacactg gaatctggca 1860
gagtgcacat ttgaagcatc gggagaaggg gtcatcataa aaaagcgcca gataactccg 1920
gatgtatata aggtcactcc agtgatgaac acacatccgt accaatcaga agccgtatca 1980
gatgtttggt ctctctcaaa gacatccatg actttccaac ccaagaaagc aagtcttcag 2040
cctctcacca tatccttgga tgaattgttc tcatctagag gagaattcat ctctgtcgga 2100
ggtaacggac gaatgtctca taaagaggcc atcctgctcg gtctgaggta caaaaagttg 2160
tacaatcagg cgagagtcaa atattctctg tagactatga aaaaaagtaa cagatatcac 2220
aatctaagtg ttatcccaat ccattcatca tgagttcctt aaagaagatt ctcggtctga 2280
aggggaaagg taagaaatct aagaaattag ggatcgcacc acccccttat gaagaggaca 2340
ctagcatgga gtatgctccg agcgctccaa ttgacaaatc ctattttgga gttgacgaga 2400
tggacaccta tgatccgaat caattaagat atgagaaatt cttctttaca gtgaaaatga 2460
cggttagatc taatcgtccg ttcagaacat actcagatgt ggcagccgct gtatcccatt 2520
gggatcacat gtacatcgga atggcaggga aacgtccctt ctacaaaatc ttggcttttt 2580
tgggttcttc taatctaaag gccactccag cggtattggc agatcaaggt caaccagagt 2640
atcacgctca ctgcgaaggc agggcttatt tgccacatag gatggggaag acccctccca 2700
tgctcaatgt accagagcac ttcagaagac cattcaatat aggtctttac aagggaacga 2760
ttgagctcac aatgaccatc tacgatgatg agtcactgga agcagctcct atgatctggg 2820
atcatttcaa ttcttccaaa ttttctgatt tcagagagaa ggccttaatg tttggcctga 2880
ttgtcgagaa aaaggcatct ggagcgtggg tcctggattc tatcagccac ttcaaatgag 2940
ctagtctagc ttccagcttc tgaacaatcc ccggtttact cagtctctcc taattccagc 3000
ctttcgaaca actaatatcc tgtcttttct atccctatga aaaaaactaa cagatctcga 3060
gatggcggtt cctattgcac agaaatcaga gcctcattcc cttagtagtg aagcattgat 3120
gaggagagca gtgtctttgg taacagatag cacctctacc tttctctctc agaccacata 3180
tgcgttgatt gaagctatta ctgaatatac taaggctgtt tataccttaa cttctcttta 3240
ccgacaatat acaagtttac ttgggaaaat gaattcagag gaggaagatg aagtgtggca 3300
ggtgatcata ggagccagag ctgagatgac ttcaaaacac caagagtact tgaagctgga 3360
aaccacttgg atgactgcag ttggtctttc agagatggca gcagaagctg catatcaaac 3420
tggcgcagat caggcctcta taaccgccag gaatcacatt cagctggtga aactgcaggt 3480
ggaagaggtg caccagctct cccggaaagc agaaaccaag ctggcagaag cacagataga 3540
agagctccgt cagaaaacac aggaggaagg ggaggagcgg gctgagtcgg agcaggaggc 3600
ctacctgcgt gaggattgac tcgagtatat tttaattttt aatttttatg aaaaaaacta 3660
acagagatcg atctgtttcc ttgacaccat gaagtgcctt ttgtacttag cttttttatt 3720
catcggggtg aattgcaagt tcaccatagt ttttccacac aaccgaaaag gaaactggaa 3780
aaatgttcct tccaattacc attattgccc gtcaagctca gatttaaatt ggcataatga 3840
cttaataggc acagccttac aagtcaaaat gcccaagagt cacaaggcta ttcaagcaga 3900
cggttggatg tgtcatgctt ccaaatgggt cactacttgt gatttccgct ggtacggacc 3960
ggagtatata acacattcca tccgatcctt cactccatct gtagaacaat gcaaggaaag 4020
cattgaacaa acgaaacaag gaacttggct gaatccaggc ttccctcctc aaagttgtgg 4080
atatgcaact gtgacggatg ctgaagcagc gattgtccag gtgactcctc accatgtgct 4140
tgttgatgaa tacacaggag aatgggttga ttcacagttc atcaacggaa aatgcagcaa 4200
tgacatatgc cccactgtcc ataactccac aacctggcat tccgactata aggtcaaagg 4260
gctatgtgat tctaacctca tttccatgga catcaccttc ttctcagagg acggagagct 4320
atcatcccta ggaaaggagg gcacagggtt cagaagtaac tactttgctt atgaaactgg 4380
agacaaggcc tgcaaaatgc agtactgcaa gcattgggga gtcagactcc catcaggtgt 4440
ctggttcgag atggctgata aggatctctt tgctgcagcc agattccctg aatgcccaga 4500
agggtcaagt atctctgctc catctcagac ctcagtggat gtaagtctca ttcaggacgt 4560
tgagaggatc ttggattatt ccctctgcca agaaacctgg agcaaaatca gagcgggtct 4620
tcccatctct ccagtggatc tcagctatct tgctcctaaa aacccaggaa ccggtcctgt 4680
ctttaccata atcaatggta ccctaaaata ctttgagacc agatacatca gagtcgatat 4740
tgctgctcca atcctctcaa gaatggtcgg aatgatcagt ggaactacca cagaaaggga 4800
actgtgggat gactgggctc catatgaaga cgtggaaatt ggacccaatg gagttctgag 4860
gaccagttca ggatataagt ttcctttata tatgattgga catggtatgt tggactccga 4920
tcttcatctt agctcaaagg ctcaggtgtt tgaacatcct cacattcaag acgctgcttc 4980
gcagcttcct gatgatgaga ctttattttt tggtgatact gggctatcca aaaatccaat 5040
cgagtttgta gaaggttggt tcagtagttg gaagagctct attgcctctt tttgctttat 5100
catagggtta atcattggac tattcttggt tctccgagtt ggtatttatc tttgcattaa 5160
attaaagcac accaagaaaa gacagattta tacagacata gagatgaacc gacttggaaa 5220
gtaactcaaa tcctgcacaa cagattcttc atgtttgaac caaatcaact tgtgatatca 5280
tgctcaaaga ggccttaatt atattttaat ttttaatttt tatgaaaaaa actaacagca 5340
atcatggaag tccacgattt tgagaccgac gagttcaatg atttcaatga agatgactat 5400
gccacaagag aattcctgaa tcccgatgag cgcatgacgt acttgaatca tgctgattac 5460
aatttgaatt ctcctctaat tagtgatgat attgacaatt tgatcaggaa attcaattct 5520
cttccgattc cctcgatgtg ggatagtaag aactgggatg gagttcttga gatgttaaca 5580
tcatgtcaag ccaatcccat ctcaacatct cagatgcata aatggatggg aagttggtta 5640
atgtctgata atcatgatgc cagtcaaggg tatagttttt tacatgaagt ggacaaagag 5700
gcagaaataa catttgacgt ggtggagacc ttcatccgcg gctggggcaa caaaccaatt 5760
gaatacatca aaaaggaaag atggactgac tcattcaaaa ttctcgctta tttgtgtcaa 5820
aagtttttgg acttacacaa gttgacatta atcttaaatg ctgtctctga ggtggaattg 5880
ctcaacttgg cgaggacttt caaaggcaaa gtcagaagaa gttctcatgg aacgaacata 5940
tgcaggatta gggttcccag cttgggtcct acttttattt cagaaggatg ggcttacttc 6000
aagaaacttg atattctaat ggaccgaaac tttctgttaa tggtcaaaga tgtgattata 6060
gggaggatgc aaacggtgct atccatggta tgtagaatag acaacctgtt ctcagagcaa 6120
gacatcttct cccttctaaa tatctacaga attggagata aaattgtgga gaggcaggga 6180
aatttttctt atgacttgat taaaatggtg gaaccgatat gcaacttgaa gctgatgaaa 6240
ttagcaagag aatcaaggcc tttagtccca caattccctc attttgaaaa tcatatcaag 6300
acttctgttg atgaaggggc aaaaattgac cgaggtataa gattcctcca tgatcagata 6360
atgagtgtga aaacagtgga tctcacactg gtgatttatg gatcgttcag acattggggt 6420
catcctttta tagattatta cactggacta gaaaaattac attcccaagt aaccatgaag 6480
aaagatattg atgtgtcata tgcaaaagca cttgcaagtg atttagctcg gattgttcta 6540
tttcaacagt tcaatgatca taaaaagtgg ttcgtgaatg gagacttgct ccctcatgat 6600
catcccttta aaagtcatgt taaagaaaat acatggccca cagctgctca agttcaagat 6660
tttggagata aatggcatga acttccgctg attaaatgtt ttgaaatacc cgacttacta 6720
gacccatcga taatatactc tgacaaaagt cattcaatga ataggtcaga ggtgttgaaa 6780
catgtccgaa tgaatccgaa cactcctatc cctagtaaaa aggtgttgca gactatgttg 6840
gacacaaagg ctaccaattg gaaagaattt cttaaagaga ttgatgagaa gggcttagat 6900
gatgatgatc taattattgg tcttaaagga aaggagaggg aactgaagtt ggcaggtaga 6960
tttttctccc taatgtcttg gaaattgcga gaatactttg taattaccga atatttgata 7020
aagactcatt tcgtccctat gtttaaaggc ctgacaatgg cggacgatct aactgcagtc 7080
attaaaaaga tgttagattc ctcatccggc caaggattga agtcatatga ggcaatttgc 7140
atagccaatc acattgatta cgaaaaatgg aataaccacc aaaggaagtt atcaaacggc 7200
ccagtgttcc gagttatggg ccagttctta ggttatccat ccttaatcga gagaactcat 7260
gaattttttg agaaaagtct tatatactac aatggaagac cagacttgat gcgtgttcac 7320
aacaacacac tgatcaattc aacctcccaa cgagtttgtt ggcaaggaca agagggtgga 7380
ctggaaggtc tacggcaaaa aggatggagt atcctcaatc tactggttat tcaaagagag 7440
gctaaaatca gaaacactgc tgtcaaagtc ttggcacaag gtgataatca agttatttgc 7500
acacagtata aaacgaagaa atcgagaaac gttgtagaat tacagggtgc tctcaatcaa 7560
atggtttcta ataatgagaa aattatgact gcaatcaaaa tagggacagg gaagttagga 7620
cttttgataa atgacgatga gactatgcaa tctgcagatt acttgaatta tggaaaaata 7680
ccgattttcc gtggagtgat tagagggtta gagaccaaga gatggtcacg agtgacttgt 7740
gtcaccaatg accaaatacc cacttgtgct aatataatga gctcagtttc cacaaatgct 7800
ctcaccgtag ctcattttgc tgagaaccca atcaatgcca tgatacagta caattatttt 7860
gggacatttg ctagactctt gttgatgatg catgatcctg ctcttcgtca atcattgtat 7920
gaagttcaag ataagatacc gggcttgcac agttctactt tcaaatacgc catgttgtat 7980
ttggaccctt ccattggagg agtgtcgggc atgtctttgt ccaggttttt gattagagcc 8040
ttcccagatc ccgtaacaga aagtctctca ttctggagat tcatccatgt acatgctcga 8100
agtgagcatc tgaaggagat gagtgcagta tttggaaacc ccgagatagc caagtttcga 8160
ataactcaca tagacaagct agtagaagat ccaacctctc tgaacatcgc tatgggaatg 8220
agtccagcga acttgttaaa gactgaggtt aaaaaatgct taatcgaatc aagacaaacc 8280
atcaggaacc aggtgattaa ggatgcaacc atatatttgt atcatgaaga ggatcggctc 8340
agaagtttct tatggtcaat aaatcctctg ttccctagat ttttaagtga attcaaatca 8400
ggcacttttt tgggagtcgc agacgggctc atcagtctat ttcaaaattc tcgtactatt 8460
cggaactcct ttaagaaaaa gtatcatagg gaattggatg atttgattgt gaggagtgag 8520
gtatcctctt tgacacattt agggaaactt catttgagaa ggggatcatg taaaatgtgg 8580
acatgttcag ctactcatgc tgacacatta agatacaaat cctggggccg tacagttatt 8640
gggacaactg taccccatcc attagaaatg ttgggtccac aacatcgaaa agagactcct 8700
tgtgcaccat gtaacacatc agggttcaat tatgtttctg tgcattgtcc agacgggatc 8760
catgacgtct ttagttcacg gggaccattg cctgcttatc tagggtctaa aacatctgaa 8820
tctacatcta ttttgcagcc ttgggaaagg gaaagcaaag tcccactgat taaaagagct 8880
acacgtctta gagatgctat ctcttggttt gttgaacccg actctaaact agcaatgact 8940
atactttcta acatccactc tttaacaggc gaagaatgga ccaaaaggca gcatgggttc 9000
aaaagaacag ggtctgccct tcataggttt tcgacatctc ggatgagcca tggtgggttc 9060
gcatctcaga gcactgcagc attgaccagg ttgatggcaa ctacagacac catgagggat 9120
ctgggagatc agaatttcga ctttttattc caagcaacgt tgctctatgc tcaaattacc 9180
accactgttg caagagacgg atggatcacc agttgtacag atcattatca tattgcctgt 9240
aagtcctgtt tgagacccat agaagagatc accctggact caagtatgga ctacacgccc 9300
ccagatgtat cccatgtgct gaagacatgg aggaatgggg aaggttcgtg gggacaagag 9360
ataaaacaga tctatccttt agaagggaat tggaagaatt tagcacctgc tgagcaatcc 9420
tatcaagtcg gcagatgtat aggttttcta tatggagact tggcgtatag aaaatctact 9480
catgccgagg acagttctct atttcctcta tctatacaag gtcgtattag aggtcgaggt 9540
ttcttaaaag ggttgctaga cggattaatg agagcaagtt gctgccaagt aatacaccgg 9600
agaagtctgg ctcatttgaa gaggccggcc aacgcagtgt acggaggttt gatttacttg 9660
attgataaat tgagtgtatc acctccattc ctttctctta ctagatcagg acctattaga 9720
gacgaattag aaacgattcc ccacaagatc ccaacctcct atccgacaag caaccgtgat 9780
atgggggtga ttgtcagaaa ttacttcaaa taccaatgcc gtctaattga aaagggaaaa 9840
tacagatcac attattcaca attatggtta ttctcagatg tcttatccat agacttcatt 9900
ggaccattct ctatttccac caccctcttg caaatcctat acaagccatt tttatctggg 9960
aaagataaga atgagttgag agagctggca aatctttctt cattgctaag atcaggagag 10020
gggtgggaag acatacatgt gaaattcttc accaaggaca tattattgtg tccagaggaa 10080
atcagacatg cttgcaagtt cgggattgct aaggataata ataaagacat gagctatccc 10140
ccttggggaa gggaatccag agggacaatt acaacaatcc ctgtttatta tacgaccacc 10200
ccttacccaa agatgctaga gatgcctcca agaatccaaa atcccctgct gtccggaatc 10260
aggttgggcc aattaccaac tggcgctcat tataaaattc ggagtatatt acatggaatg 10320
ggaatccatt acagggactt cttgagttgt ggagacggct ccggagggat gactgctgca 10380
ttactacgag aaaatgtgca tagcagagga atattcaata gtctgttaga attatcaggg 10440
tcagtcatgc gaggcgcctc tcctgagccc cccagtgccc tagaaacttt aggaggagat 10500
aaatcgagat gtgtaaatgg tgaaacatgt tgggaatatc catctgactt atgtgaccca 10560
aggacttggg actatttcct ccgactcaaa gcaggcttgg ggcttcaaat tgatttaatt 10620
gtaatggata tggaagttcg ggattcttct actagcctga aaattgagac gaatgttaga 10680
aattatgtgc accggatttt ggatgagcaa ggagttttaa tctacaagac ttatggaaca 10740
tatatttgtg agagcgaaaa gaatgcagta acaatccttg gtcccatgtt caagacggtc 10800
gacttagttc aaacagaatt tagtagttct caaacgtctg aagtatatat ggtatgtaaa 10860
ggtttgaaga aattaatcga tgaacccaat cccgattggt cttccatcaa tgaatcctgg 10920
aaaaacctgt acgcattcca gtcatcagaa caggaatttg ccagagcaaa gaaggttagt 10980
acatacttta ccttgacagg tattccctcc caattcattc ctgatccttt tgtaaacatt 11040
gagactatgc tacaaatatt cggagtaccc acgggtgtgt ctcatgcggc tgccttaaaa 11100
tcatctgata gacctgcaga tttattgacc attagccttt tttatatggc gattatatcg 11160
tattataaca tcaatcatat cagagtagga ccgatacctc cgaacccccc atcagatgga 11220
attgcacaaa atgtggggat cgctataact ggtataagct tttggctgag tttgatggag 11280
aaagacattc cactatatca acagtgtttg gcagttatcc agcaatcatt tccgattagg 11340
tgggaggcta tttcagtaaa aggaggatac aagcagaagt ggagtactag aggtgatggg 11400
ctcccaaaag atacccgaat ttcagactcc ttggccccaa tcgggaactg gatcagatct 11460
ttggaattgg tccgaaacca agttcgtcta aatccattca ataagatctt gttcaatcag 11520
ctatgtcgta cagtggataa tcatttgaag tggtcaaatt tgcgaaaaaa cacaggaatg 11580
attgaatgga tcaatgggcg aatttcaaaa gaagaccggt ctatactgat gttgaagagt 11640
gacctacatg aggaaaactc ttggagagat taaaaaatca ggaggagact ccaaacttta 11700
agtatgaaaa aaactttgat ccttaagacc ctcttgtggt ttttattttt tatctggttt 11760
tgtggtcttc gt 11772
<210> 10
<211> 12052
<212> DNA
<213> 人工序列
<220>
<223> 合成构建体
<400> 10
acgaagacaa acaaaccatt attatcatta aaaggctcag gagaaacttt aacagtaatc 60
aaaatgtctg ttacagtcaa gagaatcatt gacaacacag tcatagttcc aaaacttcct 120
gcaaatgagg atccagtgga atacccggca gattacttca gaaaatcaaa ggagattcct 180
ctttacatca atactacaaa aagtttgtca gatctaagag gatatgtcta ccaaggcctc 240
aaatccggaa atgtatcaat catacatgtc aacagctact tgtatggagc attaaaggac 300
atccggggta agttggataa agattggtca agtttcggaa taaacatcgg gaaagcaggg 360
gatacaatcg gaatatttga ccttgtatcc ttgaaagccc tggacggcgt acttccagat 420
ggagtatcgg atgcttccag aaccagcgca gatgacaaat ggttgccttt gtatctactt 480
ggcttataca gagtgggcag aacacaaatg cctgaataca gaaaaaagct catggatggg 540
ctgacaaatc aatgcaaaat gatcaatgaa cagtttgaac ctcttgtgcc agaaggtcgt 600
gacatttttg atgtgtgggg aaatgacagt aattacacaa aaattgtcgc tgcagtggac 660
atgttcttcc acatgttcaa aaaacatgaa tgtgcctcgt tcagatacgg aactattgtt 720
tccagattca aagattgtgc tgcattggca acatttggac acctctgcaa aataaccgga 780
atgtctacag aagatgtaac gacctggatc ttgaaccgag aagttgcaga tgaaatggtc 840
caaatgatgc ttccaggcca agaaattgac aaggccgatt catacatgcc ttatttgatc 900
gactttggat tgtcttctaa gtctccatat tcttccgtca aaaaccctgc cttccacttc 960
tgggggcaat tgacagctct tctgctcaga tccaccagag caaggaatgc ccgacagcct 1020
gatgacattg agtatacatc tcttactaca gcaggtttgt tgtacgctta tgcagtagga 1080
tcctctgccg acttggcaca acagttttgt gttggagata acaaatacac tccagatgat 1140
agtaccggag gattgacgac taatgcaccg ccacaaggca gagatgtggt cgaatggctc 1200
ggatggtttg aagatcaaaa cagaaaaccg actcctgata tgatgcagta tgcgaaaaga 1260
gcagtcatgt cactgcaagg cctaagagag aagacaattg gcaagtatgc taagtcagaa 1320
tttgacaaat gaccctataa ttctcagatc acctattata tattatgcta catatgaaaa 1380
aaactaacag atatcatgga taatctcaca aaagttcgtg agtatctcaa gtcctactct 1440
cgtctagatc aggcggtagg agagatagat gagatcgaag cacaacgagc tgaaaagtcc 1500
aattatgagt tgttccaaga ggacggagtg gaagagcata ctaggccctc ttattttcag 1560
gcagcagatg attctgacac agaatctgaa ccagaaattg aagacaatca aggcttgtat 1620
gtaccagatc cggaagctga gcaagttgaa ggctttatac aggggccttt agatgactat 1680
gcagatgagg acgtggatgt tgtattcact tcggactgga aacagcctga gcttgaatcc 1740
gacgagcatg gaaagacctt acggttgaca ttgccagagg gtttaagtgg agagcagaaa 1800
tcccagtggc ttttgacgat taaagcagtc gttcaaagtg ccaaacactg gaatctggca 1860
gagtgcacat ttgaagcatc gggagaaggg gtcatcataa aaaagcgcca gataactccg 1920
gatgtatata aggtcactcc agtgatgaac acacatccgt accaatcaga agccgtatca 1980
gatgtttggt ctctctcaaa gacatccatg actttccaac ccaagaaagc aagtcttcag 2040
cctctcacca tatccttgga tgaattgttc tcatctagag gagaattcat ctctgtcgga 2100
ggtaacggac gaatgtctca taaagaggcc atcctgctcg gtctgaggta caaaaagttg 2160
tacaatcagg cgagagtcaa atattctctg tagactatga aaaaaagtaa cagatatcac 2220
aatctaagtg ttatcccaat ccattcatca tgagttcctt aaagaagatt ctcggtctga 2280
aggggaaagg taagaaatct aagaaattag ggatcgcacc acccccttat gaagaggaca 2340
ctagcatgga gtatgctccg agcgctccaa ttgacaaatc ctattttgga gttgacgaga 2400
tggacaccta tgatccgaat caattaagat atgagaaatt cttctttaca gtgaaaatga 2460
cggttagatc taatcgtccg ttcagaacat actcagatgt ggcagccgct gtatcccatt 2520
gggatcacat gtacatcgga atggcaggga aacgtccctt ctacaaaatc ttggcttttt 2580
tgggttcttc taatctaaag gccactccag cggtattggc agatcaaggt caaccagagt 2640
atcacgctca ctgcgaaggc agggcttatt tgccacatag gatggggaag acccctccca 2700
tgctcaatgt accagagcac ttcagaagac cattcaatat aggtctttac aagggaacga 2760
ttgagctcac aatgaccatc tacgatgatg agtcactgga agcagctcct atgatctggg 2820
atcatttcaa ttcttccaaa ttttctgatt tcagagagaa ggccttaatg tttggcctga 2880
ttgtcgagaa aaaggcatct ggagcgtggg tcctggattc tatcagccac ttcaaatgag 2940
ctagtctagc ttccagcttc tgaacaatcc ccggtttact cagtctctcc taattccagc 3000
ctttcgaaca actaatatcc tgtcttttct atccctatga aaaaaactaa cagatctcga 3060
gatggcggct ctgaagagtt ggctgtcgcg cagcgtaact tcattcttca ggtacagaca 3120
gtgtttgtgt gttcctgttg tggctaactt taagaagcgg tgtttctcag aattgataag 3180
accatggcac aaaactgtga cgattggctt tggagtaacc ctgtgtgcgg ttcctattgc 3240
acagaaatca gagcctcatt cccttagtag tgaagcattg atgaggagag cagtgtcttt 3300
ggtaacagat agcacctcta cctttctctc tcagaccaca tatgcgttga ttgaagctat 3360
tactgaatat actaaggctg tttatacctt aacttctctt taccgacaat atacaagttt 3420
acttgggaaa atgaattcag aggaggaaga tgaagtgtgg caggtgatca taggagccag 3480
agctgagatg acttcaaaac accaagagta cttgaagctg gaaaccactt ggatgactgc 3540
agttggtctt tcagagatgg cagcagaagc tgcatatcaa actggcgcag atcaggcctc 3600
tataaccgcc aggaatcaca ttcagctggt gaaactgcag gtggaagagg tgcaccagct 3660
ctcccggaaa gcagaaacca agctggcaga agcacagata gaagagctcc gtcagaaaac 3720
acaggaggaa ggggaggagc gggctgagtc ggagcaggag gcctacctgc gtgaggattg 3780
actcgagtat attttaattt ttaattttta tgaaaaaaac taacagatct cgagctgtta 3840
atgctaatcg tgataggggt ttttgcctcc aactgactcc tacatattag cattaacagc 3900
tcgagtatat tttaattttt aatttttatg aaaaaaacta acagagatcg atctgtttcc 3960
ttgacaccat gaagtgcctt ttgtacttag cttttttatt catcggggtg aattgcaagt 4020
tcaccatagt ttttccacac aaccgaaaag gaaactggaa aaatgttcct tccaattacc 4080
attattgccc gtcaagctca gatttaaatt ggcataatga cttaataggc acagccttac 4140
aagtcaaaat gcccaagagt cacaaggcta ttcaagcaga cggttggatg tgtcatgctt 4200
ccaaatgggt cactacttgt gatttccgct ggtacggacc ggagtatata acacattcca 4260
tccgatcctt cactccatct gtagaacaat gcaaggaaag cattgaacaa acgaaacaag 4320
gaacttggct gaatccaggc ttccctcctc aaagttgtgg atatgcaact gtgacggatg 4380
ctgaagcagc gattgtccag gtgactcctc accatgtgct tgttgatgaa tacacaggag 4440
aatgggttga ttcacagttc atcaacggaa aatgcagcaa tgacatatgc cccactgtcc 4500
ataactccac aacctggcat tccgactata aggtcaaagg gctatgtgat tctaacctca 4560
tttccatgga catcaccttc ttctcagagg acggagagct atcatcccta ggaaaggagg 4620
gcacagggtt cagaagtaac tactttgctt atgaaactgg agacaaggcc tgcaaaatgc 4680
agtactgcaa gcattgggga gtcagactcc catcaggtgt ctggttcgag atggctgata 4740
aggatctctt tgctgcagcc agattccctg aatgcccaga agggtcaagt atctctgctc 4800
catctcagac ctcagtggat gtaagtctca ttcaggacgt tgagaggatc ttggattatt 4860
ccctctgcca agaaacctgg agcaaaatca gagcgggtct tcccatctct ccagtggatc 4920
tcagctatct tgctcctaaa aacccaggaa ccggtcctgt ctttaccata atcaatggta 4980
ccctaaaata ctttgagacc agatacatca gagtcgatat tgctgctcca atcctctcaa 5040
gaatggtcgg aatgatcagt ggaactacca cagaaaggga actgtgggat gactgggctc 5100
catatgaaga cgtggaaatt ggacccaatg gagttctgag gaccagttca ggatataagt 5160
ttcctttata tatgattgga catggtatgt tggactccga tcttcatctt agctcaaagg 5220
ctcaggtgtt tgaacatcct cacattcaag acgctgcttc gcagcttcct gatgatgaga 5280
ctttattttt tggtgatact gggctatcca aaaatccaat cgagtttgta gaaggttggt 5340
tcagtagttg gaagagctct attgcctctt tttgctttat catagggtta atcattggac 5400
tattcttggt tctccgagtt ggtatttatc tttgcattaa attaaagcac accaagaaaa 5460
gacagattta tacagacata gagatgaacc gacttggaaa gtaactcaaa tcctgcacaa 5520
cagattcttc atgtttgaac caaatcaact tgtgatatca tgctcaaaga ggccttaatt 5580
atattttaat ttttaatttt tatgaaaaaa actaacagca atcatggaag tccacgattt 5640
tgagaccgac gagttcaatg atttcaatga agatgactat gccacaagag aattcctgaa 5700
tcccgatgag cgcatgacgt acttgaatca tgctgattac aatttgaatt ctcctctaat 5760
tagtgatgat attgacaatt tgatcaggaa attcaattct cttccgattc cctcgatgtg 5820
ggatagtaag aactgggatg gagttcttga gatgttaaca tcatgtcaag ccaatcccat 5880
ctcaacatct cagatgcata aatggatggg aagttggtta atgtctgata atcatgatgc 5940
cagtcaaggg tatagttttt tacatgaagt ggacaaagag gcagaaataa catttgacgt 6000
ggtggagacc ttcatccgcg gctggggcaa caaaccaatt gaatacatca aaaaggaaag 6060
atggactgac tcattcaaaa ttctcgctta tttgtgtcaa aagtttttgg acttacacaa 6120
gttgacatta atcttaaatg ctgtctctga ggtggaattg ctcaacttgg cgaggacttt 6180
caaaggcaaa gtcagaagaa gttctcatgg aacgaacata tgcaggatta gggttcccag 6240
cttgggtcct acttttattt cagaaggatg ggcttacttc aagaaacttg atattctaat 6300
ggaccgaaac tttctgttaa tggtcaaaga tgtgattata gggaggatgc aaacggtgct 6360
atccatggta tgtagaatag acaacctgtt ctcagagcaa gacatcttct cccttctaaa 6420
tatctacaga attggagata aaattgtgga gaggcaggga aatttttctt atgacttgat 6480
taaaatggtg gaaccgatat gcaacttgaa gctgatgaaa ttagcaagag aatcaaggcc 6540
tttagtccca caattccctc attttgaaaa tcatatcaag acttctgttg atgaaggggc 6600
aaaaattgac cgaggtataa gattcctcca tgatcagata atgagtgtga aaacagtgga 6660
tctcacactg gtgatttatg gatcgttcag acattggggt catcctttta tagattatta 6720
cactggacta gaaaaattac attcccaagt aaccatgaag aaagatattg atgtgtcata 6780
tgcaaaagca cttgcaagtg atttagctcg gattgttcta tttcaacagt tcaatgatca 6840
taaaaagtgg ttcgtgaatg gagacttgct ccctcatgat catcccttta aaagtcatgt 6900
taaagaaaat acatggccca cagctgctca agttcaagat tttggagata aatggcatga 6960
acttccgctg attaaatgtt ttgaaatacc cgacttacta gacccatcga taatatactc 7020
tgacaaaagt cattcaatga ataggtcaga ggtgttgaaa catgtccgaa tgaatccgaa 7080
cactcctatc cctagtaaaa aggtgttgca gactatgttg gacacaaagg ctaccaattg 7140
gaaagaattt cttaaagaga ttgatgagaa gggcttagat gatgatgatc taattattgg 7200
tcttaaagga aaggagaggg aactgaagtt ggcaggtaga tttttctccc taatgtcttg 7260
gaaattgcga gaatactttg taattaccga atatttgata aagactcatt tcgtccctat 7320
gtttaaaggc ctgacaatgg cggacgatct aactgcagtc attaaaaaga tgttagattc 7380
ctcatccggc caaggattga agtcatatga ggcaatttgc atagccaatc acattgatta 7440
cgaaaaatgg aataaccacc aaaggaagtt atcaaacggc ccagtgttcc gagttatggg 7500
ccagttctta ggttatccat ccttaatcga gagaactcat gaattttttg agaaaagtct 7560
tatatactac aatggaagac cagacttgat gcgtgttcac aacaacacac tgatcaattc 7620
aacctcccaa cgagtttgtt ggcaaggaca agagggtgga ctggaaggtc tacggcaaaa 7680
aggatggagt atcctcaatc tactggttat tcaaagagag gctaaaatca gaaacactgc 7740
tgtcaaagtc ttggcacaag gtgataatca agttatttgc acacagtata aaacgaagaa 7800
atcgagaaac gttgtagaat tacagggtgc tctcaatcaa atggtttcta ataatgagaa 7860
aattatgact gcaatcaaaa tagggacagg gaagttagga cttttgataa atgacgatga 7920
gactatgcaa tctgcagatt acttgaatta tggaaaaata ccgattttcc gtggagtgat 7980
tagagggtta gagaccaaga gatggtcacg agtgacttgt gtcaccaatg accaaatacc 8040
cacttgtgct aatataatga gctcagtttc cacaaatgct ctcaccgtag ctcattttgc 8100
tgagaaccca atcaatgcca tgatacagta caattatttt gggacatttg ctagactctt 8160
gttgatgatg catgatcctg ctcttcgtca atcattgtat gaagttcaag ataagatacc 8220
gggcttgcac agttctactt tcaaatacgc catgttgtat ttggaccctt ccattggagg 8280
agtgtcgggc atgtctttgt ccaggttttt gattagagcc ttcccagatc ccgtaacaga 8340
aagtctctca ttctggagat tcatccatgt acatgctcga agtgagcatc tgaaggagat 8400
gagtgcagta tttggaaacc ccgagatagc caagtttcga ataactcaca tagacaagct 8460
agtagaagat ccaacctctc tgaacatcgc tatgggaatg agtccagcga acttgttaaa 8520
gactgaggtt aaaaaatgct taatcgaatc aagacaaacc atcaggaacc aggtgattaa 8580
ggatgcaacc atatatttgt atcatgaaga ggatcggctc agaagtttct tatggtcaat 8640
aaatcctctg ttccctagat ttttaagtga attcaaatca ggcacttttt tgggagtcgc 8700
agacgggctc atcagtctat ttcaaaattc tcgtactatt cggaactcct ttaagaaaaa 8760
gtatcatagg gaattggatg atttgattgt gaggagtgag gtatcctctt tgacacattt 8820
agggaaactt catttgagaa ggggatcatg taaaatgtgg acatgttcag ctactcatgc 8880
tgacacatta agatacaaat cctggggccg tacagttatt gggacaactg taccccatcc 8940
attagaaatg ttgggtccac aacatcgaaa agagactcct tgtgcaccat gtaacacatc 9000
agggttcaat tatgtttctg tgcattgtcc agacgggatc catgacgtct ttagttcacg 9060
gggaccattg cctgcttatc tagggtctaa aacatctgaa tctacatcta ttttgcagcc 9120
ttgggaaagg gaaagcaaag tcccactgat taaaagagct acacgtctta gagatgctat 9180
ctcttggttt gttgaacccg actctaaact agcaatgact atactttcta acatccactc 9240
tttaacaggc gaagaatgga ccaaaaggca gcatgggttc aaaagaacag ggtctgccct 9300
tcataggttt tcgacatctc ggatgagcca tggtgggttc gcatctcaga gcactgcagc 9360
attgaccagg ttgatggcaa ctacagacac catgagggat ctgggagatc agaatttcga 9420
ctttttattc caagcaacgt tgctctatgc tcaaattacc accactgttg caagagacgg 9480
atggatcacc agttgtacag atcattatca tattgcctgt aagtcctgtt tgagacccat 9540
agaagagatc accctggact caagtatgga ctacacgccc ccagatgtat cccatgtgct 9600
gaagacatgg aggaatgggg aaggttcgtg gggacaagag ataaaacaga tctatccttt 9660
agaagggaat tggaagaatt tagcacctgc tgagcaatcc tatcaagtcg gcagatgtat 9720
aggttttcta tatggagact tggcgtatag aaaatctact catgccgagg acagttctct 9780
atttcctcta tctatacaag gtcgtattag aggtcgaggt ttcttaaaag ggttgctaga 9840
cggattaatg agagcaagtt gctgccaagt aatacaccgg agaagtctgg ctcatttgaa 9900
gaggccggcc aacgcagtgt acggaggttt gatttacttg attgataaat tgagtgtatc 9960
acctccattc ctttctctta ctagatcagg acctattaga gacgaattag aaacgattcc 10020
ccacaagatc ccaacctcct atccgacaag caaccgtgat atgggggtga ttgtcagaaa 10080
ttacttcaaa taccaatgcc gtctaattga aaagggaaaa tacagatcac attattcaca 10140
attatggtta ttctcagatg tcttatccat agacttcatt ggaccattct ctatttccac 10200
caccctcttg caaatcctat acaagccatt tttatctggg aaagataaga atgagttgag 10260
agagctggca aatctttctt cattgctaag atcaggagag gggtgggaag acatacatgt 10320
gaaattcttc accaaggaca tattattgtg tccagaggaa atcagacatg cttgcaagtt 10380
cgggattgct aaggataata ataaagacat gagctatccc ccttggggaa gggaatccag 10440
agggacaatt acaacaatcc ctgtttatta tacgaccacc ccttacccaa agatgctaga 10500
gatgcctcca agaatccaaa atcccctgct gtccggaatc aggttgggcc aattaccaac 10560
tggcgctcat tataaaattc ggagtatatt acatggaatg ggaatccatt acagggactt 10620
cttgagttgt ggagacggct ccggagggat gactgctgca ttactacgag aaaatgtgca 10680
tagcagagga atattcaata gtctgttaga attatcaggg tcagtcatgc gaggcgcctc 10740
tcctgagccc cccagtgccc tagaaacttt aggaggagat aaatcgagat gtgtaaatgg 10800
tgaaacatgt tgggaatatc catctgactt atgtgaccca aggacttggg actatttcct 10860
ccgactcaaa gcaggcttgg ggcttcaaat tgatttaatt gtaatggata tggaagttcg 10920
ggattcttct actagcctga aaattgagac gaatgttaga aattatgtgc accggatttt 10980
ggatgagcaa ggagttttaa tctacaagac ttatggaaca tatatttgtg agagcgaaaa 11040
gaatgcagta acaatccttg gtcccatgtt caagacggtc gacttagttc aaacagaatt 11100
tagtagttct caaacgtctg aagtatatat ggtatgtaaa ggtttgaaga aattaatcga 11160
tgaacccaat cccgattggt cttccatcaa tgaatcctgg aaaaacctgt acgcattcca 11220
gtcatcagaa caggaatttg ccagagcaaa gaaggttagt acatacttta ccttgacagg 11280
tattccctcc caattcattc ctgatccttt tgtaaacatt gagactatgc tacaaatatt 11340
cggagtaccc acgggtgtgt ctcatgcggc tgccttaaaa tcatctgata gacctgcaga 11400
tttattgacc attagccttt tttatatggc gattatatcg tattataaca tcaatcatat 11460
cagagtagga ccgatacctc cgaacccccc atcagatgga attgcacaaa atgtggggat 11520
cgctataact ggtataagct tttggctgag tttgatggag aaagacattc cactatatca 11580
acagtgtttg gcagttatcc agcaatcatt tccgattagg tgggaggcta tttcagtaaa 11640
aggaggatac aagcagaagt ggagtactag aggtgatggg ctcccaaaag atacccgaat 11700
ttcagactcc ttggccccaa tcgggaactg gatcagatct ttggaattgg tccgaaacca 11760
agttcgtcta aatccattca ataagatctt gttcaatcag ctatgtcgta cagtggataa 11820
tcatttgaag tggtcaaatt tgcgaaaaaa cacaggaatg attgaatgga tcaatgggcg 11880
aatttcaaaa gaagaccggt ctatactgat gttgaagagt gacctacatg aggaaaactc 11940
ttggagagat taaaaaatca ggaggagact ccaaacttta agtatgaaaa aaactttgat 12000
ccttaagacc ctcttgtggt ttttattttt tatctggttt tgtggtcttc gt 12052
<210> 11
<211> 11890
<212> DNA
<213> 人工序列
<220>
<223> 合成构建体
<400> 11
acgaagacaa acaaaccatt attatcatta aaaggctcag gagaaacttt aacagtaatc 60
aaaatgtctg ttacagtcaa gagaatcatt gacaacacag tcatagttcc aaaacttcct 120
gcaaatgagg atccagtgga atacccggca gattacttca gaaaatcaaa ggagattcct 180
ctttacatca atactacaaa aagtttgtca gatctaagag gatatgtcta ccaaggcctc 240
aaatccggaa atgtatcaat catacatgtc aacagctact tgtatggagc attaaaggac 300
atccggggta agttggataa agattggtca agtttcggaa taaacatcgg gaaagcaggg 360
gatacaatcg gaatatttga ccttgtatcc ttgaaagccc tggacggcgt acttccagat 420
ggagtatcgg atgcttccag aaccagcgca gatgacaaat ggttgccttt gtatctactt 480
ggcttataca gagtgggcag aacacaaatg cctgaataca gaaaaaagct catggatggg 540
ctgacaaatc aatgcaaaat gatcaatgaa cagtttgaac ctcttgtgcc agaaggtcgt 600
gacatttttg atgtgtgggg aaatgacagt aattacacaa aaattgtcgc tgcagtggac 660
atgttcttcc acatgttcaa aaaacatgaa tgtgcctcgt tcagatacgg aactattgtt 720
tccagattca aagattgtgc tgcattggca acatttggac acctctgcaa aataaccgga 780
atgtctacag aagatgtaac gacctggatc ttgaaccgag aagttgcaga tgaaatggtc 840
caaatgatgc ttccaggcca agaaattgac aaggccgatt catacatgcc ttatttgatc 900
gactttggat tgtcttctaa gtctccatat tcttccgtca aaaaccctgc cttccacttc 960
tgggggcaat tgacagctct tctgctcaga tccaccagag caaggaatgc ccgacagcct 1020
gatgacattg agtatacatc tcttactaca gcaggtttgt tgtacgctta tgcagtagga 1080
tcctctgccg acttggcaca acagttttgt gttggagata acaaatacac tccagatgat 1140
agtaccggag gattgacgac taatgcaccg ccacaaggca gagatgtggt cgaatggctc 1200
ggatggtttg aagatcaaaa cagaaaaccg actcctgata tgatgcagta tgcgaaaaga 1260
gcagtcatgt cactgcaagg cctaagagag aagacaattg gcaagtatgc taagtcagaa 1320
tttgacaaat gaccctataa ttctcagatc acctattata tattatgcta catatgaaaa 1380
aaactaacag atatcatgga taatctcaca aaagttcgtg agtatctcaa gtcctactct 1440
cgtctagatc aggcggtagg agagatagat gagatcgaag cacaacgagc tgaaaagtcc 1500
aattatgagt tgttccaaga ggacggagtg gaagagcata ctaggccctc ttattttcag 1560
gcagcagatg attctgacac agaatctgaa ccagaaattg aagacaatca aggcttgtat 1620
gtaccagatc cggaagctga gcaagttgaa ggctttatac aggggccttt agatgactat 1680
gcagatgagg acgtggatgt tgtattcact tcggactgga aacagcctga gcttgaatcc 1740
gacgagcatg gaaagacctt acggttgaca ttgccagagg gtttaagtgg agagcagaaa 1800
tcccagtggc ttttgacgat taaagcagtc gttcaaagtg ccaaacactg gaatctggca 1860
gagtgcacat ttgaagcatc gggagaaggg gtcatcataa aaaagcgcca gataactccg 1920
gatgtatata aggtcactcc agtgatgaac acacatccgt accaatcaga agccgtatca 1980
gatgtttggt ctctctcaaa gacatccatg actttccaac ccaagaaagc aagtcttcag 2040
cctctcacca tatccttgga tgaattgttc tcatctagag gagaattcat ctctgtcgga 2100
ggtaacggac gaatgtctca taaagaggcc atcctgctcg gtctgaggta caaaaagttg 2160
tacaatcagg cgagagtcaa atattctctg tagactatga aaaaaagtaa cagatatcac 2220
aatctaagtg ttatcccaat ccattcatca tgagttcctt aaagaagatt ctcggtctga 2280
aggggaaagg taagaaatct aagaaattag ggatcgcacc acccccttat gaagaggaca 2340
ctagcatgga gtatgctccg agcgctccaa ttgacaaatc ctattttgga gttgacgaga 2400
tggacaccta tgatccgaat caattaagat atgagaaatt cttctttaca gtgaaaatga 2460
cggttagatc taatcgtccg ttcagaacat actcagatgt ggcagccgct gtatcccatt 2520
gggatcacat gtacatcgga atggcaggga aacgtccctt ctacaaaatc ttggcttttt 2580
tgggttcttc taatctaaag gccactccag cggtattggc agatcaaggt caaccagagt 2640
atcacgctca ctgcgaaggc agggcttatt tgccacatag gatggggaag acccctccca 2700
tgctcaatgt accagagcac ttcagaagac cattcaatat aggtctttac aagggaacga 2760
ttgagctcac aatgaccatc tacgatgatg agtcactgga agcagctcct atgatctggg 2820
atcatttcaa ttcttccaaa ttttctgatt tcagagagaa ggccttaatg tttggcctga 2880
ttgtcgagaa aaaggcatct ggagcgtggg tcctggattc tatcagccac ttcaaatgag 2940
ctagtctagc ttccagcttc tgaacaatcc ccggtttact cagtctctcc taattccagc 3000
ctttcgaaca actaatatcc tgtcttttct atccctatga aaaaaactaa cagatctcga 3060
gatggcggtt cctattgcac agaaatcaga gcctcattcc cttagtagtg aagcattgat 3120
gaggagagca gtgtctttgg taacagatag cacctctacc tttctctctc agaccacata 3180
tgcgttgatt gaagctatta ctgaatatac taaggctgtt tataccttaa cttctcttta 3240
ccgacaatat acaagtttac ttgggaaaat gaattcagag gaggaagatg aagtgtggca 3300
ggtgatcata ggagccagag ctgagatgac ttcaaaacac caagagtact tgaagctgga 3360
aaccacttgg atgactgcag ttggtctttc agagatggca gcagaagctg catatcaaac 3420
tggcgcagat caggcctcta taaccgccag gaatcacatt cagctggtga aactgcaggt 3480
ggaagaggtg caccagctct cccggaaagc agaaaccaag ctggcagaag cacagataga 3540
agagctccgt cagaaaacac aggaggaagg ggaggagcgg gctgagtcgg agcaggaggc 3600
ctacctgcgt gaggattgac tcgagtatat tttaattttt aatttttatg aaaaaaacta 3660
acagatctcg agctgttaat gctaatcgtg ataggggttt ttgcctccaa ctgactccta 3720
catattagca ttaacagctc gagtatattt taatttttaa tttttatgaa aaaaactaac 3780
agagatcgat ctgtttcctt gacaccatga agtgcctttt gtacttagct tttttattca 3840
tcggggtgaa ttgcaagttc accatagttt ttccacacaa ccgaaaagga aactggaaaa 3900
atgttccttc caattaccat tattgcccgt caagctcaga tttaaattgg cataatgact 3960
taataggcac agccttacaa gtcaaaatgc ccaagagtca caaggctatt caagcagacg 4020
gttggatgtg tcatgcttcc aaatgggtca ctacttgtga tttccgctgg tacggaccgg 4080
agtatataac acattccatc cgatccttca ctccatctgt agaacaatgc aaggaaagca 4140
ttgaacaaac gaaacaagga acttggctga atccaggctt ccctcctcaa agttgtggat 4200
atgcaactgt gacggatgct gaagcagcga ttgtccaggt gactcctcac catgtgcttg 4260
ttgatgaata cacaggagaa tgggttgatt cacagttcat caacggaaaa tgcagcaatg 4320
acatatgccc cactgtccat aactccacaa cctggcattc cgactataag gtcaaagggc 4380
tatgtgattc taacctcatt tccatggaca tcaccttctt ctcagaggac ggagagctat 4440
catccctagg aaaggagggc acagggttca gaagtaacta ctttgcttat gaaactggag 4500
acaaggcctg caaaatgcag tactgcaagc attggggagt cagactccca tcaggtgtct 4560
ggttcgagat ggctgataag gatctctttg ctgcagccag attccctgaa tgcccagaag 4620
ggtcaagtat ctctgctcca tctcagacct cagtggatgt aagtctcatt caggacgttg 4680
agaggatctt ggattattcc ctctgccaag aaacctggag caaaatcaga gcgggtcttc 4740
ccatctctcc agtggatctc agctatcttg ctcctaaaaa cccaggaacc ggtcctgtct 4800
ttaccataat caatggtacc ctaaaatact ttgagaccag atacatcaga gtcgatattg 4860
ctgctccaat cctctcaaga atggtcggaa tgatcagtgg aactaccaca gaaagggaac 4920
tgtgggatga ctgggctcca tatgaagacg tggaaattgg acccaatgga gttctgagga 4980
ccagttcagg atataagttt cctttatata tgattggaca tggtatgttg gactccgatc 5040
ttcatcttag ctcaaaggct caggtgtttg aacatcctca cattcaagac gctgcttcgc 5100
agcttcctga tgatgagact ttattttttg gtgatactgg gctatccaaa aatccaatcg 5160
agtttgtaga aggttggttc agtagttgga agagctctat tgcctctttt tgctttatca 5220
tagggttaat cattggacta ttcttggttc tccgagttgg tatttatctt tgcattaaat 5280
taaagcacac caagaaaaga cagatttata cagacataga gatgaaccga cttggaaagt 5340
aactcaaatc ctgcacaaca gattcttcat gtttgaacca aatcaacttg tgatatcatg 5400
ctcaaagagg ccttaattat attttaattt ttaattttta tgaaaaaaac taacagcaat 5460
catggaagtc cacgattttg agaccgacga gttcaatgat ttcaatgaag atgactatgc 5520
cacaagagaa ttcctgaatc ccgatgagcg catgacgtac ttgaatcatg ctgattacaa 5580
tttgaattct cctctaatta gtgatgatat tgacaatttg atcaggaaat tcaattctct 5640
tccgattccc tcgatgtggg atagtaagaa ctgggatgga gttcttgaga tgttaacatc 5700
atgtcaagcc aatcccatct caacatctca gatgcataaa tggatgggaa gttggttaat 5760
gtctgataat catgatgcca gtcaagggta tagtttttta catgaagtgg acaaagaggc 5820
agaaataaca tttgacgtgg tggagacctt catccgcggc tggggcaaca aaccaattga 5880
atacatcaaa aaggaaagat ggactgactc attcaaaatt ctcgcttatt tgtgtcaaaa 5940
gtttttggac ttacacaagt tgacattaat cttaaatgct gtctctgagg tggaattgct 6000
caacttggcg aggactttca aaggcaaagt cagaagaagt tctcatggaa cgaacatatg 6060
caggattagg gttcccagct tgggtcctac ttttatttca gaaggatggg cttacttcaa 6120
gaaacttgat attctaatgg accgaaactt tctgttaatg gtcaaagatg tgattatagg 6180
gaggatgcaa acggtgctat ccatggtatg tagaatagac aacctgttct cagagcaaga 6240
catcttctcc cttctaaata tctacagaat tggagataaa attgtggaga ggcagggaaa 6300
tttttcttat gacttgatta aaatggtgga accgatatgc aacttgaagc tgatgaaatt 6360
agcaagagaa tcaaggcctt tagtcccaca attccctcat tttgaaaatc atatcaagac 6420
ttctgttgat gaaggggcaa aaattgaccg aggtataaga ttcctccatg atcagataat 6480
gagtgtgaaa acagtggatc tcacactggt gatttatgga tcgttcagac attggggtca 6540
tccttttata gattattaca ctggactaga aaaattacat tcccaagtaa ccatgaagaa 6600
agatattgat gtgtcatatg caaaagcact tgcaagtgat ttagctcgga ttgttctatt 6660
tcaacagttc aatgatcata aaaagtggtt cgtgaatgga gacttgctcc ctcatgatca 6720
tccctttaaa agtcatgtta aagaaaatac atggcccaca gctgctcaag ttcaagattt 6780
tggagataaa tggcatgaac ttccgctgat taaatgtttt gaaatacccg acttactaga 6840
cccatcgata atatactctg acaaaagtca ttcaatgaat aggtcagagg tgttgaaaca 6900
tgtccgaatg aatccgaaca ctcctatccc tagtaaaaag gtgttgcaga ctatgttgga 6960
cacaaaggct accaattgga aagaatttct taaagagatt gatgagaagg gcttagatga 7020
tgatgatcta attattggtc ttaaaggaaa ggagagggaa ctgaagttgg caggtagatt 7080
tttctcccta atgtcttgga aattgcgaga atactttgta attaccgaat atttgataaa 7140
gactcatttc gtccctatgt ttaaaggcct gacaatggcg gacgatctaa ctgcagtcat 7200
taaaaagatg ttagattcct catccggcca aggattgaag tcatatgagg caatttgcat 7260
agccaatcac attgattacg aaaaatggaa taaccaccaa aggaagttat caaacggccc 7320
agtgttccga gttatgggcc agttcttagg ttatccatcc ttaatcgaga gaactcatga 7380
attttttgag aaaagtctta tatactacaa tggaagacca gacttgatgc gtgttcacaa 7440
caacacactg atcaattcaa cctcccaacg agtttgttgg caaggacaag agggtggact 7500
ggaaggtcta cggcaaaaag gatggagtat cctcaatcta ctggttattc aaagagaggc 7560
taaaatcaga aacactgctg tcaaagtctt ggcacaaggt gataatcaag ttatttgcac 7620
acagtataaa acgaagaaat cgagaaacgt tgtagaatta cagggtgctc tcaatcaaat 7680
ggtttctaat aatgagaaaa ttatgactgc aatcaaaata gggacaggga agttaggact 7740
tttgataaat gacgatgaga ctatgcaatc tgcagattac ttgaattatg gaaaaatacc 7800
gattttccgt ggagtgatta gagggttaga gaccaagaga tggtcacgag tgacttgtgt 7860
caccaatgac caaataccca cttgtgctaa tataatgagc tcagtttcca caaatgctct 7920
caccgtagct cattttgctg agaacccaat caatgccatg atacagtaca attattttgg 7980
gacatttgct agactcttgt tgatgatgca tgatcctgct cttcgtcaat cattgtatga 8040
agttcaagat aagataccgg gcttgcacag ttctactttc aaatacgcca tgttgtattt 8100
ggacccttcc attggaggag tgtcgggcat gtctttgtcc aggtttttga ttagagcctt 8160
cccagatccc gtaacagaaa gtctctcatt ctggagattc atccatgtac atgctcgaag 8220
tgagcatctg aaggagatga gtgcagtatt tggaaacccc gagatagcca agtttcgaat 8280
aactcacata gacaagctag tagaagatcc aacctctctg aacatcgcta tgggaatgag 8340
tccagcgaac ttgttaaaga ctgaggttaa aaaatgctta atcgaatcaa gacaaaccat 8400
caggaaccag gtgattaagg atgcaaccat atatttgtat catgaagagg atcggctcag 8460
aagtttctta tggtcaataa atcctctgtt ccctagattt ttaagtgaat tcaaatcagg 8520
cacttttttg ggagtcgcag acgggctcat cagtctattt caaaattctc gtactattcg 8580
gaactccttt aagaaaaagt atcataggga attggatgat ttgattgtga ggagtgaggt 8640
atcctctttg acacatttag ggaaacttca tttgagaagg ggatcatgta aaatgtggac 8700
atgttcagct actcatgctg acacattaag atacaaatcc tggggccgta cagttattgg 8760
gacaactgta ccccatccat tagaaatgtt gggtccacaa catcgaaaag agactccttg 8820
tgcaccatgt aacacatcag ggttcaatta tgtttctgtg cattgtccag acgggatcca 8880
tgacgtcttt agttcacggg gaccattgcc tgcttatcta gggtctaaaa catctgaatc 8940
tacatctatt ttgcagcctt gggaaaggga aagcaaagtc ccactgatta aaagagctac 9000
acgtcttaga gatgctatct cttggtttgt tgaacccgac tctaaactag caatgactat 9060
actttctaac atccactctt taacaggcga agaatggacc aaaaggcagc atgggttcaa 9120
aagaacaggg tctgcccttc ataggttttc gacatctcgg atgagccatg gtgggttcgc 9180
atctcagagc actgcagcat tgaccaggtt gatggcaact acagacacca tgagggatct 9240
gggagatcag aatttcgact ttttattcca agcaacgttg ctctatgctc aaattaccac 9300
cactgttgca agagacggat ggatcaccag ttgtacagat cattatcata ttgcctgtaa 9360
gtcctgtttg agacccatag aagagatcac cctggactca agtatggact acacgccccc 9420
agatgtatcc catgtgctga agacatggag gaatggggaa ggttcgtggg gacaagagat 9480
aaaacagatc tatcctttag aagggaattg gaagaattta gcacctgctg agcaatccta 9540
tcaagtcggc agatgtatag gttttctata tggagacttg gcgtatagaa aatctactca 9600
tgccgaggac agttctctat ttcctctatc tatacaaggt cgtattagag gtcgaggttt 9660
cttaaaaggg ttgctagacg gattaatgag agcaagttgc tgccaagtaa tacaccggag 9720
aagtctggct catttgaaga ggccggccaa cgcagtgtac ggaggtttga tttacttgat 9780
tgataaattg agtgtatcac ctccattcct ttctcttact agatcaggac ctattagaga 9840
cgaattagaa acgattcccc acaagatccc aacctcctat ccgacaagca accgtgatat 9900
gggggtgatt gtcagaaatt acttcaaata ccaatgccgt ctaattgaaa agggaaaata 9960
cagatcacat tattcacaat tatggttatt ctcagatgtc ttatccatag acttcattgg 10020
accattctct atttccacca ccctcttgca aatcctatac aagccatttt tatctgggaa 10080
agataagaat gagttgagag agctggcaaa tctttcttca ttgctaagat caggagaggg 10140
gtgggaagac atacatgtga aattcttcac caaggacata ttattgtgtc cagaggaaat 10200
cagacatgct tgcaagttcg ggattgctaa ggataataat aaagacatga gctatccccc 10260
ttggggaagg gaatccagag ggacaattac aacaatccct gtttattata cgaccacccc 10320
ttacccaaag atgctagaga tgcctccaag aatccaaaat cccctgctgt ccggaatcag 10380
gttgggccaa ttaccaactg gcgctcatta taaaattcgg agtatattac atggaatggg 10440
aatccattac agggacttct tgagttgtgg agacggctcc ggagggatga ctgctgcatt 10500
actacgagaa aatgtgcata gcagaggaat attcaatagt ctgttagaat tatcagggtc 10560
agtcatgcga ggcgcctctc ctgagccccc cagtgcccta gaaactttag gaggagataa 10620
atcgagatgt gtaaatggtg aaacatgttg ggaatatcca tctgacttat gtgacccaag 10680
gacttgggac tatttcctcc gactcaaagc aggcttgggg cttcaaattg atttaattgt 10740
aatggatatg gaagttcggg attcttctac tagcctgaaa attgagacga atgttagaaa 10800
ttatgtgcac cggattttgg atgagcaagg agttttaatc tacaagactt atggaacata 10860
tatttgtgag agcgaaaaga atgcagtaac aatccttggt cccatgttca agacggtcga 10920
cttagttcaa acagaattta gtagttctca aacgtctgaa gtatatatgg tatgtaaagg 10980
tttgaagaaa ttaatcgatg aacccaatcc cgattggtct tccatcaatg aatcctggaa 11040
aaacctgtac gcattccagt catcagaaca ggaatttgcc agagcaaaga aggttagtac 11100
atactttacc ttgacaggta ttccctccca attcattcct gatccttttg taaacattga 11160
gactatgcta caaatattcg gagtacccac gggtgtgtct catgcggctg ccttaaaatc 11220
atctgataga cctgcagatt tattgaccat tagccttttt tatatggcga ttatatcgta 11280
ttataacatc aatcatatca gagtaggacc gatacctccg aaccccccat cagatggaat 11340
tgcacaaaat gtggggatcg ctataactgg tataagcttt tggctgagtt tgatggagaa 11400
agacattcca ctatatcaac agtgtttggc agttatccag caatcatttc cgattaggtg 11460
ggaggctatt tcagtaaaag gaggatacaa gcagaagtgg agtactagag gtgatgggct 11520
cccaaaagat acccgaattt cagactcctt ggccccaatc gggaactgga tcagatcttt 11580
ggaattggtc cgaaaccaag ttcgtctaaa tccattcaat aagatcttgt tcaatcagct 11640
atgtcgtaca gtggataatc atttgaagtg gtcaaatttg cgaaaaaaca caggaatgat 11700
tgaatggatc aatgggcgaa tttcaaaaga agaccggtct atactgatgt tgaagagtga 11760
cctacatgag gaaaactctt ggagagatta aaaaatcagg aggagactcc aaactttaag 11820
tatgaaaaaa actttgatcc ttaagaccct cttgtggttt ttatttttta tctggttttg 11880
tggtcttcgt 11890
Claims (8)
1.一种重组水疱性口炎病毒(VSV)载体,包含被插入在单股负链病毒目中的非节段负链RNA病毒的基因组内的编码第二线粒体衍生的胱天蛋白酶激活剂(SMAC)蛋白的核酸,
其中所述SMAC蛋白由氨基酸序列SEQ ID NO:1组成,
其中病毒基因组包含至少核蛋白(N或NP)基因、磷蛋白(P)基因、糖蛋白(G)基因和基质蛋白(M)基因,
其中所述G基因编码修饰的G蛋白,所述修饰的G蛋白由氨基酸序列SEQ ID NO:6组成,并且
其中编码SMAC蛋白的所述核酸被插入在所述M基因和糖蛋白(G)基因之间。
2.如权利要求1所述的重组病毒载体,还包含编码微RNA-155的核酸。
3.如权利要求2所述的重组病毒载体,其中所述编码微RNA-155的核酸具有核酸序列SEQ ID NO:7。
4.如权利要求1所述的重组病毒载体,其中所述重组病毒载体包含核酸序列SEQ IDNO:8、9、10、或11。
5.一种细胞,包含如权利要求1-4中任一项所述的重组病毒载体。
6.一种重组病毒颗粒,包含如权利要求1-4中任一项所述的重组病毒载体。
7.一种组合物,包含在药学上可接受的赋形剂中的如权利要求6所述的重组病毒颗粒。
8.如权利要求7所述的组合物在制备用于治疗患有肿瘤的受试者的药物中的用途,其中所述肿瘤为乳腺肿瘤、胰腺癌或肛门囊癌,其中当所述药物被使用时,有效量的所述组合物被施用至所述受试者。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762508430P | 2017-05-19 | 2017-05-19 | |
US62/508,430 | 2017-05-19 | ||
PCT/US2018/032915 WO2018213412A1 (en) | 2017-05-19 | 2018-05-16 | Recombinant oncolytic virus |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110636853A CN110636853A (zh) | 2019-12-31 |
CN110636853B true CN110636853B (zh) | 2024-10-18 |
Family
ID=64274814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880032491.4A Active CN110636853B (zh) | 2017-05-19 | 2018-05-16 | 重组溶瘤病毒 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20200199624A1 (zh) |
EP (1) | EP3624825A4 (zh) |
CN (1) | CN110636853B (zh) |
WO (1) | WO2018213412A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019195936A1 (en) * | 2018-04-10 | 2019-10-17 | Ilkow Carolina Solange | Microrna-based compositions and methods used in disease treatment |
WO2021211902A2 (en) * | 2020-04-15 | 2021-10-21 | Humane Genomics | Artificial oncolytic viruses and related methods |
WO2022033469A1 (zh) * | 2020-08-14 | 2022-02-17 | 上海行深生物科技有限公司 | 重组溶瘤病毒及其构建方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2857879A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
WO2016079527A1 (en) * | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US8163893B2 (en) * | 2006-02-15 | 2012-04-24 | The Regents Of The University Of Caifornia | Pseudotyped retroviral vectors and methods of use thereof |
CA2420534A1 (en) * | 2000-08-24 | 2002-02-28 | Thomas Jefferson University | An iap binding peptide or polypeptide and methods of using the same |
WO2003072725A2 (en) * | 2002-02-21 | 2003-09-04 | Mount Sinai School Of Medicine | Recombinant negative strand virus rna expression systems and vaccines |
WO2003086470A2 (en) * | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
CN1788088B (zh) * | 2003-03-27 | 2012-09-26 | 渥太华健康研究学会 | 突变的水泡性口炎病毒及其用途 |
CN105902559A (zh) * | 2005-08-01 | 2016-08-31 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
AU2006291165B2 (en) * | 2005-09-12 | 2013-03-14 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
US20090175826A1 (en) * | 2006-06-05 | 2009-07-09 | Elankumaran Subbiah | Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same |
MX337062B (es) * | 2009-12-10 | 2016-02-11 | Ottawa Hospital Res Inst | Rabdovirus oncolítico. |
ES2545357T3 (es) * | 2010-09-02 | 2015-09-10 | Mayo Foundation For Medical Education And Research | Virus de la estomatitis vesicular |
WO2014089668A1 (en) * | 2012-12-12 | 2014-06-19 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for the treatment of brain cancers |
WO2015077714A1 (en) * | 2013-11-22 | 2015-05-28 | Yale University | Chimeric vsv virus compositions and methods of use thereof for treatment of cancer |
WO2015154197A1 (en) * | 2014-04-11 | 2015-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
WO2015164726A2 (en) * | 2014-04-25 | 2015-10-29 | Acharjee Sujata | Chimeric vsv-g proteins as nucleic acid transfer vehicles |
EP3419643A4 (en) * | 2016-02-24 | 2020-04-01 | Children's Hospital of Eastern Ontario Research Institute Inc. | SMC COMBINATION THERAPY FOR TREATING CANCER |
CN106265764B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
-
2018
- 2018-05-16 CN CN201880032491.4A patent/CN110636853B/zh active Active
- 2018-05-16 US US16/614,441 patent/US20200199624A1/en active Pending
- 2018-05-16 WO PCT/US2018/032915 patent/WO2018213412A1/en active Application Filing
- 2018-05-16 EP EP18801713.1A patent/EP3624825A4/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2857879A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
WO2016079527A1 (en) * | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
Also Published As
Publication number | Publication date |
---|---|
EP3624825A4 (en) | 2021-03-10 |
US20200199624A1 (en) | 2020-06-25 |
WO2018213412A1 (en) | 2018-11-22 |
EP3624825A1 (en) | 2020-03-25 |
CN110636853A (zh) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9803216B2 (en) | Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same | |
CN101868546B (zh) | 痘病毒溶瘤载体 | |
US20210169956A1 (en) | Increased activity of oncolytic newcastle disease virus | |
JP7110203B2 (ja) | 腫瘍溶解性ウイルスおよび治療用分子 | |
KR102544032B1 (ko) | 암을 치료하기 위한 치료 조성물 및 사용 방법 | |
Liu et al. | Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses | |
CN110636853B (zh) | 重组溶瘤病毒 | |
CN109554353A (zh) | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
CN116917470A (zh) | PAN-RAS mRNA癌症疫苗 | |
CN112739359A (zh) | Apmv及其用于治疗癌症的用途 | |
US11932879B2 (en) | Mumps virus as a potential oncolytic agent | |
CN110157686B (zh) | 一种免疫检查点激活免疫共刺激的复制型溶瘤腺病毒及其构建方法和应用 | |
Bai et al. | TNF-related apoptosis-inducing Ligand delivered by rNDV is a novel agent for cancer gene therapy | |
KR20230005265A (ko) | Sars-cov-2에 대한 백신 및 이의 제조 | |
US20230147975A1 (en) | Pharmaceutical formulation comprising a combination of recombinant newcastle disease viruses for the treatment of cancer | |
US20220325297A1 (en) | Recombinant oncolytic newcastle disease viruses with increased activity | |
Li et al. | A recombinant oncolytic influenza virus carrying GV1001 triggers an antitumor immune response | |
AU2020351014A1 (en) | New oncolytic Newcastle Disease Viruses and recombinant NDV strains | |
CN112823019B (zh) | 乙型肝炎病毒复制抑制剂和包含该抑制剂的乙型肝炎治疗用药物组合物 | |
US20230331815A1 (en) | Methods and compositions for treating viral infection | |
EP3795161A1 (en) | Recombinant oncolytic newcastle disease viruses with increased activity and improved viral safety | |
TW202413636A (zh) | 嵌合痘病毒 | |
CN116782917A (zh) | 用于全身递送的溶瘤病毒及增强的抗肿瘤活性 | |
WO2020156693A1 (en) | Recombinant oncolytic newcastle disease viruses with increased activity | |
WO2009043960A1 (es) | Agentes anti-tumorales basados en la proteína viral a238l. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40017244 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |